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Intraperitoneal transplantation of alginate-microencapsulated human hepatocytes is an attractive 
option for the management of acute liver failure by providing short-term support to bridge 
patients to liver transplantation or allow native liver regeneration. Its success depends on 
mechanical stability, optimal permeability, and biocompatibility of the encapsulated cells to 
provide good viability and function. The main aims of this study were to optimise protocols for 
production and cryopreservation of human hepatocyte microbeads (HMBs) for future clinical 
use. 
HMBs were prepared using sterile ultrapure materials. Physical integrity of HMBs was 
evaluated using an osmotic stress test. A polymerisation of 15min provided mechanical stability 
with well-maintained cell viability and function. Cell content in HMBs was optimised and a 
density of 3.5x10
6
cells/ml alginate provided the highest cell viability with hepatocytes evenly 
distributed within microbeads. Permeability of optimised HMBs was measured and the largest 
protein which could diffuse out of microbeads had a molecular weight of 164kDa. Immune 
activation of human peripheral blood mononuclear cells was assessed by flow cytometry after 
co-culture with empty microbeads and HMBs. No evidence of cellular immune activation was 
observed. Optimisation of hepatocyte microbead cryopreservation was performed using rat and 
human hepatocytes. Improved outcome of cryopreservation was found when hepatocyte 
microbeads were cryopreserved in UW solution containing 10% DMSO, 5% glucose and 60µM 
benzyloxycarbonyl-Val-Ala-DL-Asp-fluoromethylketone (ZVAD). 
Safety, therapeutic effects, and immunogenicity of hepatocyte microbeads produced were 
confirmed in immunocompetent rats with and without acute liver failure. HMBs showed 
functionality with no inflammatory response in rats over 7 days. Transplantation of rat 
hepatocyte microbeads was safe and able to support the failing liver. Cryopreserved microbeads 
showed an encouraging outcome, but may require greater cell numbers compared to fresh 
microbead.  
In conclusion, optimised protocols for production and cryopreservation of GMP grade alginate-
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Acute liver failure is (ALF) is a devastating and complex condition which causes an abrupt loss 
of hepatic function in a person with previously normal liver function leading to encephalopathy, 
coagulopathy and progressive multiple organ failure within a short period of time. ALF 
represents a syndrome of heterogeneous conditions rather than a specific disease in which the 
underlying etiology, age of the patients and the time course are involved in the outcome (Bernal 
et al. 2010; O'Grady 2005). In adults, O’Grady et al (1993) classified ALF into 3 categories 
regarding the progression of hepatic encephalopathy from the initial liver injury these are 
hyperacute (≤7 days), acute (8-28 days) and subacute (>28 days). This definition provides clues 
to the underlying cause and prognostic outcome with medical supportive care. In patients with 
rapid evolution, hyperacute, the most likely causes are acetaminophen toxicity or hepatitis A 
and E and have a better chance of recovery compared to subacute patients. In children, the signs 
of hepatic encephalopathy are difficult to identify as it can be subtle or late presentation during 
the course of illness. Therefore, for children modifications of ALF criteria are used based 
mainly on coagulopathy, an International normalized ratio (INR) >1.5 with encephalopathy or 
INR>2.0 without any encephalopathy (Squires et al. 2006). 
The most common etiology of ALF in adults are viruses and drugs however, there are 
geographic variations where acetaminophen and other drug induced liver injury are the common 
causes in a developed country (Bernal and Wendon 2013). The causes of ALF in children differ 
from adults because these also vary by age. Viral hepatitis is the most common in south East 
Asia and Latin America, whereas in Northern America and Europe, the most common etiology 
remains indeterminate. However, acetaminophen overdose and Wilson disease have become 
more frequent in the older children with ages 3 to 18 years (Squires et al. 2006; Dhawan 2012). 
According to the unpredictable natural history of ALF the mortality rate of ALF is variable 
depending on the etiology ranging from 10% to 90% without liver transplantation. In the pre-
liver transplantation era, the mortality rate was 80% or higher (Hoofnagle et al. 1995). However, 
the development of multidisciplinary critical care protocols and the use of emergency liver 
transplantation have considerably improved survival rates in recent years with overall mortality 
rate about 30% (Lee et al. 2008). Orthotopic liver transplantation (OLT) is currently the only 
effective approach for treatment. However, the limitations of this therapeutic approach are well 
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known, namely scarcity of organ donors, surgical risk, and requirement for life-long 
immunosuppressive drugs. Furthermore, the decision to proceed to transplantation is not always 
straightforward, because some of these patients might have a chance of spontaneous liver 
recovery. To date, various prognostic evaluation systems have been used to select the ALF 
patient for OLT but none of them provide accurate prediction (Mochida et al. 2008; Bernuau et 
al. 1986; O'Grady et al. 1993). 
More recently, auxiliary orthotopic transplantation has become an exciting concept to bridge 
ALF patients to survival without the need for life-long immunosuppression. The right lobe of 
the native liver is usually resected and replaced with the donor graft while the native left lobe 
remains in situ. The donor graft provides supportive function while the native liver regenerates. 
Within 1-3 years, the immunosuppression is carefully withdrawn resulting in atrophy of the 
allograft. The success of this technique supports the concept of spontaneous recovery of liver 
cell mass. In our experience 20 children underwent auxiliary liver transplantation and 17 
survived. Of these 11 children (65% of the survivors) showed complete native liver recovery 
and subsequent withdrawal of immunosuppression (Faraj et al. 2010). Currently, the alternative 
concepts of liver transplantation to provide adjunctive and temporary liver support for patients 
with ALF the other potential are being investigated including liver support systems and 
hepatocyte or stem cells transplantation  
1.1 Extracorporeal Liver Support Systems  
Extracorporeal liver support consists of artificial and bioartificial liver supports systems. The 
concept of temporary extracorporeal liver support is a life support system comparable to kidney 
dialysis machines, but specifically for liver failure patients. These systems have been 
extensively investigated for over three decades; however, the clinical outcomes have not shown 
significant benefit in improving transplant free survival (Liu et al. 2004; Stutchfield et al. 2011; 
Struecker et al. 2013). Artificial liver support systems are non biological devices incorporating 
hemodialysis, hemofiltration and/or plasma exchange units based on albumin dialysis to clear 
toxins that accumulate in patients. There are two artificial liver support devices have been 
extensively evaluated in the clinical setting, the Molecular Absorbent Recirculating System 
(MARS
®
; Gambro, Stockholm, Sweden) and the fractionated plasma separation and absorption 
system (Prometheus
®
, Fresenius Medical Care, Bad Homburg, Germany), (Khuroo et al. 2004; 
Oppert et al. 2009; Schaefer and Schmitt 2013). Bioartificial systems consist of either porcine 
hepatocytes or hepatoblastoma cells in bioreactors that aim to perform both detoxification and 
synthetic functions. To maintain these complex tasks, liver cells are cultured in a 3D manner 
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within a network of hollow fibers or a porous barrier to isolate cells from immunoglobulins and 
leukocytes in patient’s blood or plasma. HepatAssist® system (Alliqua Inc. Langhorne, PA, 
USA) which is based on cryopreserved porcine hepatocytes and the Extracorporeal Liver Assist 
Device (ELAD
®
; Vital Therapies Inc., San Diego, CA, USA) uses a hepatoblastoma cell line are 
the most common two systems which have been studied (Millis et al. 2002; Demetriou et al. 
2004). The limitations of artificial support systems are due to detoxification being more 
complex than just removal of albumin-bound toxins. In addition, the charcoal and resin might 
absorb growth factors and cytokines that might effect on liver regeneration. The clinical proof 
of efficacy of bioartificial systems is limited by the risk of tumorgenic products, 
immunogenicity (anti-pig IgG and IgM) and xenozoonoses (Struecker et al. 2013). 
1.2 Hepatocyte Transplantation 
Hepatocyte transplantation has been shown to be of benefit as a bridge to transplantation for 
patients with ALF (Fisher and Strom 2006). Hepatocytes provide the essential functions that the 
native liver has lost. The use of hepatocyte infusion into the portovenous system has some 
advantages compared to whole organ or auxiliary liver transplantation. Cell therapy is far less 
invasive than organ transplantation and can be repeated several times if required during the 
clinical course. Hepatocytes are isolated from liver donors that are unsuitable for OLT. Cells 
isolated from one donor can be transplanted into several patients and also can be cryopreserved 
and stored for the scheduled or emergency use. Importantly, the native liver remains in place, 
allowing for the possibility of regeneration and spontaneous recovery (Hughes et al. 2012; 
Dhawan et al. 2010). In addition, in ALF high levels of growth factors may stimulate the 
transplanted hepatocytes to proliferate in the host liver which may result in their beneficial 
effect (Meyburg et al. 2009). Transplantation of hepatocytes has been investigated in various 
ALF animal models. Animals were transplanted with 1-2% of the liver mass via splenic, portal 
or peritoneal transplantation and this led to improvement of the survival rate compared to the 
control groups (Demetriou et al. 1988; Sommer et al. 1979; Sutherland et al. 1977). However, in 
clinical setting to provide efficient function the number of hepatocytes needed maybe higher 
than that for metabolic disorders (5-10% liver mass) and require repeated infusion. The results 
of hepatocyte transplantation in 37 patients with ALF were reviewed by Fischer et al. (2006) in 
which most cases received repeated administration of allogeneic adult human hepatocytes. The 
doses of cells were extremely varied between patients ranging from less than 0.01% up to 
approximately 5% of liver mass in some cases. After transplantation, seven cases fully 
recovered without OLT and half of the patients showed improvement in hepatic encephalopathy 
and a reduction in blood ammonia (Fisher and Strom 2006). Although, the results were 
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promising, all studies to date have been uncontrolled and the sample sizes are too small to draw 
any conclusions. The overall data of hepatocyte transplantation for ALF in both children and 
adult are summarised in Table 1.1. 
Nevertheless, the main obstacles of intrahepatic hepatocyte transplantation in coagulopathic 
patients are the potential risk of bleeding as a result of invasive catheter placement, critical 
shortage of hepatocytes and immunologic reaction necessitating immunosuppression (Soltys et 
al. 2010). To circumvent these limitations, intraperitoneal transplantation as a minimal invasive 
route of cell delivery with cells protected from host immune reaction may be of interest. 
Intraperitoneal transplantation of microencapsulated hepatocytes (hepatocyte microbeads) could 
be an attractive option (Umehara et al. 2001; Aoki et al. 2000). Furthermore the limited supply 
of human liver to isolate primary hepatocytes could be addressed by establishing a good quality 
hepatocyte bank and the uses of alternative cell sources of hepatocyte-like cells such as liver 
stem and /or progenitor, fetal liver and embryonic stem cells (Herrera et al. 2013; Najimi et al. 
2007).  
1.3 Alternative Cell Sources 
The limited availability of primary hepatocytes has encouraged researchers to investigate new 
sustainable sources of cells. Stem cells from both fetal and adult donors are good candidates due 
to their self-renewal and ability to differentiate into hepatocyte-like cells under specific 
conditions (Ishikawa et al. 2012). Hepatocyte-like cells derived from embryonic stem cells 
(ESC) and induced pluripotent stem cells (iPS) which involves reprogramming of the 
development process have shown some benefits in ALF animal models. Machimoto et al. 
(2007) showed that transplantation of hepatic progenitor cells isolated from fetal liver improved 
the survival rate of mice with liver injury. However, the disadvantages of these cells are the 
complexity of the differentiation protocol, ethical issues and more importantly the safety 
concerns of tumourgenicity and immunogenicity which have withheld them so far from clinical 
use. Mesenchymal stem cells (MSC) either from bone marrow, adipose tissue or umbilical cord 
have been intensively studied, given their promise of clinical application. Recently, Li et al. 
(2012) demonstrated that intraportally transplanted human bone marrow MSCs rescued pigs 
with ALF perhaps by promoting liver regeneration and hepatic transdifferentiation. Of note, 
comparison of the therapeutic effects of adult, fetal and embryonic stem cell-derived 
hepatocytes in ALF mice indicated that adult hepatocytes were the most effective cells 




Table 1.1 Clinical experiences of hepatocyte transplantation for patients with ALF 
Etiology Study Pts Infusion Cell dose Route Outcome 
Drug 
 Soriano et al. (1997) 16 yr 1 4.x10
7 
PV Died day 2 
  12 yr 3 1x10
8 
PV Died day 7 
  10 yr 3 2.8x10
9 
PV Died day 7 
 Bilir et al.(2000) 32 yr 1 1.3x10
9 
IS Died day 14 
  35 yr 1 1x10
9 
IS Died day 20 
  55 yr 1 3.9x10
9 
IS Died 6 hrs 
 Strom et al.(1999) 13 yr 1 1x10
9 
PV Died day 4 
  43 yr NA NA NA Died day 35 
 Fisher et al. (2000) 14 yr 1 2.5x10
9 
PV OLT day 1 
 Fisher and Strom (2006) 27 yr 1 2.8x10
7 
IS OLT day 10 
  26 yr 1 1.2x10
9 
IS OLT day 2 





IS Died day 1 
  35 yr 1 5.4x10
9 
PV Died day 18 
  35 yr 1 3.7x10
9 
PV Full recovery 
  51 yr 1 3.9x10
9 
PV Died day 3 
 Habibullah et al.(1994)
a
 32 yr 1 6x10
7
/kg IP Died 30 hrs 
  29 yr 1 6x10
7
/kg IP Died 37 hrs 
  20 yr 1 6x10
7
/kg IP Died 48 hrs 
  20 yr 1 6x10
7
/kg IP Full recovery 
  24 yr 1 6x10
7
/kg IP Full recovery 
Viral 
 Fisher and Strom (2006) 4 yr 2 1.7x10
9 
PV Died day 2 
  54 yr 1 6.6x10
9 
PV Died day 7 
 Bilir et al. (2000) 29 yr 1 1x10
10 
PV,IS Died 18 hrs 
  65 yr 1 3x10
10 
PV,IS Died d52 
 Strom et al. (1999) 28 yr 1 1.69x10
8 
IS OLT day 3 
  37 yr 1 1.2x10
8 
IS Died day 5 
  43 yr 3 2.43x10
8 
PV OLT day 1 
 Fisher et al. (2000) 37 yr 1 8.8x10
8 
IS Full recovery 
 Habibullah et al. (1994)
a
  40 yr 1 6x10
7
/kg IP Died 13 hrs 
Idiopathic 
 Soriano et al. (1997) 3 yr 9 4x10
9 
PV Full recovery 
  5 yr 7 2x10
9 
PV OLT day 4 




PV OLT day 1 







IS OLT day5, died day 
13 
  48yr 1 7.5x10
8 
PV Died day 1 
 Habibullah et al. (1994)
a
 8yr 1 6x107/kg IP Full recovery 
Others (Mushroom poisoning, post-surgical, acute fatty liver of pregnancy) 
 Schneider et al. (2006) 64 yr 1 4.9x10
91 
PV Full recovery 





IS Died day 2 
 Khan et al.(2004)
a
 26 yr 1  IP Full recovery 
a
Fetal hepatocytes. Abbreviation: IP, intraperitoneal; IS, intrasplenic; NA, not available; OLT, orthotopic 
liver transplantation; and PV, portal vein.  
22 
 
1.4 Decellularised-recellularised Liver Matrix 
Tissue engineering has recently developed a novel technique to generate transplantable liver 
grafts with a decellularised liver matrix. This decellularisation process involves removing cells 
and other antigenic material from the liver, but preserves the structural and functional 
characteristics of the native microvascular network and this serves as an ideal biomatrix for 
cellular repopulation. This is followed by recellularisation with cells such as adult hepatocytes, 
stem cells, and stellate cells. The liver matrix is matured in a bio-reactor and then a functional 
liver organoid is produced and implanted in a patient with ALF or it can be incorporated in an 
extracorporeal liver support system. Uygun et al (2010) recellularised the median lobe of rat 
liver with adult hepatocytes and demonstrated comparable viability and function of hepatocytes 
in the neo-liver to that in normal culture conditions. The liver graft was perfused with minimal 
ischemic damage after transplantation into rats (Uygun et al. 2010). Bao et al (2011) 
recellularised rat hepatocyte spheroids into a decellularised liver lobe and implanted this into the 
portal system of rats that had undergone 90% hepatectomy. The transplanted rats showed 
improvement of their liver function and prolonged survival. Although, the results of 
experimental studies are encouraging, the translation of whole organ engineering into the clinic 




Strategies for cell-based therapy in ALF 
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Figure 1.1: Schematic presentation of the strategies of cell therapy in patients with ALF. 
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1.5  Cell Microencapsulation 
Cell encapsulation technology is based on immobilization of transplanted cells in an artificial, 
semipermeable membrane structure which aims to protect cells from both mechanical stress and 
the host’s immune response, while allowing bi-directional diffusion of nutrient, oxygen and 
metabolic products which is essential for cell survival and does not interfere with cell function 
(Figure 1.2). As a result, the encapsulated cells can be transplanted without the need for 
immunosuppression. (Hernandez et al. 2010; Uludag et al. 2000; Zimmermann et al. 2007). 
Moreover, this three-dimensional (3-D) scaffold system provides the possibility of 
transplantation of non-human cells (xenotransplantation) which might be considered as an 
alternative source of cells. Microencapsulation provides a number of advantages over other cell 
therapy systems or devices, including greater surface to volume ratio, ease of implantation and 
retrievability by lavage and needle aspiration (Lanza et al. 1996). Encapsulation has been 
explored and continues to develop over the past three decades due to the promising outcomes. 
The pioneering study carried out by Chang using ultrathin polymer membrane microcapsules 
introduced the term of “artificial cells” (Chang 1964). Later in 1980 Lim and Sun. performed 
the first successful transplantation of xenograft islet microcapsules in rats. Since then, there 
have been tremendous efforts towards developing and understanding the technological and 
biological requirements for transplantation of microencapsulated cells in small and large animal 
models. Pre-clinical in vivo studies were shown to be successful in diabetes (Lim and Sun 
1980), haemophilia (Hortelano et al. 1996), cancer (Cirone et al. 2002), renal failure (Prakash 
and Chang 1996), and Huntington’s disease (Emerich et al. 2006). The encouraging results of 
animal studies have provided a scientific basis for microencapsulated cell transplantation in 
several clinical trials (Calafiore et al. 2006; Lohr et al. 2001; Soon-Shiong et al. 1994). 
However, the progress in this field of research relatively lags behind the expectation. As a 
consequence, in the past few years, a number of studies focused on a stepwise analysis on the 
essential obstacles and limitations of the microencapsulation technique and microcapsule 
properties to gear up this method closer to a realistic proposal for clinical application (Orive et 




Figure 1.2: Schematic diagram of cell encapsulation illustrates the semi-permeable structure 
allowing bi-directional diffusion of oxygen, nutrients therapeutic and waste products while 
protecting cells from immune cells and antibodies. 
1.6 Microencapsulation Methods 
Microcapsules can be classified into five categories based on their structure as demonstrated in 
Figure 1.3 (Whelehan and Marison 2011). Type A, liquid-core microcapsules or simple/single 
core microcapsule; type B, double/multi-shells; type C, polynuclear (multi-core); type D, 
microbeads/microspheres, and type E, irregular or non-spherical shape. Microcapsules are 
typically spherical in shape with a well-defined shell and core (type A-C). The multiple shells 
(layers) are added to modify stability and permeability of microcapsules. However, microbeads 
(type D) in which cells are entrapped within a solid matrix without a coating membrane is the 
most common use in biomedical field. Microbeads can be converted to type A microcapsule by 
adding outer layer followed by depolymerisation of the centre of microbeads. Lim and Sun 
(1980) developed the classical technique of coating poly-L-lysine (PLL) on the surface of the 
alginate microcapsules which has been widely used. However, liquefaction or depolymerisation 
of inner core in the original protocol reduces the structural stability of microcapsules. 
Generally, all methods for microencapsulation are based on simple dropping of polymer into a 
crosslinking solution bath to form solid beads. With the traditional simple dropping technique, 
through a needle, is difficult to the control size of microbeads and there is a low production rate. 
Currently, the prevalent technique is a controlled-size droplet extrusion through a nozzle using 
different mechanical forces to increase the rate of production. The main commonly used are 
coaxial air flow, electrostatic extrusion, vibrating nozzle and jet-cutting (Figure 1.4). The 
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coaxial air-flow and the electrostatic generate droplets at the nozzle tip with additional air-flow 
or electric field surrounding an outer nozzle to enhance dropping (Lewińska et al. 2004; Prüsse 
et al. 2008). The vibrating-jet (nozzle) technique is one of the most widely used methods based 
on the principle of laminar jet-break by vibration frequency with defined amplitude to the 
extruded jet (Senuma et al. 2000; Whelehan and Marison 2011). JetCutter is a new technology 
for high-throughput encapsulation based on a mechanical impact of the rotating cutting wire on 
the liquid jet (Schwinger et al. 2002). Prüsse et al (2008) compared these microencapsulation 
technologies using different viscosities of sodium alginate performed by seven laboratories in 
Europe. They demonstrated that microbeads prepared with alginate contents of 0.5-2.0% were 
uniform in their spherical size all 4 technologies, but only electrostatic and JetCutter produced 
uniform microbeads with high viscosity alginate (3-4%). The production rate of the vibrating 
technique is 20-40 times higher than those of the coaxial air-flow and electrostatic technologies, 
but about 10 times lower than the JetCutter. The JetCutter seems to be an efficient technology 
ranging from lab-scale to industrial production; however, application for the clinical purposes 





Figure 1.3: The microcapsules structural classification.(A) single-core or liquid-core 
microcapsule; (B) double/multi-shells microcapsules; (C) polynuclear (multi-core); (D) 
microbeads/microspheres and (E) irregular or non-spherical shape. [Adapted from Whelehan 




Figure 1.4: Schematic representative of microbeads’ production technologies. [Adapted from 
Prüsse et al. (2008)].  
1.7 Alginates for Cell Encapsulation 
Suitable biomaterials are important in development of encapsulation technologies. Many 
different materials are employed to encapsulate cells such as alginate, chitosan, and agarose. 
Among them, alginate is the most extensively studied and used nowadays due to its excellent 
ionotropic properties, low toxicity and biocompatibility. Alginates are natural polymers found in 
brown seaweeds and in bacterial species. They are composed of linear copolymers of 1-4 linked 
ß-D-mannuronic acid (M) and α-L-glucoronic acid (G) residues. The blocks contain of 
consecutive G residue and consecutive M and alternating M and G residues (Figure 1.5A). They 





), and aluminium (Al
3+
) or polyelectrolytes crosslink with the 
carboxyl group blocks of glucoronic residues, between two different chains resulting in a three-
dimensional network (Figure 1.5B). These structural patterns are similar to extracellular 
matrixes (ECM) of living tissue, therefore are benefit for delivery of bioactive agents (small 
chemical drugs and proteins) and cell transplantation. The mechanical strength, elasticity, and 
swelling characteristics are dependent on the nature of the cross-linking cations, the M:G ratio, 
the percentage of the block structures and the length of polymeric chains (Zimmermann et al. 
2001). Stiffness of cross-linked alginate increases: MG < MM < GG blocks, while the flexibility 
increases: GG < MM < MG blocks. Alginates tend to be contaminated with endotoxins and 
proteins due to their natural origin and are difficult to purify using an in house protocol 
(Zimmermann et al. 2007). However, commercial ultrapure alginate is now available.  
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Modification of alginate is becoming interesting approach to improve the quality of 
microencapsulation by creating polymers that mimic the ECM. A variety of ECM molecules 
(collagen and fibronectin) or synthetic peptides like arginine-glycine-aspartic acid (RGD) were 
studied by mixing together with alginate. Nevertheless, although these modified materials have 
been developed, the in vivo data and the biocompatibility data have not been well-studied. 
Therefore, to date alginate is the most suitable biomaterial for cell encapsulation (Murua et al. 
2008). 
Glicklis and colleagues examined the behavior of rat hepatocytes seeded within a three 3D 
scaffold based on alginate with diameters of 100-150µm, seeding hepatocytes onto the alginate 
sponges was efficient. Total cell number within the sponges did not change over 2 weeks 
demonstrated by DNA measurements indicating that hepatocytes do not proliferate under these 
culture conditions. Most of the seeded cells were viable and provided function including 
albumin production and fibronectin synthesis. They concluded that 3D arrangement of 
hepatocytes within alginate provides a useful environment to facilitate the performance of 
hepatocytes (Glicklis et al. 2000). 
The key elements for alginate microencapsulation for clinical transplantation are 
biocompatibility, stability, permeability and size of microbeads. These parameters need to be 
fine-tuned since enhancing one parameter might cause negative effects on other parameters. 
Moreover, reproducible methods using precise parameters to obtain the optimal quality of 
microcapsules are important, moreover the technique should not affect cell viability and 
integrity both during the encapsulation steps, and after transplantation. Indeed, the success for 
alginate microbeads is maintenance of free exchange of nutrients and oxygen, while waste 
products are freely secreted simultaneously to avoid swelling and subsequent rupture of 
microbeads. Capsule breakage would result in functional loss of cells with graft failure and 







Figure 1.5: (A) The alginate chemical structure, and (B) glucoronate blocks bind the divalent 
ion, “egg box model”. [Adapted from NorvaMatrix]. 
1.7.1  Biocompatibility 
Biocompatibility of alginate microbeads is a critical issue for long-term efficacy following 
transplantation so that alginate microbeads can function without eliciting any undesirable local 
or systemic host responses. Numerous studies have explored three main factors which determine 
the biocompatibility of alginate. Firstly, the degree of alginate purity was shown to be of great 
importance in determining biocompatibility in both in vitro and in vivo studies (De Vos et al. 
1997; Orive et al. 2002). As alginate is a natural polymer, it is important to minimise endotoxin 
and protein content which can affect biocompatibility. According to the Food and Drug 
Administration clinical-grade alginate must have total content of endotoxin < 350EU per 
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patient. Currently, purified GMP alginates have endotoxin content < 100EU/g. Secondly, the 
composition of alginate has been an area of controversy as several studies proposed that alginate 
with high-M content provokes inflammatory responses by stimulating monocytes to produced 
cytokines e.g. interleukins (IL-1, IL-6), and tumor necrosis factor-α (TNF-α), (Espevik et al. 
1993; Otterlei et al. 1991). On the other hand, some studies reported more severe cellular 
overgrowth in high-G alginate capsules (Clayton et al. 1991; De Vos et al. 1997). Finally, the 
positive charge of some polycations used such as poly-L-lysine (PLL) on alginate microbeads is 
shown to be immunogenic. Orive G et al. (2006) found that alginate-PLL-alginate (APA) 
microbeads activated complement and IL-1 and TNF-α production by macrophages (Orive et al. 
2006). Tam et al. (2011) reported that alginate coating was unable to “neutralize” the positive 
charge of PLL on the membrane, hence did not improve the biocompatibility of alginate-
polycation microbeads. Additionally, it has been recognised recently that the implantation 
procedure of microencapsulated cells itself initiated a host response caused by disruption of host 
vasculature associated with the release of bioactive proteins such as fibrinogen, thrombin, 
histamine, and fibronectin. These factors may adhere the microcapsule surface and have a 
chemotactic effect on inflammatory cells during the first days after implantation. Neutrophils, 
basophils, lymphocytes are primarily involve in a transient non-specific reaction which 
gradually disappears from the graft site. Whereas macrophages and some fibroblasts remain 
attached and lead to pericapsular fibrosis at later stages that interfere with diffusion of nutrients 
and oxygen supply. Some small cytokines released during a chronic inflammation process might 
directly damage encapsulated cells leading to cell death and graft failure (De Vos et al. 2006; 
Orive et al. 2006), (Figure 1.6). The degree of biocompatibility of microbeads can be assessed 
by evaluation of pericapsular cell overgrowth, viability of encapsulated cells, and recovery rate 





Figure 1.6: A simplified diagram showing the process of acute and chronic inflammatory 
responses against implanted biomaterial. [Adapted from Hernandez et al. (2010)]. 
1.7.2  Mechanical Stability of Microbeads 
The mechanical properties of microbeads are one of the important factors to ensure the 
persistent therapeutic efficacy of encapsulated cells. Microbeads applied for transplantation 
must be durable to maintain their physical integrity for a period as long as the cells function. 
The mechanical stability of microbeads needed includes stiffness (resistance to deformation) 
and toughness (resistance to fracture) to structurally protect transplanted cells. Nevertheless, 
microbeads may lose their mechanical integrity during the transplantation procedure 
(mechanical stress) or over time post transplantation due to exposure to the hostile environment 
and immune system in a specific transplantation site (Schmidt et al. 2008; Thanos et al. 2007), 
(Figure 1.7). Disintegration of microbeads means impaired immunoprotection from the host 
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response resulting in graft failure. The stability of microbeads mainly depends on the ionic 
linkage between alginate backbone and the gelling cations; divalent (usually calcium) or 
polycations. Under physiological conditions, the microbeads show a tendency to disintegrate 
due to osmotic swelling and calcium ions are constantly exchanged with monovalent ions. In 
fact, increasing the strength of microbeads has to be carefully adjusted owing to the influence on 
other parameters such as permeability and intracellular microenvironment (Chang 2005). Up to 
now, various techniques to improve the mechanical properties and stabilities of have been 
studied. One strategy to enhance the durability of microbeads is using cations with higher 
affinity (Mørch et al. 2006). Among divalent cations, Ba
2+
 provides higher mechanical strength 
of microcapsule than Ca
2+
 and is commonly used to encapsulate pancreatic islets due to long-
term durability (Duvivier-Kali et al. 2001; Li et al. 2006). Zimmermann et al. (2005) produced 
Ba
2+
-gelled microbeads of ultrahigh viscosity of alginate (35%M and 65%G) using a crystal gun 
method strengthening the integrity without impeding flux across the membrane. Although Ba
2+
 
offered high affinity, its toxicity is a concern for clinical used. Covalent stabilisation of alginate 
microbeads has been recently achieved using Staudinger ligation, which is chemoselective 
ligation of azide and phosphine groups. Gattas-Asfura and Stabler (2009) demonstrated that 
covalent binding with phosphine-terminated poly (ethylene glycol) conjugated with azide-
functionalized alginate provide high resistance against osmotic swelling. Addition of an 
alginate-tyramine conjugates which could form both ionic crosslinks with Ca
2+
 and covalent 
links through enzymatic reaction (Sakai and Kawakami 2008). Photoinitaited polymerisation is 
also popular due to the formation of covalent crosslinks, however, photoinitiator solutions and 
the free radical generation following initiation of bond formation can lead to cell toxicity 
(Williams et al. 2005). Coating with polycations such as PLL and poly-L-ornithine (Thanos et 
al. 2007) on surface of the alginate microbeads have been attempted to improve the stability. 
The addition of this polymer layer also effect on permeability within microbeads. Therefore, 
increasing mechanical stability might limit mass transport properties. Moreover, the serious 
drawback of polycations coating is the poor biocompatibility (Anderson et al. 2008; Orive et al. 
2006). 
Microbeads mechanical stability can be assessed by many techniques including subjecting 
microbeads to osmotic shock (osmotic pressure test), applying compressive force, and high 
speed shaking. None of these techniques is well established. Example: osmotic pressure test in 
which microbeads are exposed to deleterious solutions causing swelling of capsules is one of 





Figure 1.7: The impact of external forces on the structural stability of microbeads. (a) Stiff 
microbeads maintain their integrity under stress, while (b) brittle and tough microbeads are 
damaged and fail to protect the cells. [Adapted from Schmidt et al. (2008)]. 
1.7.3  Permeability of Microbeads 
The permeability is a fundamental factor for microbeads as a semi-permeable structure which 
aims to protect the enclosed cells from host immune response but permits nutrients, oxygen and 
metabolites to diffuse across microbeads is needed. Metabolic function and viability of cells 
especially hepatocytes are primarily controlled by transport of oxygen, therefore maintenance of 
sufficient oxygen levels within microbeads is desirable to avoid local necrotic and/or 
hypometabolic cells. Even though this basic principle of permeability has been studied for many 
years, the standard requirement to meet these aims still has not been described. The permeability 
of microbeads is influenced by several factors including the concentration and composition of 
alginate electric charge on microbead surface, and actual size of the microbead. Stabler et al 
(2001) showed that microbeads produced with high molecular weight and concentration of high 
guluronic acid prolonged diffusion of metabolic molecules and interfered with cell growth. The 
effect of residue charges, presence of counter ions, polar and hydrophobic interactions on the 
diffusion of solute have been demonstrated in several studies. The surface charges can be 
measured by the zeta potential and hydrophilicity. A hydrophilic surface is favored for 
microbeads because of its high wettability and low water contact angle, whereas hydrophobic 
surfaces possess a potential for protein adsorption and denaturation leading to immune cells 
adherence to the surface. Tam et al (2011) showed that a polycation coating on alginate 
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microbeads increases the hydrophobicity. A negative surface-charge comparable to the 
encapsulated cell membrane is desirable for microbeads. Similar to hydrophobic surfaces, 
positive charge stimulate adsorption of protein.  
To determine the permeability of microbeads, two main factors are of interest a) the rate of 
solute diffusion which correlates with mass transfer and diffusion coefficient, and b) the pore 
size represents the exclusion limit or molecular weight cut-off (MWCO). MCWO defined as a 
minimum molecular weight of a solute that is entirely rejected by microcapsule membranes (De 
Vos et al. 2009). Most of the studies only focus on MWCO to measure the permeability. 
Rokstad et al. (2011) suggested uncoated Ca
2+-
alginate microbeads are permeable to a molecular 
weight (MW) up to 350kDa, whilst with coated ones the MWCO is much smaller, 120 kDa 
(Dixit et al. 1990). Moreover, coated Ba
2+-
microbeads offer smaller pore size with a MWCO of 
70 kDa (Chang and Prakash 1998). However, MWCO is not enough to predict the diffusion 
properties due to the fact that immersion of microbeads in different solutes results in variation 
of the alginate/solute interaction. Moreover, non-uniform pore size and their distribution across 
membranes may play an important role in microbead permeability. Generally, measurement of 
microbeads permeability is more accurate when using two complementary methods namely size 
exclusion chromatography with dextran molecular weight standards and a series of biologically 
relevant proteins using encapsulated protein A–sepharose (Brissova et al. 1998). Recently, a 
new technique known as the inverse-size exclusion chromatography (ISEC) has been used and 
this is more reliable since this method provides information on both MWCO and on the pore 
size distribution (De Vos et al. 2009). Vaithilingam et al determined the permeability of Ba
2+
 
microbeads using ISEC and found MWCO of a 250 kDa which is permeable to immunoglobulin 
G (IgG), (Vaithilingam et al. 2011). Ideally, immunoglobulins should be completely excluded, 
however several studies shown that even IgG permeate into microbeads the encapsulated cells 
still survive and function (Kobayashi et al. 2003; Lanza et al. 1995). The molecular weight of 
substances of interest is shown in Table 1.2. 
1.7.4  Microbead Size and Morphology 
The spherical shape and suitable size of microbeads is another important factor to take into 
consideration for optimal permeability, mechanical stability and immunocompatibility. 
Conventionally, the diameter of microbeads is between 200µm to 3.0mm (Chang 1995). The 
large size of microbeads may limit an adequate mass transfer properties leading to cellular 
necrosis as the reduction of surface area-to-volume ratio. Stabler et al (2001) observed cells 
death in the centre of microbeads with diameter of 0.9-1mm. Canaple et al (2002) reported that 
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smaller microbeads size (400µm) enhances cell functions by minimising the mass transfer time 
compared to larger microbeads (1mm). In addition, smaller size microbeads are more 
biocompatible than the larger microbeads (Sakai et al. 2006). However, reduction in size 
(<350µm) may lead to decrease in the microbead structural stability (De Vos et al. 1996). 
Zimmermann et al. (2007) reported that the diameter of microbeads needs to be approximately 
600µm for Ba
2+
-gelled microbeads to achieve maximum stability and permeability.  
Physical irregularities of microbeads such as tails, craters and protruding cells may elicit 
immunological response after transplantation. The studies conducted by De Vos et al have 
shown cellular overgrowth infiltrating around a defective site of microbeads (De Vos et al. 
1996; De Vos et al. 2002). 
 
Table 1.2: Molecular weight of various proteins, antibodies, complements and common 
metabolites. 
Substances Molecular weight 
(kDa) 
Substances Molecular weight 
(kDa) 
Immunoglobulin M 950 Prothrombin 72 
Fibrinogen 340 Albumin 66.25 
Factor V 330 Hemoglobin 64 
Complement C4 210 Tumor necrosis factor 51 
Complement C5 195 Factor VII 50 
Immunoglobulin E 190 Nerve growth factor 13 
Complement C3 185 Insulin 9 
Immunoglobulin A 170 Complement C3a 5.73 
Complement C2 170 Complement C5a 4 
Complement C8 163 Glucose 0.20 
Immunoglobulin D 160 Tyrosine 0.16 
Immunoglobulin G 150 Phenylalanine 0.15 
Complement C6 110 Glutamine 0.13 
Complement C7 100 Asparagine 0.11 




1.8 Microencapsulated Hepatocytes 
Microencapsulated hepatocytes (hepatocyte microbeads) were initially developed as a means to 
improve bioartificial liver support system studies in pre-clinical ALF animal models. The 
microbead structure protects cells from mechanical forces such as shear force, and also from the 
direct effect of toxic substances in liver failure plasma (Nagaki et al. 2005). Transplanting 
hepatocyte microbeads can functionally replace the missing metabolic and synthetic function of 
damaged hepatocytes either for a short period bridging an ALF patient to OLT or to allow liver 
regeneration potential recovery without the need for OLT. Intraperitoneal transplantation offers 
considerable advantages in treatment of patients with ALF, without the requirement for 
immunosuppression. 
1.8.1  Microencapsulated Cells for Bioartificial Liver  
Fundamentally, a bioartificial liver system should consist of a large amount of functional 
hepatocytes able to support or stabilise the critical condition of ALF. Hepatocyte cell lines such 
as HepG2, C3A and hepatocytes are the most investigated alternative source of cells instead of 
primary human hepatocytes. Originally, these cells were placed in a bioreactor with direct 
contact of patient blood and/or plasma flow, without secure barriers. Therefore, researchers 
developed systems to address this problem by placing hepatocytes as spheroids in hollow-fibers, 
or microcarriers coated with various biological matrices (Lazar et al. 1995; Nyberg et al. 1993; 
Rozga et al. 1993). However, these systems could not provide an adequate immunoprotective 
barrier. Hence, microencapsulated cells became the method of interest to overcome this 
challenge. Joly et al. (1997) showed that microencapsulated porcine hepatocytes provided 
function and protected cells from large molecular weight molecules, such as immunoglobulins 
suitable for the design of an extracorporeal bioartificial liver (Joly et al. 1997). Several studies 
have shown that alginate encapsulation of hepatocyte-derived cell lines enhances proliferation 
with the expression of differentiated hepatocyte function compared with conventional 
monolayer culture (Kinasiewicz et al. 2008; Rahman et al. 2004; Selden et al. 1999). Khalil et al 
(2001) encapsulated HepG2 and cultured them for 8-9 days to let cells proliferate and then form 
multiple colonies inside. The synthetic and detoxificatory liver functions of HepG2 were 
significantly increased with encapsulated liver cell spheroids (ELS). Moreover, these ELS 
showed the ability to maintain their function in human liver failure plasma due to a protective 
effect by alginate encapsulation (Coward et al. 2009). Another potential advantage of 
microbeads is cryopreservability with recovery of function on thawing in a highly-convenient 
physical form, so as to be ready for charging an extracorporeal device when needed. Currently, 
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the studies in the field of bioartificial liver are continuing with the aim to address the challenge 
of design and production of the devices (Table 1.3) and scale-up from bench to bedside with 
microbeads. The preclinical studies using microbeads in a bioartificial liver device are shown in 
Table 1.4. 
 
Table 1.3: The main design constraints for bioartificial livers (Chan et al. 2004). 
Parameter/component Desired value and property 
Minimum functional capacity 1%-10% of liver 
Maximum promising volume 1L 
Maximum distance between cells and nutrient 
supply 
1mm 
Maximum size of cell aggregates 100µm 
Scaffold material Biocompatible and supports hepatocytes 
differentiated function 
 
Table 1.4: Published preclinical data of bioartificial livers using microencapsulated cells for 
ALF 
Cells ALF animal model  Outcome  Study 
HepG2 
 
Rabbit; acetaminophen Improved systemic parameter of liver 
failure 
Rahman et al.(2004) 
 
Pig; hepatic artery ligation Improved biochemical parameters of 
liver failure 
Selden et al. (2013) 
Porcine hepatocytes 
 




Pig; D-galactosamine (iv) Prolonged survival time and improved 
biochemical parameters 




Pig; portahepatis ligation Improved encephalopathy Desille et al. (2002) 
 
Dog; portacaval shunt and 
CBD ligation 
Improved survival rate and 
biochemical parameters 
Chen et al. (2003) 
a
Internal bioartificial liver  device, 
b
alginate/chitosan microbeads. Abbreviation: 




1.8.2  Microencapsulated Cells for Transplantation 
The concept of hepatocyte microencapsulation for treatment of liver diseases such as ALF and 
metabolic liver disease has been investigated for over two decades. Since 1986, Wong and 
Chang showed encouraging results of microencapsulated hepatocytes for treatment of ALF in a 
rat model. One year later Sun et al. (1987) successfully encapsulated rat hepatocytes using a 
modified alginate-polylysine membrane and demonstrated superior viability and function in 
vitro and after transplantation in the peritoneal cavity of rats for 35 days. The work from the 
same group highlighted that microencapsulated hepatocytes continued to function in vitro up to 
5 weeks. The encapsulated cells produced urea, prothrombin and cholinesterase activity into the 
medium.  
Transplantation of microencapsulated hepatocytes as both allo-and xenograft has been 
extensively studied in animal models without the use of immunosuppression. Intraperitoneal 
transplantation is the most common site used for microbeads in all studies reported except one 
that carried out intrasplenic administration (Aoki et al. 2005). Most of the studies have been 
done using small animals. Only a few studies have been conducted in larger animals for 
example Khan and co-workers (1995) studied ureagenesis of retrieved microcapsulated rat 
hepatocytes in normal rabbits. Rodents were the main animal models used including the Gunn 
rat (Crigler-Najjar type I), Wistar rat, Lewis rat and C57BL/6 mice. The outcome of 
transplantation of microencapsulated hepatocytes in Gunn rats showed a significant reduction of 
hyperbilirubinemia (Dixit et al. 1990; Bruni and Chang 1991), and repeated (monthly) 
transplantation provided long-term correction of hyperbilirubin without any complications 
(Dixit et al. 1992). Dixit et al. (1993) investigated morphology and function of hepatocyte 
microbeads after transplantation in Gunn rats with congenital hyperbilirubinemia for 6 months. 
The hepatocytes in the microbeads remained functioning for 4-6 weeks while viability 
decreased to 50% by the 4th week and almost all cells were dead by the 8th week. In terms of 
morphology, the number of broken or damaged microbeads was higher than intact ones after 2 
months of transplantation and started to further disintegrate. At six months no intact microbeads 
could be recovered from the peritoneal cavity. In addition, numerous microbeads were attached 
throughout the omentum with neo-vascularisation at one month post-transplantation. In contrast, 
all empty microcapsules appeared intact and dispersed throughout the peritoneal cavity until 6 
months.  
In the preclinical setting, a number of approaches such as surgical models and the use of 
hepatotoxic drugs have been developed to induce ALF in a wide variety of animals. Ideally, the 
model should provide a similar pattern to humans with well-defined clinical and biochemical 
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criteria (Newsome et al. 2000). Terblanche and Hickman (1991) established the main criteria for 
an ALF animal model which are widely accepted in research. The model should be reversible, 
suitable for treatment to improve survival, and reproducible giving the recognised clinical 
course (biochemical, histological and clinical changes) and interval of death from ALF. The 
animal size should large enough to permit sufficient blood and tissue samples for analysis. 
Finally, any method used must represent the minimal risk for researchers. The different 
approaches to induce ALF possess individual advantage and disadvantages. Surgical models by 
partial/total hepatectomy lack the effect of inflammatory mediators produced by 
damaged/necrotic hepatocytes and may lack the possibility for reversibility. These limitations 
are overcome in a hepatic ischemic model, however the complexity of the surgical procedure 
require high surgical skills. Whereas chemical models including drugs and toxins are less 
complex and commonly used, the difficulties of reproducibility which may be due to animal-to-
animal variability and/or extrahepatic toxicity are the main concerns. Nevertheless, until now, 
none of the models is considered to reflect human ALF (Newsome et al. 2000; Tuñón et al. 
2009). 
Studies of microencapsulated hepatocytes have been performed in ALF animal models and most 
of them showed promising outcome of both freshly prepared or cryopreserved 
microencapsulated cells by improving survival rate and biochemical parameters of liver failure 
(Table 1.5). The total cell number transplanted as microcapsules required to support the ALF 
condition varies greatly between studies. Some studies suggested that transplantation of 
microencapsulated hepatocytes constituting less than 5% of the total liver mass was sufficient 
for supporting the failing liver and prolonging survival rate of the animals (Umehara et al. 2001; 
Aoki et al. 2005). However, the optimal cell number required in ALF models remains 
controversial. Although the results of microencapsulated cells for treating ALF are promising in 
preclinical studies, nearly all studies were done in rodents. The effect of treatment probably 
should be evaluated in large animal models prior to translation to clinical use. Recently, 
Machaidze et al. (2011) demonstrated that porcine hepatocyte microbeads improved metabolic 
function and survival in baboons with ALF [poster presentation at Cell Transplantation Society 
meeting, Miami 23-26 October, 2011]. 
Over the past few years, several groups have studied methods to improve hepatocyte specific 
function and prolong their viability. Co-culturing hepatocytes with different cell types including 
epithelial-like cells, fibroblast like cells and mesenchymal stem cells are some of these 
approaches. Liu Z et al. (2000) demonstrated the beneficial effect of allogenic bone marrow 
cells on hepatocytes when co-cultured or co-encapsulated compared to hepatocytes alone by 
providing longer viability. Shi and co-workers (2009) obtained similar results for co-
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encapsulated hepatocytes with bone marrow mesenchymal stem cells (MSCs). They observed 
improvement of liver function and survival rate of rats with ALF after transplantation of co-
encapsulated cells. In addition, some MSCs transdifferentiated into hepatocyte-like cells after 
transplantation which expressed albumin and other hepatocyte specific markers. Co-
encapsulated hepatocytes with others cells have been shown to have greater function in vitro 
and improve survival rate of animals with ALF as shown in Table 1.6. The mechanisms which 
underlie the cooperative effect of co-encapsulation with other cell types have not been clearly 
elucidated. Presumptive mechanisms responsible may be from direct cell-cell and cell-matrix 
contact or paracrine effects on hepatocytes (Liu and Chang 2002; Shi et al. 2009). Nevertheless, 
the therapeutic use of stem cells or transgenic cells is not ready for clinical use because it would 
expose patients to the risk of cancer.  
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Table 1.5: Summarised data of microencapsulated hepatocyte transplantation in preclinical studies 
Study Donors/ 
Recipients 





1 Rats/Rats D-galactosamine APA-liquid core NA Improved survival rate Wong and Chang (1986) 
2 Rats/Rats D-galactosamine APA-liquid core NA Improved survival rate  
Viable cells in recovered microcapsules 
Sun et al. (1987) 
3 Rats/Rats D-galactosamine APA-liquid core NA Improved survival rate Cai et al. (1988) 
4 Rats/Mice D-galactosamine APA-liquid core NA Viability of recovered microcapsules was 
increased 
Wong and Chang (1988) 
5 Rats/Gunn Rats
a
 NA APA-solid core 1x10
7 
Reduced serum bilirubin Dixit et al. (1990) 
6 Pigs/Rats D-galactosamine APA-solid core 5x10
7
 Improved survival rate Rivas-Vetencourt et al. 
(1997) 




Improved survival rate 
Decreased ammonia 
Umehara et al. (2001) 
8 Rats/Rats 90% hepatectomy APA-solid core (IS) 2x10
7 
Improved survival rate 
Enable liver regeneration 
Viable cells in recovered microcapsules 




Table 1.5: (Continued) 
Study Donors/ 
Recipients 










Improved survival rate Mai et al. (2005)
b 




Improved survival rate Mei et al. (2009)
b 




 Improved survival rate without 
modifying liver regeneration 
Sgroi et al. (2011) 
12 Pigs/Baboons 75% hepatectomy & 
warm ischemia 
APA-liquid core NA Improved survival rate and 
metabolic function 





/ Rats D-galactosamine APA- sold core 2x10
6 
Improved survival rate and 
metabolic function 
Zhang et al. (2011)
 
a 
Gunn rat is a model for congenital unconjugated hyperbilirubinemia; 
b 
also used cryopreserved microencapsulated hepatocytes for transplantation; 
c
poster presentation at Cell Transplantation Society meeting, Miami 23-26 October, 2011; 
d 
hepatic like-cells from human umbilical cord blood. 




Table 1.6: Summary of co-encapsulated hepatocytes with other cells transplantation in preclinical studies  









Improved viability of 




Liu and Chang (2002) 
2 Rat HC+BMSC Rat with 
D-galactosamine 










Shi et al. (2009) 
3 
 




APA-solid core HC 1.25x10
6 




Improved survival rate, metabolic 
function  and liver regeneration
(b)
 
Teng et al. (2010) 
4 Rat HC+HUVECs Rat with 
D-galactosamine 








Qiu et al. (2012) 
(a)
 Statistically significant when compared to microencapsulated hepatocytes and empty capsules and 
(b)
 statistically significant when compared to 
microencapsulated hepatocytes and co-microencapsulated hepatocytes with hFLSCs. Abbreviation: APA, alginate-poly-L-lysine-alginate; bFGF, basic 
fibroblast growth factor; BMSCs, bone marrow mesenchymal stem cells; HC, hepatocytes; hFLSC, human fetal liver stromal cells; and HUVECs, 





Cryopreservation of hepatocytes for long-term storage and availability in an emergency with 
high quality of cells is key issue in cell therapy for both direct transplantation and bioartificial 
liver support. The fundamental of cryopreservation is to preserve the cells by rapid cooling 
down until freezing and then storing at low temperature over a period of time. The challenge of 
this method is how to freeze the cells without damaging the cellular structure or metabolism and 
maintain high viability after recovering the cells (Fuller 2004).  
The difficulty of developing a good cryopreservation procedure is due to the cells being 
subjected to hostile conditions during both freezing and thawing steps. When the temperature 
drops from 37C to <140C (Karlsson and Toner 1996), biophysical changes occur and water 
will transfer to a crystalline state resulting in ice crystal formation which is the key basis of cell 
damage. Once ice formation has started, the electrolyte concentration surrounding the cells is 
greatly increased, and then intracellular water will diffuse outward by osmosis causing cell 
shrinkage. The extent of cell dehydration depends on the rate of cooling. Cells may acquire 
equilibrium with external solution when reaching sufficiently low temperature (<80C), 
osmotic shrinking gives adequate highly viscosity of the intracellular compartment so that the 
cells eventually vitrify which is relatively stable for preservation (Fuller 2004). However, if the 
cooling is slower than the optimum rate, cells encounter extreme osmotic loss of water and cells 
will collapse on themselves (plasmolysis). Cell death due to prolong exposure to hypertonic 
conditions may occur since the stress of dehydration damages the ultrastructure of cell 
membranes (destabilisation of lipid bilayer and solubilisation of membrane protein), and 
denatures proteins. On the other hand, rapid freezing does not allow sufficient time for water to 
diffuse and equilibrate between intra-and extracellular components. Consequently, the 
intracellular water rapidly freezes and forms intracellular ice crystals which can disrupt 
intracellular structures and the plasma membrane (Mazur 1970). Thawing is another critical step 
that might cause detrimental effects on cells with the influences of temperature and osmotic 
changes. If the thawing rate is too slow then the intracellular ice will reform and coalesce into 
larger crystals and damage cell membranes. Furthermore, rapidly dilution of cryoprotectant by 
ice-cold medium may generate concentration gradients leading to osmotic shock due to inflow 
of water into the cells. Therefore, optimisation of freezing and thawing is important to prevent 
mechanical damage from excess intracellular water loss and ice formation (Loretz et al. 1989; 
Pegg 2002). Another mechanism involved in cell death during cryopreservation is apoptosis. 
Apoptosis of cells, such as hepatocytes, has been initiated during isolation due to the separation 
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of anchorage-dependent cells from ECM, known as anoikis (Cardone et al. 1997; Frisch and 
Francis 1994). Nevertheless, the specific mechanism of cryopreservation-induced apoptosis 
remains unclear. Yaki and colleagues (2001) suggested that the possible underlying mechanisms 
are continued anoikis which activates pro-apoptotic cascade including caspases or from the 
release of cytochrome c from damaged mitochondria to stimulate caspase activation. 
Hepatocytes are very sensitive to cryoinjury, therefore the need of optimisation of 
cryopreservation technique is essential. Numerous studies have investigated a wide range of 
modifications in each step including pretreatment of cells prior freezing, rate of freezing, 
cryoprotectant, basal freezing medium and thawing cells. 
1.9.1  Pretreatment of Cell Prior Freezing  
The quality of cells before freezing is one of the important factors to achieve high yield and 
viable cells after thawing. Percoll
®
 purification has been used to remove dead cells from the cell 
suspension to improve viability, however, a great amount of cell loss was observed. In addition 
Percoll is not suitable in clinical use. Pretreatment of hepatocytes by incubating with 
cryoprotective substances that enhance cellular adenosine triphosphate (ATP) or antioxidants 
such as fructose and/or alpha-lipoic acid and glucose and insulin showed improvement of 
viability and attachment of recovered cells (Loven et al. 2005; Terry et al. 2005). 
1.9.2  Cryoprotectants 
Cryoprotectant is an additive compound that provides protective effect for cells throughout the 
cryopreservation process (Karlsson and Toner 1996; Fuller 2004). Cryoprotectants are classified 
into two types based on their ability to pass through cell membranes. First are permeating 
cryoprotectants such as DMSO, glycerol and 1,2-propanediol. The second group is non-
permeating including sugars, polyvinyl pyrrolidone, and hydroxyethyl starch. Up to date, 
DMSO is the most commonly used. DMSO rapidly permeates into cells to bind to water which 
then decreases ice crystal formation. It interacts electrostatically with phospholipid bilayers and 
preserves membrane integrity during freeze-thaw. In addition, DMSO is an oxygen free radical 
scavenger which is an enhancing factor for cryoprotectants (Fuller 2004). However, DMSO has 
unfavorable effects at high concentration and high temperature and is potentially toxic to the 
cells. Different concentrations of DMSO used for cryopreservation have been studied and 10% 
is the most effective and commonly used (Terry et al. 2006). The addition of DMSO is usually 
carried out at 4C. More recently, studies have shown that trehalose provide protective effect on 
cellular membrane during different stress condition (Katenz et al. 2007). 
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1.9.3  Basal Freezing Solution 
Many different freezing solutions have been used for hepatocyte cryopreservation. Some studies 
use culture medium (WEM or DMEM) with or without FCS and simply add cryoprotectants 
before freezing. However, use of FCS is limited to research use due to the possible of adverse 
reactions and zoonosis. Arikura and co-workers demonstrated that University of Wisconsin 
(UW) solution which was originally developed for hypothermic preservation of organs provided 
cytoprotective effect during cryopreservation of rat hepatocytes (Arikura et al. 2002). UW is an 
intracellular-based solution containing several useful components including lactobionate which 
prevents cell edema and acidosis, hydroxyethyl starch and raffinose increase the intracellular 
osmotic pressure and support the cell membrane. In addition, UW also consists of glutathione 
adenosine (suppress oxidative stress) and allopurinol (stimulates ATP synthesis). 
HypoThermosol (HTS), another hypothermic preservation solution was studied by Sosef et al. 
(2005). They reported that using HTS for cryopreservation reduced the level of cell death and 
provided high viability and hepatocyte function of rat hepatocytes.  
1.9.4  Freezing Protocols and Storage 
Currently, most of the freezing protocols are based on Diener et al (1993) using multi-step slow 
cooling protocols in a controlled rate freezer (CRF). They introduce the key steps of the rapid 
cooling at the point when crystallisation is expected to occur to prevent the heat latent fusion 
and control ice nucleation, and a “hold” step to achieve enough cellular dehydration, and 
consequently diminish the risk of intracellular ice formation. The slow-controlled rate freezing 
protocol is generally accepted as the best strategy for cryopreservation of hepatocytes. A more 
simple technique and still use in laboratories is using isopropanol progressive freezing 
container, “Mr. Frosty”, to freeze the cells at a constant rate of -1C/min by placing them in -
80C freezers (Alexandre et al. 2002). However, the rate of freezing might not be constant and 
thus cause damage to the cells. Other method is direct freezing in freezers (-20C and -80C) for 
a period of time and then plunged into liquid nitrogen (Chesné and Guillouzo 1988; Swales et 
al. 1996). 
The storage after freezing should be keep at temperature less than -130C at which no chemical 
reactions occur. Therefore, cells can be stored and the recovery with viable function can be 
maintained for years (Mazur 1984; Chesné et al. 1993). 
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1.9.5  Thawing 
Rapid thawing at 37C with slow dilution of cryoprotectants with ice cold medium is the well-
known optimal protocol used. This method prevents cell damage from ice crystal reformation, 
osmotic shock and toxicity of cryoprotectants. Some studies added substances to the thawing 
solution to minimise osmotic shock after thawing (Chesné and Guillouzo 1988; Swales et al. 
1996; Baust et al. 2002). Human serum albumin was also added in thawing medium for clinical 
use (Mitry et al. 2010).  
Cryopreservation of hepatocytes has been extensively investigated and developed since 1980s 
(Fuller et al. 1980; Chesné and Guillouzo 1988; Loretz et al. 1989). Many groups have 
attempted to develop new cryopreservation protocols to adequately protect hepatocytes (Adams 
et al. 1995; Hengstler et al. 2000; Ostrowska et al. 2000; Katenz et al. 2007; Terry et al. 2010); 
nevertheless, optimum results without cell damage have not been obtained so far (Stéphenne et 
al. 2010). 
1.10  Cryopreservation of Hepatocyte Microbeads  
With hepatocytes in conventional storage conditions (cell suspension) the cell membrane is no 
longer supported by extracellular matrix which may lead to vulnerability of the outer 
cytoskeletal structure (Koebe et al. 1999). Microencapsulation is an attractive technique for 
protecting hepatocytes against freezing injury. In 1993, Dixit et al cryopreserved 
microencapsulated rat hepatocytes in a freezing solution consisting of 10% DMSO, 20% FCS 
and 70% RPMI kept at -70C for 24h and then stored in liquid nitrogen. They reported that 
cryopreserved encapsulated hepatocytes provided comparable function to cells in culture and in 
Gunn rats. These findings highlighted the possible protective effects of microencapsulation for 
cryopreservation processes. More recently, Aoki and his team studied hepatic function, viability 
and morphology of cryopreserved microencapsulated rat and human hepatocytes in vitro and 
after transplantation into rat spleen. They found that these cryopreserved microbeads retained 
hepatocyte function with high viability after thawing and transplantation (Aoki et al. 2005). The 
mechanisms of protection started to be elucidated by Mahler et al (2003). They described that 
the alginate gel keeps hepatocytes separate from each other avoiding mechanical stress from 
compaction when extracellular fluid decreases and may help support hepatocyte plasma 
membranes. In addition, alginate also prevented cold-induced apoptosis in hepatocytes indicated 
by low level of caspase 3 activity in encapsulated cells. Kusano et al. (2008) studied alginate 
microbeads in depth using cryomicroscopy during the freezing and thawing processes and 
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compared the ultrastructure of encapsulated and nonencapsulated cells to examine the extent of 
injury. The findings showed that alginate gel protects hepatocytes from physical damage caused 
by ice crystal formation (Kusano et al. 2008). However, alginate gel used in encapsulation is 
water rich, which might complicate cryopreservation and therefore optimisation of 
cryopreservation procedures is needed.  
1.11  Alginate Encapsulated Hepatocyte Transplantation in ALF-A 
Pilot Study 
In humans, there are no previous published studies using hepatocytes microbeads for treatment 
of liver diseases. However, therapeutic application of microencapsulated islets has been 
reported in type 1 diabetic patients with promising outcome (Soon-Shiong et al. 1994; Calafiore 
et al. 2006; Basta et al. 2011). An open-label study of neonatal porcine islets encapsulated in 
alginate microcapsule (Diabecell
®
) in patients with type 1 diabetes is currently recruiting 
patients. To date, King’s College Hospital is the only centre that has started a pilot study of 
treatment of children with ALF by intraperitoneal transplantation of human hepatocyte 
microbeads. The study is in progress, and the results are encouraging.  
However, due to shortage of donor organs and lack of availability of freshly isolated 
hepatocytes, cryopreserved cells were used for the preparation of the microbeads transplanted in 
these patients. Although the outcome was promising, the disadvantage of using cryopreserved 
cells is their lower viability compared to fresh cells. Therefore, establishment of an optimised 
protocol for cryopreservation of encapsulated hepatocytes that could to lead to preservation of 
cell viability, synthetic and metabolic activities on thawing is needed. The main advantages of 
this process are to have readily available “high” quality hepatocyte microbeads for clinical 





1.12  Hypothesis and Aims 
1.12.1    Hypothesis 
Optimisation of protocols for production and cryopreservation of GMP grade alginate 
microencapsulated human hepatocytes (microbeads) would lead to enhanced cell function and 
activity, and could be used for clinical transplantation. If cryopreservation of clinical grader 
microbeads is successful, it would be advantageous as they will be available for immediate use 
in emergency case. 
1.12.2    Aims 
 To optimise methods for alginate human hepatocyte microbeads production using GMP 
grade materials  
 To investigate the alloimmune response towards clinical grade human hepatocyte 
microbeads 
 To carry out investigation aiming at establishing an optimised cryopreservation protocol 
for human and rat hepatocyte microbeads  
 To investigate the efficacy and safety of fresh and cryopreserved hepatocyte microbeads 





2. General Material and Methods 
2.1  Materials 
All chemicals and buffer solutions were purchased from Sigma-Aldrich Ltd. (Gillimgham, UK), 
unless otherwise stated. 
2.1.1 Equipment 
Encapsulator (Model: IE-50R; Inotech Encapsulation AG, Dottikon, Switzerland), Dynex MRX 
plate reader (Dynex Technologies Ltd., West Sussex, UK), TecanGeNios Pro plate reader 
(Tecan Group Ltd., Männedrof, Switzerland), and fluorescent microscope (Leica microsystems 
Ltd., Milton Keynes, UK). 
2.1.2  Hepatocytes Isolation Buffer Solutions and Chemicals 
Hank’s balanced salt solution (HBSS) without calcium or magnesium, Eagle’s Minimum 
Essential Medium (EMEM) without phenol red and with calcium and magnesium, and 1M 4-(2-
hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES; Lonza Vervieres, S.p.r.l Vervieres, 
Belgium), ethylene glycol tetraacetic acid (EGTA; Sigma-Aldrich Company Ltd., Dorset, UK). 
Collagenase P (Roche, East Sussex, UK), Earle's Balanced Salt Solution (EBSS; Life 
Technologies, Paisley, UK), isoflurane (Abbott Laboratories, Queenborough, UK), Heparin 
1,000 IU/ml (CP Pharmaceuticals Ltd., Wrexham, UK), intravascular catheters (Jelco

; Smiths 
Medical International Ltd., Lancashire, UK), 2-0 Vicryl
® 
sutures (Ethicon Inc. Livingston, 
Scotland), 4-0 silk suture (Harvard Apparatus Ltd., Kent, UK), silicon-rubber tubing 
(Masterflex

; Cole Palmer, Hanwell, UK), sterile non-woven swabs (10cm x 10cm; Shermond, 
Brighton, UK), two hundred micrometer nylon Cell MicroSieves (BioDesign Inc. of New 
York, NY, USA).  
2.1.3  Cell and Microbeads Culture  
Phenol red-free William’s E medium (WEM), heat-inactivated foetal calf serum (FCS), 2mM L-
glutamine, dexamethasone (100x), insulin (bovine pancreas, 100x), penicillin/streptomycin 
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(Sigma-Aldrich Company Ltd., Gillingham, UK.), CMRL medium (Mediatech, Inc., 
Vancouver, Canada), 6-well, 12-well, 24-well and 96-well plates (Nunc Nalgene, Hereford, 
UK). 
2.1.4 Encapsulation 
Highly purified sodium alginate; low viscosity and high glucoronic acid (PRONOVA™ SLG20; 
NovaMatrix, Sandvika, Norway). 0.9% Sodium chloride (0.9% NaCl; Baxter Healthcare Ltd., 
Norfolk, UK.), calcium chloride (Arum Pharmaceuticals Ltd., Romford, UK). 
2.1.5 Cryopreservation and Thawing  
University of Wisconsin (UW) solution (Bristol-Myers Squibb AB, Hounslow, UK), DMSO 
(WAK-Chemie Medical GmbH, Steinbac, Germany), controlled-rate freezer (Planer, Model: 
Kryo10 CRF; Planer plc, Middlesex, UK), 50% glucose (Hamlin, Pharmaceuticals Ltd., 
Gloucester, UK.), Cryovial

 (2.0ml and 5.0ml; Elkay Laboratories products UK Ltd., 
Hampshire, UK), human serum albumin (20%; Baxter Medical AB, Berkshire, UK). 
2.1.6 Chemicals and Solutions 
Dulbecco's Phosphate-Buffered Saline (DPBS; Gibco, Paisley, UK), VECTASHIELD 
Mounting media (Vector laboratories Ltd., Peterborough, UK), phosphate-buffered saline (PBS; 
Life Technologies, Paisley, UK), and ß -glucuronidase/arylsulfatase (Roche, East Sussex, UK). 
2.2  Methods 
2.2.1 Human Hepatocyte Isolation 
Human hepatocytes were isolated from donor liver tissue (rejected or unused for 
transplantation) or the non-tumoural margin of liver resections from metastatic cancer cases. All 
tissues were consented for research in accordance with the Research Ethics Committee of 
King’s College Hospital. The donor tissues were maintained in UW solution, while liver tissues 
from surgical resection were flushed with ice-cold HBSS to remove blood before isolation. The 
hepatocyte isolation was carried out using a modified collagenase perfusion method based on a 
published protocol (Mitry 2009). This technique involves the uses of three buffer solutions. The 
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first solution consists of EGTA (a calcium chelating agent) which breaks the desmosomal 
junctions of adjacent hepatocytes.  The second is plain HBSS to wash out the EGTA and the last 
solution contains the tissue digestion enzyme collagenase. Briefly, major blood vessels on tissue 
cut surface were cannulated and the cannulae secured in place by suturing. Smaller blood 
vessels were sealed to prevent leakage of perfusion solutions. The three buffer solutions were 
prepared under sterile conditions in a laminar flow cabinet, and maintained at 37C with 
oxygenation throughout the perfusion. The tissue was perfused with the first solution [calcium-
free HBSS+1M HEPES+0.5mM EGTA]. The liver tissue was then perfused with plain calcium-
free HBSS, followed by EMEM containing 0.05% collagenase P. The volume of perfusion 
solution used varied according to the size of liver tissue. In addition, re-circulation of 
collagenase solution was carried out until the tissue was well digested. The cannulae and sutures 
were removed, and the digested tissue was minced in ice-cold EMEM using a pair of sterile 
scissors. The released cell suspension was passed through two layers of sterile swabs (gauze). 
Hepatocytes were purified by washing three times with ice-cold EMEM and centrifugation at 
50xg, 4C for 4min. The total number of hepatocytes and viability were estimated using the 
standard trypan blue exclusion test. All hepatocytes prepared in this study are summarised in 
Appendix I and II. 
2.2.2 Rat Hepatocyte Isolation 
Rat liver was obtained from 200-400g, 8-12 wks old, male Sprague Dawley rats (Harlan Olec, 
Bicester, UK). Animals were housed and received care according to the UK Animal (Scientific) 
Procedures Act of 1986 and the ethical review process of King’s College London. Animals were 
housed under a 12-hour light-dark cycle in a room with temperature 212C and humidity 
5510%, and allowed to acclimatise to these conditions for at least 7 days before use. 
Hepatocyte isolation was performed using in situ collagenase perfusion technique of the liver as 
previously published (Wu and Gupta 2009); (Neufeld 1997) with some modifications. Three 
perfusion buffer solutions were buffer 1 (EBSS 1M HEPES+0.5mM EGTA), buffer 2 (plain 
EBSS) and buffer 3 (2mM CaCl2+0.025% collagenase P). All solutions were adjusted to pH 7.4 
and kept at 37°C in water bath and delivered with a peristaltic pump (Waterson-Marlow 313, 
Watson-Marlow Limited, Falmouth, UK). The animals were anesthetised with isoflurane 
inhalation for the procedure. The rats were secured by taping down the extremities, and then the 
abdominal area was shaved and disinfected with 70% ethanol. A mid-line laparotomy incision 
was performed followed by injection of 100IU of heparin into the inferior vena cava. A 20-
guage intravascular catheter (Jelco
®
) was inserted in the portal vein, placed and secured just 
before the bifurcation with 2-0 silk suture. Liver perfusion with buffer 1 was immediately 
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started at the rate of 20ml/min for 5min. To drain the solution, the abdominal aorta was cut after 
initiating the perfusion. The chest cavity was then opened to insert another cannula, 14-guage, 
into the right atrium via the superior vena cava. The outflow end of the pumping system was 
then transferred from the cannula in the portal vein to the cannula in the heart. The tissue was 
then perfused with buffer 2 for 5min, followed by buffer 3 which contained collagenase for 
10min or until the liver was completely digested. The digested liver was immediately removed 
into a sterile plastic bowl containing 50ml ice-cold EMEM, and the tissue gently minced to 
release the cells. Cell suspension was filtered through swabs and 200µm nylon mesh. Isolated 
hepatocytes were purified by 3x low speed centrifugation (50xg, 4C for 5min) and washed with 
ice-cold EMEM. The total number of hepatocytes and viability were determined using the 
standard trypan blue exclusion test. 
2.2.3 Cell Viability and Yield -Trypan Blue Exclusion Test 
Equal volumes of 0.4% trypan blue and cell suspension were gently mixed and left for 1min at 
room temperature. The two chambers of a neubauer haemocytometer were each filled with 10μl 
of cell/trypan blue suspension and total cell number and cell viability (clear cells that excluded 




In order to separate the viable hepatocytes and improve the overall percentage of viability, 
different concentrations of Percoll
® 
and centrifugation settings were tested. Percoll
®
 (1.13g/ml) 
was mixed with 10x HBSS at 9:1 (v:v). Diluted Percoll
® 
was added to the cell suspension to 
obtain a final concentration of Percoll
® 
to 15-35% and cell density of less than 1x 10
6
cells/ml. 
The mixture was then centrifuged at 2 different speeds (250xg or 100xg), at 4C for 10min to 
separate viable from dead cells. The viable hepatocytes were purified by washing with ice-cold 
EMEM and centrifuged at 50xg, 4C for 4min. Total cell number and viability were determined. 
The optimal setting for human hepatocytes was 25% Percoll
® 
and centrifugation at 200xg, while 
for rat hepatocytes was 35% Percoll
® 
and centrifugation at 250xg. These settings were used 
throughout the study. 
2.2.5 Culture of Human and Rat Hepatocytes 
Isolated human and rat hepatocytes were resuspended in standard hepatocyte culture medium 
which consisted of WEM supplemented with 10% FCS, 10mM HEPES, 2mM L-glutamine, 
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0.1μM dexamethasone, 0.1μM insulin, penicillin (50U/ml) and streptomycin (50μg/ml). 
Hepatocytes were plated in collagen type-I coated 24-, 12- or 6-well plates (Nunc A/S, 




, and incubated in a 
humidified incubator at 37C, 5% CO2. Serum-free culture medium was also used in some 
experiments to avoid any effects of FCS on assay measurements. 
2.2.5.1   Hepatocyte Protein Content 
Hepatocytes seeded onto 24-well plates (3.0x10
5
viable cells/well) were incubated for 24h. After 
incubation, total cell lysate was performed based on Mitry et al. (1997). The protein content of 
each cell lysate sample was determined using the modified Lowry technique (Schacterle and 
Pollack 1973; Lowry et al. 1951). Briefly, 50µl of alkaline copper reagent was added to the 
samples and incubated at room temperature (RT) for 10min. The diluted Folin-Ciocalteu’s 
reagent (200l) was then added, and left for 15min. The duplicates of bovine serum albumin 
standards (0-1mg) and samples were measured at a 650nm wavelength using Dynex MRX plate 
reader. 
2.2.6 Empty and Human Hepatocyte Microbeads 
Empty and human hepatocyte microbeads (EMBs and HMBs) were produced using the IE-50R 
encapsulator (Inotech Encapsulation AG) using clinical grade and GMP materials. 
PRONOVA™ SLG20 sodium alginate (low viscosity and high glucoronic acid; NovaMatrix) 
was dissolved in 0.9% NaCl to give a final concentration of 1.5% alginate solution (w/v), with 
mixing overnight using a magnetic stirrer. The calcium ion-polymerisation solution consisted of 
1.2 % CaCl2 diluted in 0.9% NaCl. The human hepatocyte pellet was gently mixed with alginate 
solution. The sodium alginate (without or with hepatocytes) was drawn into a 50ml syringe, 
which was then attached to the encapsulator. EMBs and HMBs were produced using a 250µm 
nozzle, and polymerised in 1.2% CaCl2 solution for 15min. The microbeads were washed twice 
(7min each) with 0.9% NaCl to remove excess CaCl2, and finally collected in a sterile flask. 
2.2.7 Hepatocyte Microbeads Culture 
HMBs were resuspended in culture medium consisting of CMRL medium supplemented with 
10% FCS, 2mM L-glutamine, 0.1μM dexamethasone, 0.1μM insulin, penicillin (50U/ml) and 
streptomycin (50μg/ml). HMBs were cultured in the medium at a ratio of 1:4 (v:v) and 
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maintained in a humidified incubator at 37C, 5% CO2 for 24h up to 7 days. Supernatants were 
removed and media changed every alternate day. 
2.2.7.1   Depolymerisation of Microbeads to Recover Hepatocytes 
Six alginate depolymerisation protocols based on previous studies (Ringel et al. 2005; Serra et 
al. 2011; Hang et al. 2010; Massie et al. 2011) with some modifications were tested. Briefly, 
250l microbeads were placed in a 1.5ml microfuge tube and washed with PBS. Hepatocytes 
were released from microbeads by mixing with 500l of depolymerisation solution containing 
calcium chelators (sodium citrate, EDTA or EGTA) and incubation at either RT or 37C. The 
released cells were collected by centrifugation at 100xg for 5min. The yield and viability of the 
released cells were estimated. The protocol containing 100mM sodium citrate, 10mM HEPES, 
150mM NaCl and 0.1% glucose (37C, 10min) was less detrimental to viability of the released 
cells with less cell loss compared to pre-encapsulation. This optimised protocol was used 
throughout the study.  
2.2.7.2   Hepatocyte Protein Content in Microbead 
After depolymerisation and recovery of the hepatocytes from microbeads, cells were lysed and 
the measurement of protein concentration was performed using the modified Lowry technique 
(Section 2.2.5.1). 
2.2.8 Cryopreservation Hepatocytes, and Microbeads 
The cryopreservation protocol used throughout the study was based on the protocol for 
cryopreservation of clinical grade human hepatocytes at the Institute of Liver Studies, King’s 
College Hospital, and various cryoprotectants were tested. Table 2.1 shows the standard 
freezing protocol used at Institute of Liver Studies, King’s College Hospital. 
2.2.8.1   Cryopreservation of Hepatocytes  
Cryopreservation solution consisted of UW solution containing 10% DMSO (v/v) and 5% 
glucose (v/v) was prepared and maintained on ice. Hepatocytes were pelleted and then 
resuspended in cryopreservation solutions at the density of 1.0x10
7
cells/ml followed by adding 
the hepatocytes suspension into cryovials. The cell suspension was then maintained on ice 
before the freezing process started (Terry et al. 2010). 
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2.2.8.2   Cryopreservation of Hepatocyte Microbeads 
Microbeads (1ml) were slowly mixed with cryopreservation solution (4ml; UW/10% DMSO/ 
5% glucose) in 5ml cryovials. The microbeads suspensions were then maintained on ice before 
transfer to the controlled-rate freezer (CRF). Table 2.1 shows the standard freezing protocol 
used at the Institute of Liver Studies King’s College Hospital. 
 
Table 2.1: Standard CRF protocol for human hepatocytes  
Step Start 
Temperature 
Rate Time End 
Temperature 
1 8°C -1°C/min 8min 0°C 
2 0°C Hold 8min 0°C 
3 0°C -2°C/min 4min -8°C 
4 -8°C -35°C/min 33sec -28°C 
5 -28°C -2.5°C/min 2min -33°C 
6 -33°C +2°C/min 2min -28°C 
7 -28°C -1°C/min 32min -60°C 
8 -60°C -10°C/min 4min -100°C 
9 -100°C -20°C/min 2min -140°C 
 
When the CRF had reached the start temperature, the cryovials were placed into the tube rack 
inside the chamber, and the set freezing program was run. After the freezing process was 
completed, the tubes were immediately transferred to a -140C freezer and stored for 2 weeks. 
2.2.8.3   Thawing Cryopreserved Cells and Microbeads 
The thawing protocol was based on published protocols (Terry et al. 2010; Steinberg et al. 
1999). Briefly, frozen cell suspension was quickly thawed using a 37C water bath with gentle 
shaking until ice crystals just disappeared, while the tubes were still cold. Ice-cold EMEM was 
slowly added (drop wise) with gentle shaking to dilute the cryopreservation solution, until a 
total volume of 10x thawed cell suspension volume was reached. Hepatocytes were pelleted at 
50xg, 4C for 5min. The supernatant was removed and the cells were washed 2x with ice-cold 
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EMEM and centrifugation at 50xg, 4C for 5min. The pellet was resuspended in a known 
volume of WEM. The cell number and viability was determined using the trypan blue exclusion 
test (Section 2.2.3). The cells were then placed into culture medium at specific culture 
conditions according to the experimental setup. 
Similarly cryopreserved HMBs were thawed and diluted as above, without the need for 
centrifugation as the microbeads easily settle. Note: the thawing solution included adding 2% 
(v/v) HSA to ice-cold EMEM. 
2.2.9 Cell Attachment and Viability 
For these assays, cells were cultured in collagen-coated 96-well plates (5.0x10
4
cells/well). The 
measurements were perform in duplicate and repeated at least 3 times. 
2.2.9.1   Sulphorhodamine (SRB) – Cell Attachment 
Hepatocyte attachment was assessed using the Sulphorhodamine B (SRB) assay (Mitry et al. 
2000). Culture medium was removed from each well of the 96-well plate and cells were fixed 
using 50% trichloroacetic acid (TCA; Sigma-Aldrich). Plates were incubated for 60 min at 4°C. 
Wells were rinsed 5 times with tap-water. Fixed cells were stained with 0.4% SRB (Sigma-
Aldrich) solution for at least 60 min at room temperature. Wells were rinsed 5 times with 1% 
acetic acid to remove unbound dye, and then left to air dry. Cell membrane bound SRB dye was 
then solubilised in 10mmol/l unbuffered TRIZMA-base (Sigma-Aldrich) solution on a plate 
shaker for 1h at RT. Plates were read at OD 564nm using the Dynex MRX microplate reader. 
2.2.9.2   MTT Assay - Overall Metabolic Activity 
The mitochondrial dehydrogenase activity of the plated hepatocytes was assessed using the 
MTT (3-[4, 5-dimethylthiazol-2-y1]-2,5-diphenyl tetrazolium bromide) assay (Mitry et al. 
2009). Briefly, culture medium was removed and wells were washed with fresh medium, 200µl 
of medium containing MTT (0.5mg/ml) was placed in each well, and plates were incubated at 
37⁰C for 4 h. The supernatant was removed and the formazan produced was dissolved in DMSO 
(200µl/well) on a plate shaker for 20min at RT. Plates were read at OD 550nm using the Dynex 
MRX plate reader. 
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2.2.10   Hepatocyte - Specific Functional Assays 
The assays described below were performed on cells cultured in collagen-coated 24-well plates 
(3.0x10
5
cells/well) and the measurements were done in duplicate. The data obtained were 
normalised based on the protein content of each well. 
2.2.10.1   Albumin Production 
Albumin production by hepatocytes was quantified in culture (supernatant) medium after 24h of 
incubation using, human or rat albumin ELISA quantitation kits (Bethyl Laboratories, 
Montgomery, USA). All steps were performed at RT. Briefly, 96-well plates (Nunc-immuno 
plates C96 Maxirorp; Nunc A/S, Roskilde, Denmark) were coated with goat affinity anti-
albumin antibody for 1h, washed with wash solution (0.05% Tween 20/Tris-buffered saline) and 
then blocked with 1% BSA/Tris-buffered saline for 30min. Duplicates of albumin standards 
(6.25-400ng/ml) and samples were placed in wells and incubated for 1h, followed by 5x washes. 
Diluted HRP detection antibody was then placed in all wells and incubated for 1h followed by 
5x washes with wash solution. Finally, TMB substrate solution (KPL, Gaithersburg, USA) was 
added the plate was kept in the dark for 15min followed addition of with stop solution to stop 
reaction. The absorbance at 450nm was measured using the Dynex MRX plate reader. 
2.2.10.2   Urea Synthesis 
Urea synthesis was analysed in supernatant collected at same time for albumin assay. Medium 
was replaced by serum free culture medium containing ammonium chloride (NH4Cl; 5mM) and 
plates were re-incubated for 6h. The supernatants were collected and analysed using 
QuantiChrom
TM
 Urea Assay Kit (BioAssay Systems, Hayward CA, USA) to determine the 
amount of urea secreted into the medium. The optical density at 470-550nm (peak absorbance at 
520nm) was measured using the Dynex MRX plate reader. 
2.2.11   Viability of Hepatocyte Microbeads 
2.2.11.1   Cell Membrane Integrity Assay 
Qualitative assessment of cell viability was performed using cell membrane integrity assay. 
100µl HMBs were washed and resuspended in 1ml Dulbecco's Phosphate-Buffered Saline 
(DPBS) followed by incubation with 10μl/ml fluorescence diacetate (FDA: Sigma-Aldrich, 
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Gilingham, UK) and 20μl/ml propidium iodide (PI; Sigma-Aldrich, Gilingham, UK), in the dark 
for 90 sec at RT. Microbeads were washed 3x with DPBS followed by adding 
VECTASHIELD
®
 Mounting Media and then visualised under fluorescent microscopy (Leica 
Microsystems Ltd.). These fluorescent dyes penetrate the structure of the microbeads and live 
cells cytoplasm appeared bright green (FDA), while dead cells had bright red stained nuclei 
(PI). The samples were examined under the fluorescence microscope and photographs of 
representative fields were taken. 
2.2.11.2   HMBs - Overall Metabolic Activity-MTT Assay 
Viability of encapsulated hepatocytes was evaluated using the MTT assay (Section 2.2.9.2) with 
some modifications. A known weight of HMBs was placed in a microfuge tube and gently 
washed with PBS. MTT solution (5mg/ml MTT in PBS) was diluted in plain medium (1:10). 
HMBs were incubated in 500μl diluted MTT at 37C for 4h, and then washed twice with PBS. 
Formazan formed by cells was dissolved using 500μl DMSO and vigorous shaking for 20min 
followed by a brief high speed centrifugation for 2min. The optical density of supernatant was 
read (550 nm) in 200μl duplicates in 96-well plate using the plate reader. The data values are 
presented as OD reading/100mg HMBs. 
2.2.12   Hepatocyte - Specific Functions of Hepatocyte Microbeads 
2.2.12.1   Albumin Production 
The amount of albumin secreted by encapsulated hepatocytes over 24h was quantified in culture 
medium using the human or rat albumin ELISA kit (Section 2.2.10.1). 
2.2.12.2   Urea Synthesis 
To quantify urea synthesis, 500μl HMBs with 1ml serum free medium containing 5mM NH4Cl 
and placed in each well of 12-well-plate. After incubation for 6h incubation, at 37C 
supernatants was collected and analysed using the urea kit (Section 2.2.10.2). 
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2.2.12.3   Cytochrome P450 (CYP1A1/2) Activity 
Cytochrome P450 (CYP1A1/2) activity was assessed using the ethoxyresorufin O-dethylase 
(EROD) method (Donato et al. 1993) with some modifications. Microbeads (500μl) were 
incubated in 1mL serum free medium containing 8μM of 7- ethoxyresorufin and 10μM of 
dicumarol for 1h. 500μl of supernatant was collected and placed in 1.5ml microfuge tube 
followed by adding of ß-glucuronidase/arylsulfatase (Roche, East Sussex, UK) and incubated 
for 2h at 37°C when the reaction was stopped by addition of ethanol. The fluorescence was 
measured at 530nm excitation, 590nm emission using a TecanGeNios Pro plate reader (Tecan 
Group Ltd., Männedrof, Switzerland). The total amount of resorufin produced was calculated 
using a resorufin standard curve (0-800pmol), and data were expressed as pmol/mg 
protein/min). 
2.2.13   Statistical Analysis 
Data were analysed using GraphPad Prism
®
 6 software (GraphPad, San Diego, CA) and SPSS 
20 software (Ver.20; IBM, Hampshire, UK). All data are presented as the meanstandard error 
of the mean (meanSEM) from at least 4 independent experiments unless otherwise stated. 
Student t-test was applied to compare two independent groups. Comparison between three or 
more groups with one independent variable was performed using one-way analysis (ANOVA) 
and multiple comparisons were adjusted by using either Turkey or Bonferroni test. A two-way 
repeated measurement ANOVA and Turkey’s multiple comparisons test were used to compare 





3. The Encapsulation and Settings Optimisation 
3.1 Introduction 
The successful application of hepatocyte microbeads for clinical transplantation requires 
optimised methods for producing a homogeneous uniform size and spherical shape, which can 
achieve mechanical stability without compromising permeability and biocompatibility. The 
techniques should be simple and provide high production yield and importantly can be 
performed under sterile conditions. Currently, most of hepatocyte microencapsulation methods 
are based on liquid extrusion through a nozzle (orifice) and incorporate mechanical forces such 
as vibration or cutting forces to generate droplets follow by gelation in a solution bath. These 
methods give size-controlled microbeads and minimize production time compared to 
conventional methods. The vibrating–jet (nozzle) technique is widely used on a laboratory scale 
and can be applied for clinical grade production due to its enclose system design with 
autoclavable production vessel (Figure 3.1 A). The controlled break up of a laminar jet to obtain 
uniform size of microbeads can be achieved with optimum parameters including frequency, 
amplitude, and liquid flow rate to create a permanent sinusoidal force (Serp et al. 2000). The 
encapsulator IE-50 R used in this study uses this principle. The diagram of the device is shown 
in Figure 3.1B. Previous studies have suggested that the favorable size of microbeads that offers 
mechanical strength and effective mass transfer is in the range from 400µm to 600µm (De Vos 
et al. 1996; Canaple et al. 2002; Zimmermann et al. 2007). For future clinical application, the 
Encapsulator IE-50 R with 250µm nozzle was used in this study. The aim of this study was 
investigated the optimal and reproducible encapsulator setting that produce the controllable size 








Figure 3.1: Encapsulator device based on vibrating jet nozzle technique (A) The encapsulator 
main control unit (left), and reaction vessel (right), and (B) the schematic representation of the 
Encapsulator IE-50 R. [Adapted from Inotech Encapsulator operation Manual, and Whelehan 
and Marison (2011)]. 
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3.2 Materials and Methods 
3.2.1 Materials 
Highly purified sodium alginate; low viscosity and high glucoronic acid (PRONOVA™ SLG20; 
NovaMatrix, Sandvika, Norway). 0.9% Sodium chloride (0.9% NaCl; Baxter Healthcare Ltd., 
Norfolk, UK.), calcium chloride (Arum Pharmarmaceuticals Ltd., Romford, UK). Encapsulator 
(Model: IE-50R; Inotech Encapsulation AG, Dottikon, Switzerland), Light microscope (Leica, 
GmbH, Wetzlar, Germany), and Image J software ver. 1.44p (National Institutes of Health, 
USA). 
3.2.2 Methods 
3.2.2.1   Optimisation of Encapsulator Settings 
Encapsulation runs were performed to determine the optimal encapsulator settings [vibration 
frequency (Hz), amplitude voltage (kV), syringe speed, and amplitude] that result in obtaining 
the highest quality microbeads. A total of 10 runs were performed without cells (empty 
microbeads; EMBs), and then an additional 6 runs were performed with human hepatocytes 
(hepatocyte microbeads; HMBs). The optimal settings were then used in the other experiments. 








Figure 3.2: Charts from Inotech Encapsulator IE-50R manual. (A) Influence of the liquid jet 
velocity and the nozzle diameter on the flow rate and (B) influence of the vibration frequency 







3.3.1 Setting Up the Encapsulator 
A total of 16 runs were performed in this set of experiments, consisting of 10 runs to produce 
EMBs, and 6 runs to produce HMBs. Details of parameters in each run used in each experiment 
for microbeads are shown in Table 3.1 and Table 3.2 respectively. The optimal settings were 
then used in other experiments. 
 








1 1880 4 0.00 292 Too large 
2 1676 4 0.00 290 Varying in sizes 
3 1386 4 0.00 350 Majority joined/fused 
4 1079 4 0.00 401 Varying sizes; tailed 
Microbeads 
5 2055 4 0.47 450 Varying in sizes; tailed and 
joined/fused microbeads 
6 1150 4 0.51 339 Varying sizes; large and/or 
joined/fused microbeads 
7 1784 3 0.55 360 Improvement on 6, however still 
too large 
8 1353 3 0.00 387 Microbeads generally small and 
uniform 
9 1206 4 0.63 326 Very large, mainly round but 
with some few odd shaped 
microbeads 











Syringe Speed Comment 
1 1312 4 0.5 340 Microbeads round, but 
large 
2 1296 3 0.72 310 Good size microbeads, 
but not uniform 
3 1295 4 0.72 281 Good shape microbeads, 
but a “little” large 
4 1295 4 0.73 316 Ideal size and shape 
microbeads 
5 1302 4 0.71 433 Microbeads small, but a 
few different shapes 
6 1303 4 0.71 236 Best microbeads size and 
shape 
 
Best quality EMBs were obtained when the encapsulator settings were set to 
frequency=1185Hz, amplitude=4, voltage=0.49kV, and syringe speed=385. The microbeads 
were round with smooth regular surface, and a mean size was 50030μm. For hepatocyte 
microbeads, they were: frequency=1303Hz, amplitude=4, voltage=0.71kV and syringe 
speed=236. Similar to the blank microbeads they were also uniform with smooth regular 
surface, and a mean size of 50050μm. These settings were used throughout the reported 








Figure 3.3: Representative images of microbeads produced using different encapsulator 
settings. Microbeads examined under light microscopy; right panel shows EMBs morphology 
and left panel shows HMBs morphology. (A)-(C) Imperfect or non-uniform microbeads and, 








The main principle to obtain uniform microbeads according to the vibrating-jet (nozzle), 
technique is optimal range of vibration frequency and jet velocity (Heinzen et al., 2004). 
Microbead size can be adjusted by other parameters including nozzle diameter and viscosity of 
alginate. The general rule of Inotech encapsulator (IE-50R) for producing microbeads using 
sodium alginate at concentration 1.5%-2.0% is that the size of microbeads is approximately 
twice the nozzle diameter. The increasing frequency of the setting, the microbeads produced are 
smaller for a given nozzle size, while higher speed of the setting provided high production 
capacity with larger size microbeads. Surface tension of calcium chloride might cause deformity 
of microbeads (tail) if the setting is not appropriate.  
In this study, the optimal settings for EMBs and HMBs were achieved. Certain settings gave 
standing chain of drops which were clearly seen through the Stroboscope light. Microbeads 
productions run with these setting were of uniform spherical shape and size of 500µm (with the 
range of ±20%). And also reproducible outcomes were obtained with these settings. For 
consistency and better reproducibility, all materials involving in the process of encapsulation 
should stay with the same quality/brands.  
In conclusion, the encapsulator used in this study was easy to set-up and use. Also, high quality 





4. Optimisation of Microbeads Production 
4.1 Introduction 
The clinical application of microbeads is critically dependent on the ability of microbeads to 
protect the encapsulated cells from immune system. As a result, the mechanical stability of 
microbeads is a crucial factor for clinical transplantation. Microbeads need to maintain their 
integrity during transplantation and in the implant site, as their breakage would result in 
functional loss of cells and immune rejection. In addition, microbeads need to be strong enough 
to resist stress during cryopreservation and thawing. The mechanical stability can be optimised 
by using different types and concentration of cation, fine-tuning the duration time of cross-
linking (polymerisation), and adjusting the spatial distribution of cells. Although, cations with 




provide high stability, Ca
2+
 was used in this study for safety 
reasons. The polymerisation (gelling) process involves interaction of alginate polymers 
(negative charge) with cations and time required for crosslinking. Theoretically, a longer 
duration of polymerisation allows more time to form cross-links to give better durability of 
microbeads and also smaller pore size of the microbeads membrane. However, increasing the 
gelling time may have detrimental effects on cell viability by prolonging exposure to chemicals 
and also reduces of oxygen and nutrient permeability.  
The number of cells per microbead is one of parameters that have to be considered to obtain 
sufficient function. As a consequence of increasing the number of cells, the demand of oxygen 
and nutrient would increase while the compactness of cells within the microbeads might impede 
mass transport. The nutrient and oxygen transport-limitation across microbead could lead to 
cells death especially in the centre of microbeads (Huang et al. 2012). In addition, incorporation 
with various numbers of hepatocytes in alginate would have effects on the structure and the 
stability of the microbeads produced. 
The aims of this study were to determining the effects of polymerisation on the mechanical 
stability of microbeads and encapsulated hepatocyte viability and function and also studying the 
influence of cell density on cell viability related to the pattern of cell distribution within 
microbeads and the effect on physical integrity to determine the ratio of cell mass per volume of 
alginate which should be used. The permeability of optimised microbeads was also evaluated.  
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4.2 Materials and Methods 
4.2.1 Materials 
All chemicals used in this study were from Sigma-Aldrich (Gillingham, UK), unless otherwise 
stated. Light microscope (Leica, GmbH, Wetzlar, Germany), Image J software ver. 1.44p 
(National Institutes of Health, USA), Leica SP5 confocal microscope (Leica Microsystems Ltd, 
Milton Keynes, UK), Volocity software (Perkin Elmer, Cambridge, UK), Mathematica ver. 8.0 
(Wolfram Inc., Oxfordsire, UK), microcon
®
 centrifugal filter device (Merck, Darmstadt, 
Germany), and Mini-Protean tetra cell system and Precision Plus Protein™ standard (Bio-Rad 
Laboratories Ltd, Hertfordshire, UK).  
4.2.2 Methods 
4.2.2.1   Assessment of Physical Integrity of Microbeads using Osmotic Pressure Test 
EMBs and HMBs were produced without and with human hepatocytes (2.5x10
6
 cells/ml 
alginate), respectively (Section 2.2.6). Microbeads were made using 3 different polymerisation 
times (10, 15, and 20min). Physical stability of microbeads was determined using an osmotic 
stress test (Van Raamsdonk and Chang 2001). Briefly, after production, 250μl of EMBs were 
equilibrated in serum-free medium, then incubated for 3h in four hypotonic solutions (culture 
medium diluted with water) and one isotonic solution [either William E medium (WEM) or 
CMRL], to establish the stability of microbeads. The hypotonic solution was made by diluting 
serum free medium with distilled water. Solutions of 0%, 0.78%, 3.25%, 6.25% and 100% 
serum free medium were 0, 2.3, 9.2, 18.4 and 295mOsm, respectively. The stability of 
microbeads was assessed after 3h of incubation by measuring the microbead diameter of 100 
microbeads per sample under light microscope, and using Image J software. Microbeads 
immediately after production were used as controls. Based on EMBs findings, physical stability 




4.2.2.2   Assessment of the Effect of Polymerisation Time on Cell Viability and 
Functional in HMBs 
To study the effect of polymerisation time in CaCl2 on hepatocyte viability and function, three 
polymerisation times (10, 15, and 20min) were used in the production of HMBs and the 
products were divided into two sets. First set: HMBs were exposed to osmotic stress test 
(Section 3.2.2.2) followed by MTT assay to assess encapsulated cell viability (Section 2.2.11.2). 
Second set: HMBs were maintained in supplemented CMRL medium for 24h before being 
assessed. Viability and hepatocyte-specific functions of encapsulated cells including albumin 
(Section 2.2.12.1) and urea production (Section 2.2.12.2) were evaluated after maintenance in 
culture for a further 24h. 
4.2.2.3   Effects of Cell Density on Microbead Morphology, Cell Viability and 
Function 
HMBs were produced using four cell densities: 2.0, 2.5, 3.0 and 3.5 million cells/ml alginate 
using the same batch of cryopreserved human hepatocytes for each experiment. A higher cell 
density at 4.0x10
6
cells/ml alginate was also studied in preliminary experiments, however, it was 
observed that most of the HMBs obtained varied in size (range: 400-1200μm), and some with a 
distorted shape. Therefore, 3.5x10
6
cells/ml alginate was the maximum cell density studied. 
HMBs were maintained in culture for 3 days. Microbead morphology was examined 
immediately after production (control). Cell viability was assessed at day 1 by two techniques 
including cell membrane integrity and MTT assays (Section 2.2.11). It was assumed that an 
increase in cell number per microbead, might affect the distribution and viability of the cells, 
hence confocal microscopy with three dimensional (3D) reconstruction images of the 
microbeads were used to determine the cell viability in relation to cell distribution across the 
microbead (outer and inner halves), and in estimating the average number of cells per 
microbead. Hepatocyte-specific functions (Section 2.2.12) were evaluated on days 1 and 3. 
4.2.2.4   Confocal Microscopy to Assess Cell Distribution and Viability Across 
Microbeads 
250µL microliter HMBs were stained with FDA/PI in DPBS for 90sec at RT. VECTASHIELD
® 
Mounting Medium was added to prevent photo bleaching. HMBs were loaded onto a glass slide 
with a well followed by addition of a drop of glycerol to minimise microbead movement during 
imaging. Using a Leica SP5 confocal microscope (Leica Microsystems Ltd, Milton Keynes, 
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UK), microbeads were imaged at 700Hz using a 10x dry objective. The number of slices 
acquired as dictated by Nyquist oversampling of the optical slice volume resulting from a 
pinhole size of 1 Airy Unit at a wavelength of 595nm for the entire volume of the microbead.  
Image stacks were imported into Volocity software and both green and red objects were 
detected using a custom protocol defined therein based on size, standard deviation intensity, and 
local contrast adjustment. The centre point of each microbead was defined by bisecting lines 
through the diagonals of the microbead volume. The x-y-z centroid coordinate of each cell was 
exported, along with the x-y-z coordinate of the microbead’s centre, and then imported into 
Mathematica 8.0 (Wolfram Inc., Oxfordsire, UK). Viability was calculated as the ratio of green 
cells/total number of cells (green + red). For each microbead, the viability and cell count for 
inner and outer bead halves was calculated as a function of distance from the microbead centre 
coordinate and the outer most point on the edge of the microbead. 
4.2.2.5   Permeability Measurement 
Cryopreserved hepatocytes (n=2) were used in this set of experiments. Cell viability after 
thawing was 60% and 70%. HMBs were produced using optimised polymerisation time and cell 
density and cultured in CMRL medium supplemented with 2mM L-glutamine, 0.1μM 
dexamethasone, 0.1μM insulin, penicillin (50U/ml) and streptomycin (50μg/ml) at 37C for 
24h. Supernatants of HMBs cultures were collected and store at -80C until required for 
analysis. To assess the permeability of microbeads, the detection of proteins that diffused across 
microbead relative to the molecular size (molecular mass) was performed using 2D 
electrophoresis and proteomics analysis. 
4.2.2.5.1   Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) of 
Proteins 
The supernatants of microbead culture samples were thawed then transferred into microcon
®
 
centrifugal filter device and centrifuged at 14,000xg for 12min at RT to concentrate the proteins. 
Protein concentration was measured using modified Lowry technique (Section 2.2.5.1). To 
precipitate the proteins, the concentrated samples (100µl) were mixed with acetone (400µl) and 
incubated at -20C for 1h followed by centrifugation at 14,000xg, at RT, for 10min. 
Supernatants were gently removed and protein pellets were air-dried to eliminate any residual 
acetone residue. The pellets were resuspended in 2x Laemmli sample buffer containing β-
mercaptoethanol and heated at 95C for 5min to denature the proteins. After cooling, 10µl per 
sample, and protein standard marker (Precision Plus Protein™ Standard; MW 10-250kD) were 
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loaded onto a 12% polyacrylamide gel. Electrophoresis was performed using Mini-Protean
®
 
Tetra cell system (Bio-Rad Laboratories Ltd, Hertfordshire, UK) operated at 100 volts for 1h. 
After the run, the gel was removed from its cassette, washed three times with water and stained 
with Coomassie brilliant blue for 2h then washed again with water for at least 30min to remove 
unbound background dye from the gel, leaving stained proteins visible as blue bands on a clear 
background. The image of protein bands on gel was capture using GeneGenius image system 
(Syngene, Cambridge, UK). 
4.2.2.5.2   Proteomics Analysis 
The proteomics analysis was performed at the Centre for Translational Omics, Institute of Child 
Health & Great Ormond Street Hospital for Sick Children, University College London. Briefly, 
supernatant samples were freeze-dried and their proteins precipitated using acetone. Each 
protein pellet was resuspended in 20μl of 100mM Tris, pH 7.8, containing 6M urea, and left 
shaking at RT for 1h. Disulfide bridges were reduced and free thiol groups were 
carboamidomethylated. The reaction mixture was then diluted with 155μl H2O and vortexed, 
before the addition of 2μg sequence-grade trypsin and digestion overnight at 37 °C in a water 
bath. A standard yeast enolase digest was used as an internal standard for the quantification of 
each protein. All analyses were performed using a nanoAcquity UPLC and QTOF Premier mass 
spectrometer (Waters Corporation, Manchester, U.K.). ProteinLynx GlobalServer version 2.4 
(Waters, U.K.) was used to process all data acquired. Protein identifications were obtained by 
searching a human proteome UniProt database to which the sequence of P00924 yeast enolase 
was added manually. Protein identification from the low/high collision spectra for each sample 
was processed using a hierarchical approach where more than three fragment ions per peptide, 
seven fragment ions per protein, and more than two peptides per protein had to be matched. 
Since single peptide protein identifications are more likely to represent false-positive data 
points, all proteins with greater than two peptides identified with high confidence were 
considered for protein quantification. Carboamidomethylation was set as a fixed modification, 
and oxidation was set as variable modification. The average intensity value of the top three 
ionizing peptides to yeast enolase was used to convert the average intensity of the top three 
ionising peptides for proteins to the corresponding absolute quantity of protein loaded on 





4.3.1 Effect of Optimal Polymerisation Time on Physical Integrity 
4.3.1.1   Physical Integrity of EMBs 
EMBs obtained were of uniform shape and size. The mean diameter of microbeads in the 10min 
and 15min polymerisation groups were similar (599.2±1.4μm vs 599.2±1.8μm); whereas, 
microbeads in the 20min polymerisation group (605.7±1.2μm) were of larger size than the other 
two groups. With all hypotonic solutions tested, the size of EMBs samples were significantly 
larger compared to control (p<0.001). It was also observed that in water (most stressful osmotic 
condition), EMBS showed marked changes in diameter, but none of the microbeads ruptured 
(Figure 4.1). EMBs maintained their size when incubated for 3h in isotonic CMRL medium, but 









Figure 4.1: Representative examples of mean diameter of EMBs after exposure to osmotic 
stress. Control (top row); and after exposure to water for 3h (below) showing an increase in 












Table 4.1: The size of microbeads produced using 3 different polymerisation times, 
immediately after production and after exposure to isotonic and hypotonic solutions for 3h  
Data presented as mean SEM; p-value <0.01 was considered statistically significant; NS, not 
significant. 
 
Comparing three different polymerisation times, EMBs in the 15min polymerisation group 
tended to resist osmotic shock better than those in the 10min and 20min polymerisation groups 
by showing a significantly lower mean difference in diameter after exposure to almost all 




Polymerisation time (min) 








EMBs in WEM       
Control 567.0  1.2  577.5  1.2  587.9  1.9  
0 mOsm 696.3  5.1 < 0.001 629.9  1.3 <0.001 673.0  2.9 < 0.001 
2.3 mOsm 676.2  3.8 < 0.001 660.3  1.7  < 0.001 659.8  2.8 < 0.001 
9.2 mOsm 673.6  3.1 < 0.001 654.3  1.5 < 0.001 645.5  3.1 < 0.001 
18.4 mOsm 659.4  3.0 < 0.001 642.2  1.2 < 0.001 633.3  2.6 < 0.001 
295mOsm  561.3  0.9 0.001 559.5  1.2 < 0.001 582.0  1.9 NS 
EMBs in CMRL       
Control 599.2 1.4  599.2 1.8  605.7  1.2   
0 mOsm 700.0  2.2 < 0.001 680.6  1.8 < 0.001 724.5  1.5 < 0.001 
2.3 mOsm 697.2  2.4 < 0.001 673.7  2.5 < 0.001 705.2  1.9   < 0.001 
9.2 mOsm 671.1  1.7 < 0.001 679.7  1.7 < 0.001 697.5  1.4 < 0.001 
18.4 mOsm 667.9  2.0 < 0.001 666.9  2.2 < 0.001 691.1  1.5 < 0.001 
295mOsm  597.0  1.4 NS 595.3  1.7 NS 606.4  1.2 NS 
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4.3.1.2   Physical Stability of HMBs 
HMBs in all three control groups were uniform with a mean diameter of 584±0.9µm (10min), 
582.2±1.2µm (15min), and 584.4±1.2µm (20min), with no statistical difference between the 3 
polymerisation groups. After incubation for 3h in CMRL and water, HMBs showed a similar 
trend as is observed in EMBs with no broken microbeads in all conditions (Figure 4.2). There 
was a significant increase in mean microbeads `diameter in all samples incubated in hypotonic 
solution compared to both control and CMRL groups (p<0.001), but this was not different when 
comparing control to CMRL (3h). The 15min polymerisation HMBs group had a significantly 
better mechanical stability compared to the other two groups (p<0.001) with a mean microbead 
diameter difference of 7.1μm (10min vs 15min), and 23.5μm (20min vs 15min) after exposure 





Figure 4.2: Representative examples of mean diameter of HMBs after exposure to osmotic 
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Figure 4.3: Effects of osmotic shock on HMBs diameter. HMBs diameter were significantly 
increased in all groups after incubated in water (hypotonic solution) compared to control and 
CMRL (
#
p<0.001). HMB with 15min polymerisation provided statistically significant stable in 
diameter size compare to those of 10 and 20min, and also there was a significant difference 
between HMBs with 10min and 20min after exposure to water (***p< 0.001). 
4.3.2 Effects of Polymerisation Time on Hepatocyte Viability and Functions 
of HMBs 
There was no statistically significant difference in cell viability determined by MTT activity 
between the 3 polymerisation times for HMBs under the same conditions. Noticeably, MTT 
activity was maintained after 3h incubation in CMRL compared to control, however, in all 
groups there was a substantial decrease in cell activity in microbeads incubated in water 
(p<0.02). HMBs from 3 polymerisation groups provided similar metabolic functions after being 
maintained in culture for 24h. The amount of albumin production for 10min, 15min and 20min 
group were 569.0±112.2, 606.3±97.0, and 581.2±103.3 ng/mg protein and urea production were 
6.1±1.1, 6.1±1.2, and 6.4±1.2 μg/mg protein, respectively. 
4.3.3 Effects of Cell Density on Microbead Morphology 
The morphology of HMBs produced using different cell densities (2.0x10
6
 to 3.5x 10
6
cells/ml 
alginate) showed uniformity and smooth outside surface with no significant differences between 








Figure 4.4: Representative images of hepatocytes microbeads produced with different cell 
densities; (A) 2.0x10
6
cells/ml alginate, (B) 2.5x10
6





cells/ml alginate. On the left panel demonstrates microbeads under light 
microscopy which showed that microbeads at all densities were uniform and intact. On the right 
panel shows viability of hepatocytes microbeads using FDA/PI staining under fluorescence 
microscopy (green is viable and red is dead cells) in which 3.5x10
6
cells/ml alginate provided 








4.3.4 Effects of Cell Density on Hepatocyte Viability and Function of HMBs 
The viability of hepatocytes before encapsulation was 61.5±1.1 %. After encapsulation, HMBs 
were maintained in culture overnight to allow the encapsulated hepatocytes to recover. Cell 
viability (FDA/PI staining) showed on the following day that the density of 3.5x10
6
 cells/ml 
provided the highest viability compared to other three groups (Figure. 4.4). The 3D 
reconstructed images showed that cells were evenly distributed inside the microbead (Figure 
4.5) and the average cell number per microbead for each cell density ranged from 201 (2.0x10
6
 
cells/ml alginate) up to 447 (3.5x10
6







Figure 4.5: Representative confocal microscopy images used in 3D reconstruction to 
demonstrate (A & B) cell distribution and viability across the microbead, and (C) viability of 
cells within outer half vs inner half of same microbead. 
 
Table 4.2: Number of cells per microbead and cell densities used alginate 
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Surprisingly, with increasing cell density there was no significant difference in cell viability 
between outer and inner halves in all groups (Figure 4.6A). Analysis of the outer halves only 
showed that there was a statistically significant increase in cell viability which correlated with 









p=0.001). While inner half of 2.0x10
6
cells/ml showed the lowest viability compared to the 
others (p<0.05). The overall viability in the 3.5x10
6
 cells/ml group was significantly higher than 
2.0x10
6
 cells/ml (46.1±3.3% vs 31.7±3.3%, p=0.01) and also tended to be higher than 2.5x10
6
 
cells/ml (37.42 ± 5.17%) but this was not significant (p=0.06). Furthermore, MTT assay on day 
1 showed a similar trend where the 3.5x10
6
 cells/ml group had a higher activity than other 





cells/ml (p<0.05; Figure 4.6B). 
Urea and albumin assays showed no significant differences between the 4 groups on either day1 
or day3 (Figures. 4.7A and B). However, albumin synthesis showed a similar pattern to cell 
viability where the higher cell number gave higher production. By contrast, the CYP1A1/2 
activity on day 3 of the 2.0x10
6
cells/ml group was significantly higher than 3.0 and 3.5 
x10
6
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Figure 4.6: Effects of different cell densities on encapsulated hepatocyte viability. (A) viability 
of encapsulated hepatocytes across microbead using confocal microscopy and 3D 
reconstruction; and (B) MTT activity of hepatocyte microbeads on day 1 and day 3 of culture; 
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Figure 4.7: Hepatocyte-specific functions of HMBs produced with different cell densities; (A) 
albumin production, (B) urea production, and (C) cytochrome CYP1A1/2 activity, on day 1 and 








4.3.5 Permeability of Optimised Microbeads 
The proteins present in the supernatants of HMBs after culture were separated on 
polyacrylamide gels (Figure 4.8). The two samples were obtained from HMBs with hepatocyte 
viability of 60% (sample 1) and 70% (sample 2) before encapsulation. The intensity of some 
protein bands in sample 2 was higher than those in sample 1 which means higher amounts of 
those proteins. The thick bands represent the more abundant proteins in both samples within the 
MW range of 50 to 75kDa when compared to standard protein marker. The largest size of the 
protein showed in sample 1 was between 150-250kDa. The upper band in sample 2 was not 




Figure 4.8: Representative example of 2D SDS-PAGE of proteins contained in supernatants of 

















As the results obtained from 2D protein electrophoresis could not indicate the precise maximum 
size of proteins that diffused across microbeads, a further study was performed using 
proteomics analysis. The proteomics profile detected a total 55 proteins (Appendix III). The 
most abundant protein observed was human serum albumin (MW 69kDa) which constituted 
approximately 20% of total protein detected. The largest protein that detected was carbamoyl 
phosphate synthase ammonia (MW 164kDa) which is a ligase enzyme located in the 
mitochondria involved in the production of urea. These results were corresponded to SD-PAGE 
data as described above.  
4.4 Discussion 
4.4.1 Polymerisation Time 
In this study, we observed that the size of EMBs immediately after production in the 20min 
polymerisation group had a significantly larger size compared to 10min or 15min groups, while 
this pattern was not observed in HMBs. This finding suggests that incorporation of cells may 
have influenced microbead formation. After exposure to osmotic stress, both EMBs and HMBs 
demonstrated that a polymerisation time of 15min produced the most physically stable 
microbeads compared to the other two groups. The likely reason for this finding is that 10min 
polymerisation is too short for effective cross-linking and equilibration of external Ca
2
+ 
between the core of alginate and the external medium (Zimmermann et al. 2005), whereas an 
increase in polymerisation time to 20min made microbeads become too crosslinked and brittle 
(Thu et al. 2000; Vaithilingam et al. 2011). Therefore an optimised polymerisation time is 
required to enhance microbead integrity. Our results showed that a prolonged polymerisation 
time did not have a negative effect on encapsulated cell viability and function supporting 
previous studies (Haque et al. 2005; Vaithilingam et al. 2011). Additionally, the microbead size 
and cell viability did not change after incubation in plain CMRL medium for 3h at room 
temperature, suggesting that the microbeads could be stable in CMRL transplant medium for a 
minimum of 3h before transplantation. 
4.4.2 Effects of Cell Density on HMBs  
The current study investigated the influence of cell density on physical integrity, cell viability 
and function in order to establish the optimal ratio of cell mass per microbead to allow oxygen, 











cells/ml alginate were studied. The results showed that microbeads produced using these 
densities had a stable physical integrity with smooth surface but when the cell density exceeded 
3.5x10
6
cells/ml alginate, surface irregularities and microbead deformity were observed. These 
findings are different from a previously published study by Durkurt and colleagues (2013) who 
suggested that for rat hepatocytes the optimal density is 1.0x10
6 
cells/ml alginate. An increase in 
cell density will lead to an increase in microbead cell content leading to a considerable change 
in the microenvironment inside the microbeads with the possibility of apoptotic and hypoxic 
cell death particularly towards the microbead centre. It is difficult to assess the cells while they 
are entrapped in the three-dimensional structure. Live-Dead-Assay using fluorescent 
microscopy has generally been accepted as a method, however,  it is inaccurate due to an over-
estimation of viability caused by false-positive signals (double marked cells), (Leal-Egaña et al. 
2010). Therefore, we determined the cell number, distribution, and viability across microbeads 
using both fluorescent (2D) and confocal (3D) microscopy. It has been reported that 
encapsulated hepatocytes lose approximately 20-30% viability after encapsulation (Wang et al. 
2000). In this study, cell viability in HMBs was assessed after maintenance in culture for 1 day 
instead of immediately after preparation to allow stabilisation of cells to the microenvironment. 
We found that 3.5x10
6
cells/ml alginate HMBs provided the highest cell viability with an overall 
viability loss after encapsulation of 24%. It must be noted that, the cell viability loss could be 
attributed to quality of the available hepatocytes used, due to steatosis and cryopreservation 
injury. The 3D confocal microscopy data showed that cell viability in the centre of microbead 
did not decrease as the cell number per microbead was increased. The gel network of Ca-
alginate is an inhomogeneous structure in which the alginate and calcium concentrations are 
lower in the core than the outer part of the microbead (Quong et al. 1998; Thu et al. 2000), thus 
allowing oxygen, nutrients, and metabolites to go across the microbead. Albumin and urea 
production tended to be better in the higher cell density groups but did not reach statistical 
significance. CYP1A1/2 activity was, however, lower in the high cell density than the low cell 
density groups.  
4.4.3 Permeability of Optimised Microbeads 
The permeability of optimised HMBs, produced with ultrapure alginate at a cell density of 
3.5x10
6
cell/ml alginate and polymerisation at 15min, was evaluated with SDS-PAGE gel 
electrophoresis of protein and proteomic analysis. The new development of proteomic analysis 
technique provides detailed analysis of protein components released by HMBs and their 
diffusion into the culture medium. The results showed that albumin was the most abundant 
protein that HMBs produced and diffused into supernatant. The other proteins such as factor VII 
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(50kDa), prothrombin were not identified in current study. This could be possibly due to their 
low concentration or the low molecular mass being masked by the presence of albumin. The 
maximum protein size that diffused out from HMBs had a MW of 164kDa. Therefore, 
immunoglobulin G (IgG) which has a MW of 150kDa might permeate into the microbeads. 
Certainly, the main mechanism involved in destruction of encapsulated cells is direct contact 
between encapsulated cells and the immune effectors cells, hence, preventing cell contact is 
important. However, the immunoglobulins alone do not have the ability to destroy the 
encapsulated cells, as direct cell lysis requires the assembly of immunoglobulins and 
complements factors which involve the large glycoprotein C1q (410kDa), C3 (185kDa), C4 
(210kDa), C5 (190kDa), C8 (170kDa) and the smaller ones; C2, C6, C7, and C9 (MW range of 
79-128kDa). Some studies have shown that the permeability of alginate microbead to IgG may 
not be a major issue (Lanza et al. 1995; Duvivier-Kali et al. 2004; Schneider et al. 2005). 
Further study regarding immune reaction toward this optimised HMBs is required before 
translation to clinical use (details in Chapter 5). Proteomics analysis should be carried out on 
more supernatant samples of HMBs cultures using a technique that can overcome the possible 
masking effect of abundant proteins without losing important information. 
In this study, the cryopreserved hepatocytes were used in some experiments. It is clear that 
cryopreservation has the negative effect on hepatocyte viability and function, therefore it would 
be ideal to use freshly isolated hepatocytes in all sets of experiments. The scarcity of the human 
liver tissue is an important issue and cryopreservation seems prudent for cell therapy. 
Encapsulation of fresh hepatocytes using the optimised protocol and followed by 
cryopreservation to establish a good quality of HMBs would be of great benefit in the future. 
In conclusion, optimal settings of the encapsulator were established. Optimisation of the 
polymerisation time and cell density has contributed to the improvement in the efficiency of the 
microencapsulation hepatocytes. This optimised protocol for production of human hepatocyte 
microbeads using GMP grade materials provided good cell viability, function, and physical 





5. In Vitro Immunogenicity of Alginate Microencapsulated Human 
Hepatocytes 
5.1 Introduction 
The biocompatibility of the alginate microbeads is an important issue for efficacy following 
transplantation into the peritoneum. The strategy for functional grafting of transplanted 
encapsulated cells is based on the fact that the microbeads should provoke none or, at most, 
minimal host immune reaction to avoid cellular overgrowth. The formation of a pericapsular 
fibrotic overgrowth will interfere with oxygen and nutrient diffusion, as well as exchange of 
essential metabolites that subsequently leads to cell death (Vaithilingam et al. 2011; De Groot et 
al. 2004). The biomaterial of microbeads, or antigens/chemokines released by encapsulated cells 
through microbeads pores, may initiate a host immune response and inflammatory reaction 
leading to cellular overgrowth. The intrinsic characteristics of microbeads or microcapsules 
involving the compositions (M and G content), electrical charge on the surface, permeability, 
and types of microbeads/microcapsules (e.g. PLL-coated alginate microbead) are the factors 
determining the host responses as previously discussed in Section 1.7.1 and Section 1.7.3. 
The important issue that should be taken into consideration after transplanting microbeads into 
the peritoneal cavity is the physiochemical changes of microbeads’ surface due to protein 
adsorption, such as fibrinogen. Protein adsorption is a complex phenomenon which can have a 
significant impact on the biocompatibility of microbeads. Several studies demonstrated that 
adsorption of fibrinogen and other proteins onto the microbead surface lead to the activation of 
host effectors mechanisms including complement, immunoglobulins, and inflammatory cells 
(Tang and Eaton 1993; Vos et al. 2002; Engberg et al. 2011). It has been shown that alginate 
microbeads possess high hydrophilicity on the surface, which limits low adsorption of proteins 
and a gives low degree of denaturation. On the other hand, the alginate-PLL-alginate (APA) has 
a hydrophobic surface which enhances protein adhesion and conformational changes. The 
conformational changes of the proteins that adhere onto microbead’s surface may lead to a 
reduction in hydrophilicity (Vogler 2012; De Vos et al. 2006).  
The aim of the current study was to investigate the alloimmune response towards optimised 
clinical grade human hepatocyte microbeads (established in Chapter 4) in vitro by assessing the 
inflammatory responses of peripheral blood mononuclear cells (PBMCs) co-cultured with them. 
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Studies of host immune response also performed on hepatocytes microbeads after exposure to 
human ascitic fluid to mimic the environments following intraperitoneal transplantation in 
clinical settings.  
5.2 Materials and Methods 
5.2.1 Materials 
Ficoll-Hypaque density gradient solution (Amersham Pharmacia, Biotech UK, Little Chalfont, 
UK), and cell stimulation cocktail plus protein transport inhibitors (e-Bioscience Ltd, Hatfield, 
UK). All monoclonal antibodies, Cytofix/Cytoperm, and Perm/Wash solution (BD Pharmingen, 
Oxford, UK).  
5.2.2 Methods 
5.2.2.1   Encapsulation of Hepatocytes 
Hepatocyte isolation was performed as described in Section 2.2.1. HMBs and EMBs were 
produced using the optimised protocol described in Chapter 4. 
5.2.2.2   PBMCs Isolation 
PBMCs were obtained from either normal healthy donors (n=6) or patients with acute-on-
chronic liver disease (n=2). PBMCs were isolated with a standard Ficoll-Hypaque density 
centrifugation method (Longhi et al. 2005). Briefly, 20ml of peripheral blood were obtained and 
mixed with preservative free heparin (10 U/ml). Blood was slowly layered onto an equal 
volume of Ficoll-Hypaque density gradient solution and centrifuged at 2100 RPM, 21C for 
21min. The mononuclear cells (buffy coat) were collected and washed twice with 40ml PBS at 
1900 RPM, 21C for 5min. Total lymphocyte number and cell viability was assessed by Trypan 
blue exclusion viability exceeded 98%. 
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5.2.2.3   Assessment of Immunogenicity of Hepatocytes Microbeads 
5.2.2.3.1   Establishing Optimum Ratio of Hepatocytes and PBMCs 
To establish the optimum ratio of human hepatocytes to PBMCs that enables the maximum 
interaction between the two cell populations, PBMCs from healthy donors were co-cultured 
with human hepatocytes monolayers (n=5). The PBMCs were co-cultured with plated human 
hepatocytes at PBMCs:hepatocytes 1:5, 1:10 and 1:20 ratios. The cells were cultured in WEM 
supplemented with 10% heat-inactivated FCS, 2mM L-glutamine, 0.1μM insulin, penicillin 
(50U/ml) and streptomycin (50μg/ml) and maintained in a humidified incubator at 37C for 24h. 
After co-culture, PBMCs were harvested and subsequently stained. The proportion of activated 
PBMCs following co-culture with hepatocytes was assessed using flow cytometry (FACS), 
(Section 5.2.2.5).  
5.2.2.3.2   HMBs Co-culture with PBMCs 
PBMCs isolated from four healthy donors, were either cultured alone (monocultures) or co-
cultured with EMBs or HMBs (3.5x10
6
cells/ml alginate; n=4) in culture medium for 24h under 
the same conditions. The ratio of PBMCs to encapsulated hepatocytes co-culture was based on 
the experiment of direct co-culture of PBMCs and plated hepatocytes as described above 
(Section 5.2.2.3.1).. Microbeads were examined under a light microscope before and after co-
culture with PBMCs to evaluate the extent of cell adhesion to their surface. Proportions of 
activated PBMCs following co-culture with either EMBs or HMBs were assessed by FACS 
analysis, (Section 5.2.2.5).  
5.2.2.4   Evaluation of Immunogenicity of HMBs after Exposure to Ascitic fluid 
Human ascitic fluid was obtained from patients with acute-on-chronic liver disease (n=2). 2.4ml 
HMBs or EMBs were incubated in 6ml ascitic fluid in warm water at 37C with gentle agitation 
for 1h. The ascitic fluid was then removed and HMBs and EMBs were washed five times with 
WEM. PBMCs were isolated from the same patients from whom ascitic fluid was obtained. 
Five experimental sets were tested; PBMCs alone, EMBs + PBMCs, EMBs (ascitic-treated) + 
PBMCs, HMBs + PBMCs, and HMBs (ascitic-treated) + PBMCs groups. 1.2ml HMBs and 
EMBs with or without exposure to ascitic fluid were co-cultured in 6-well plate with 1.6x10
6
 
PBMCs in supplemented WEM and incubated at 37C for 24h (Section 5.2.2.3.1). The day after 
co-culture, PBMCs were collected, resuspended in 1ml medium and seeded in 12-well plates. In 
order to analyse the PBMCs activation and the intracellular cytokine production, 2µl of the cell 
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stimulation cocktail (plus protein transport inhibitors) was added and incubated with PBMCs for 
4h at 37C. Cell stimulation cocktail is a cocktail of phorbol 12-myristate 13-acetate (PMA), 
ionomycin, brefeldin A and monensin which is used for induction and subsequent intracellular 
detection of cytokines and other secreted proteins in both in vitro-cultured and ex vivo cells. 
PBMCs were then washed with PBS, stained and then analysed by FACS (Section 5.2.2.5). 
PBMCs monocultures were used as control in all experimental sets. 
5.2.2.5   Flow Cytometry Analysis 
Twenty four hours after culture, three-color FACS analysis was performed. PBMCs were 
stained for cell surface markers using the following antibodies: allophycocyanin (APC)-
conjugated, or phycoerythrin (PE) conjugated anti-CD3 (T cells), APC-cychrome (CY)-7-
conjugated CD4 (T cells), FITC-conjugated, or PE-CY-5-conjugated anti-CD8 (T cells), PE-
CY-7-conjugated anti-CD25 (T cells), peridinin chlorophyll protein (PerCP)-conjugated anti-
CD14 (monocytes), PE-conjugated anti-CD40L (co-stimulation molecule), FITC-conjugated 
anti-CD38 (all white blood cells), PE-CY-5-conjugated anti-CD56 (natural killer cell), FITC-
conjugated anti-CD19 (B cell), and PE-conjugated anti-CD54 (intercellular adhesion molecule-
1). Cells were incubated at 4C for 30min in the dark, then washed with PBS/1%FCS and re-
suspended in 400L PBS/1% FCS and stored at 4C until the analysis. Intracellular staining was 
performed using following antibodies: PE-anti-IFN, APC-anti-IL-2, PE-CY-7-anti-IL-17, 
APC-anti-IL-10, PE-anti-IL-4, FITC-anti-TNFα and PE-anti-IL-6. The cells were permeabilised 
with 250µl cytofix/cytoperm and incubated for 20 min at 4C. Cell were then washed with 
Perm/Wash solution twice and then stained for intracellular cytokines were stained and 
resuspended in 80µl Perm/Wash solution and incubated at 4C for 30min in the dark. The cells 
were then washed twice with Perm/Wash solution and resuspended in 400µl PBS/1%FCS prior 
to analysis. The stained cells were then analysed using the combinations of surface and 
intracellular antibody shows in Table 5.1. 
FACS analysis was performed on a Becton Dickinson ﬂuorescence activated cell sorter (FACS 
Canto II, Becton-Dickinson, Immunocytochemistry Systems, CA, USA), and FACS Diva 
software (ver.6.3.1, Biosciences, CA, USA) was used for data analysis. A minimum of 20,000 




Table 5.1: The combinations of surface and intracellular marker  
 
































































































5.2.2.6   Microbeads Morphology 
HMBs and EMBs morphology were examined under light microscopy immediately after 
production and after 24h co-culture with PBMCs. The degree of inflammatory cell adhesion on 





5.3.1 Frequency of Activated PBMCs Following Co-culture with EMBs and 
HMBs 
Frequency of activated PBMCs activation after co-culture with hepatocytes at various 
PBMCs:hepatocytes ratios (1:5, 1:10, and 1:20) are shown in Table 5.2. The percentage of 
lymphocytes positive for surface activation markers was not significantly different in the three 













 cells were significantly decreased within PBMCs co-cultured with 




was similar in the 1:5 
group and control, but it was significantly lower in the 1:10 and 1:20 groups compared to 
control (p<0.001). Therefore, the ratio of 1:5 was chosen for studying the interaction between 
HMBs and EMBs with PBMCs.  
After co-culturing microbeads with PBMCs for 24h, both EMBs and HMBs were still intact and 
maintained their uniform shape without any apparent PBMCs adherent to their surface (Figure 
5.1). The percentage of cells positive for activation markers within PBMCs is shown in Table 
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cells did not differ between the PBMCs co-cultured with microbeads (EMBs or HMBs) and 
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activated monocytes in 
PBMCs co-cultured with HMBs was significantly lower compared to those co-cultured with 
EMBs, and PBMCs monocultures (2.66±0.8 vs 22.8±7.7 and 45.7±11.0, respectively; p< 





































































+ 1.06±0.34 1.82±0.62 2.32±0.98 2.64±0.92 










Figure 5.1: Representative images of EMBs and HMBs morphology; (A and B) immediately 
after production before co-culture with PBMCs, and (C and D) after co-culture with PBMCs for 
24h.  
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+ 1.10±0.28 2.30±0.50 5.54±2.14 










on PMBCs (Q2 quadrant) after co-culture with HMBs for 24h. 
5.3.2 Immunogenicity of HMBs after Exposure to Ascitic fluid 
There was no difference in microbeads morphology (EMBs and HMBs) between those exposed 
to ascitic fluid before co-culture with PBMCs compared to the non-exposure groups, where the 





 cells seemed to be lower in PBMCs co-cultured with both groups of HMBs 
(either exposed or non-exposed to ascitic fluid) than in those co-cultured with EMBs and 
control (Table 5.4). The proportion of cells positive for other surface markers was similar in all 
groups. Additionally, there was no difference in the frequency of cell producing cytokine (IL-2, 
IL-4, IL-6, IL-10, IL-17, IFN-, and TNFα) after PBMCs stimulation in all five groups. 
  
PBMCs monoculture 
EMBs+PBMCs co-culture  HMBs+PBMCs co-culture  
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Table 5.4: Frequency of cells positive for activation markers or producing cytokines after co-
culture with EMBs and HMBs  
 














































































 26.95±2.03 30.15±0.84 40.85±7.07 25.4±0.59 32.9±12.96 
CD8
+





 3.8±1.29 3.25±1.24 4.05±1.83 3.8±1.78 3.4±2.18 
CD56
+










 10±2.67 10.3±3.07 9.25±1.73 7.5±0.49 9.8±1.19 
CD14









5.4  Discussion 
In the current study, the immunogenicity of optimised GMP grade HMBs was investigated as 
biocompatibility is one of the key factors for the success of transplantation. No studies 
published so far have investigated the alloimmune reaction against human hepatocyte 
microbeads. The appropriate ratio between human hepatocytes and PBMCs was established. 
With the exception of monocytes, no significant differences were noted in the proportion of T, 
B or NK cells positive for activation markers following co-culture with human hepatocytes at 








 cells was 
significantly lower than in the control group (PBMCs alone) when the 1:10 and 1:20 ratios were 




 cells was lower than in the control at the 1:5 ratio. 
These findings show that human hepatocytes have low immunogenicity and might even have 
inhibitory effects on monocyte reactivation. Sana et al. (2013) showed that human hepatocytes 
present a low immunogenic phenotype, and promote the cell contact-dependent production of 
IL-10 by myeloid dendritic cells after co-culture with PBMCs. IL-10 is a potent inhibitor of 
monocyte/macrophage activation which is secreted by a number of cells of the immune system, 
including monocytes and T cells (Parry et al. 1997). Therefore, the possible explanation for the 
results in present study might be that human hepatocyte induced IL-10 production by immune 
cells and subsequently suppressed the monocyte activation 
The results presented in this chapter obtained demonstrated that both HMBs and EMBs did not 
elicit immune activation in vitro. This may be due to the use of ultrapure sodium alginate; these 
findings also support and supporting previous studies which showing that inflammation and 
immune reaction are related to the purity of alginate (Orive et al. 2002; Kim et al. 2013) and to 
the uncoated microbeads used in present study (Orive et al. 2006; Tam et al. 2011). 
Interestingly, a significant decrease in the frequency of activated monocytes was observed in 
PBMCs/HMBs co-cultures. These findings reflected those obtained following direct 
hepatocyte/PBMCs co-culture. In addition, an unexpected decrease in the frequency of activated 
monocytes was seen in PBMCs/EMBs co-cultures. The reason for these findings is unclear; 
however, release of anti-inflammatory cytokines or chemokines might have played a role in the 
regulation of monocyte activation including IL-10 production as discussed above. Therefore, 
analysis of cytokines production was carried out in the next stage of this study.  
Host immune response to the transplanted alginate microbeads involves not only the biomaterial 
of microbeads or encapsulated cells but also the environment in which the transplantation 
occurs, i.e. the peritoneal cavity. In order to reproduce the ‘in vivo’ environment, microbeads 
were incubated with ascitic fluid in a transudate of plasma consisting of a variety of proteins 
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including immunoglobulins and complement. The initial results showed that the morphology of 
HMBs and EMBs after co-culture with PBMCs was intact and clean without any immune cells 
adherent on microbeads surface regardless of exposure to ascitic fluid or not. There was no 
difference in the percentage of PBMCs expressing activation markers or producing cytokines in 
the absence or presence of ascitic fluid. This may indicate that the protein adsorption on both 
EMBs and HMBs was minimal and did not change the physiochemical properties of 
microbeads’ surface. As a result, the host effector mechanisms involving reactive protein 
cascades, such as complement, immunoglobulins, and immune cells were not activated. These 
results also suggest that EMBs and HMBs were biocompatible with the immune and 
complement system. The findings of this study are in agreement with previous work by, Tam et 
al. (2009) who detected presence of immunoglobulins (IgG, IgM and IgA) adsorbed to APA 
microcapsules, but not on alginate microbeads after exposure to human serum and peritoneal 
fluid, suggesting that the positive charge at the APA capsule surface is responsible for 
immunoglobulin binding. Another study demonstrated that alginate microbeads are 
complement-compatible as they did not activate complement after incubation in human whole 
blood, whereas APA microcapsules activated accumulation of soluble terminal solution 
complex, C3a, C5a and surface activated leukocyte adhesion (Rokstad et al. 2011). In contrast, 
Haan et al. (2011) reported a large increase in TNF-α production by PBMCs when exposed to 
alginate microbeads with human peritoneal (ascitic) fluid, but not by PBMCs exposed to APA 
microcapsules. However, the peritoneal (ascitic) fluid and PBMCs used in the study by Haan 
and colleagues were not from the same donors, possibly accounting for immune over-reactivity. 
The slight decrease in the frequency of activated monocyte was detected in co-culture with both 
HMBs groups. However, the inhibitory effect was not as strong as in the experiments discussed 
above. This might be explained by the fact that PBMCs used in the first set of experiments were 
obtained from healthy donors whereas the later sets were obtained from patients ALF and 
underlying chronic liver disease. These preliminary experiments highlighted the 
biocompatibility of HMBs in ascitic fluid. This section of work was, however, limited by the 
small number of patient’s samples available hence more experiments are needed. The study of 
the immunogenicity of microbeads in vivo is important and will be discussed in Chapter 7.  
In conclusion, the present study has demonstrated that the optimised EMBs and HMBs 
produced using ultrapure alginate without PLL coating, 15min of polymerisation time and a cell 
density of 3.5x10
6
cell/ml alginate were biocompatible with the human PBMCs in vitro. The 
microbeads showed minimal protein adsorption after exposure to ascitic fluid and did not 
stimulate immune reaction and cytokine production. This supports the clinical application of 




6. Cryopreservation of Hepatocyte Microbeads for Clinical 
Transplantation 
6.1 Introduction  
Establishing banked cryopreserved hepatocyte microbeads for long-term storage would be of 
great benefit for emergency cases such as ALF. Previously published studies have shown 
protective effects of alginate microencapsulation on hepatocytes during the cryopreservation 
process (Mahler et al. 2003; Aoki et al. 2005; Kusano et al. 2008; Hang et al. 2010). Alginate 
microbeads have a high water content (>90%) together with the relatively large size of 
microbeads compared to single cells make microbeads susceptible to cryodamage by ice-crystal 
formation (Chin et al. 2004). Studies on cryopreservation of microencapsulated cells have been 
reported with variable effectiveness due to differences in cryopreservation methods. These 
differences include cell density, cryopreservation media, cryoprotectants, cooling rate and 
storage temperature (Lee et al. 2004; Heng et al. 2004; Murua et al. 2009; Massie et al. 2011). 
Most of the previous studies of a cryopreservation of microencapsulated hepatocytes used 
cryopreservation medium consisting of culture medium, 10% FCS, and 10% DMSO placed into 
cryovials and stored in liquid nitrogen (Dixit et al. 1993; Aoki et al. 2005; Kusano et al. 2008; 
Hang et al. 2010). Even though these protocols gave relatively good viability and function after 
thawing, they were not acceptable for clinical transplantation. 
Pre-treatment or preincubation of cells with various compounds at 37C before cryopreservation 
has shown beneficial effects on cryopreserved hepatocytes as these methods allow hepatocytes 
to recover from the dissociation stress (Silva et al. 1999; Terry et al. 2005). However, no study 
has shown the benefit of preincubation of microbeads before cryopreservation. 
The cryoprotectant is an important element for cryopreservation. 10% DMSO is the choice of 
cryoprotectant that has been used for clinical cryopreservation of hepatocytes (Terry et al. 
2010). The DMSO concentration that has been used for cryopreservation of microencapsulated 
cells varied from 10% up to 20%. Chin et al (2004) showed that with a microencapsulated 
kidney cell line cryopreservation with 20% DMSO and 0.25M sucrose improved cell viability 
without damaging the microcapsules. Murua and co-workers (2009) compared the efficacy of 
different concentrations of DMSO (1%, 5%, 10%, 20% and 30%) for cryopreservation of 
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microencapsulated myoblasts and found that 10% was the optimal concentration. Recently, 
carboxylated poly-L-lysine (COOH-PLL) was studied for cryopreservation of encapsulated 
vascular smooth muscle cells by Vrana et al. (2011). They showed that this cryoprotectant 
improved cell viability in encapsulated cells. They suggested that COOH-PLL has the antifreeze 
protein-like properties which could protect cell membranes (Vrana et al. 2012). 
The basal freezing solution is another challenging choice for cryopreservation of 
microencapsulated cells. Currently, a number of organ preservation solutions are available 
which can be used as cryopreservation solutions. These solutions include UW solution 
(ViaSpan), (Lee et al. 2004), Celsior (Massie et al. 2011), and HTS (Sosef et al. 2005). In 
addition, CryoStor is a family of cryopreservation solutions developed from HTS which have 
been demonstrated to yield improved cryopreservation of multiple cellular systems (Baust et al. 
2000; Stylianou et al. 2006). Malpique et al. (2010) showed that using CryoStor as 
cryopreservation medium significantly improved post thawing recovery for both 
nonencapsulated and encapsulated neurospheres compared to standard culture medium 
(Malpique et al. 2010). 
Some investigators have included other compounds in the freezing medium together with the 
cryoprotectant, such as anti-oxidant or anti-apoptosis agents with the aim of further protection 
from cryoinjury. These compounds are known as cytoprotective agents as they protect the cells 
by specific mechanisms during the cryopreservation process but do not inhibit intracellular ice 
formation. FCS is a common additive agent used in the freezing medium for the maintenance of 
encapsulated cells and microcapsules but cannot be used clinically as it is of animal origin. The 
caspase inhibitor benzyloxycarbonyl-Val-Ala-DL-Asp-fluoromethylketone, ZVAD is an anti-
apoptosis agent. Adding ZVAD improved the cell viability and function under stressful 
conditions prone to apoptosis such as isolation and cryopreservation of encapsulated 
hepatocytes (Nyberg et al. 2000; Mahler et al. 2003). Moreover, ice nucleating agents such as 
crystalline cholesterol can be added into freezing medium to reduce supercooling and 
intracellular ice formation (Massie et al. 2011).  
The freezing protocol using for cryopreservation of encapsulated cells varies including simple 
technique (Dixit et al. 1993), multi-step cooling with CRF or cryogen-free cooler (Massie et al. 
2011) and vitrification (Lawson et al. 2011). However, for clinical purposes with regard to 
sterility, toxicity and amount of production, the multi-step slow cooling protocol using CRF is 
seemed to be an appropriate choice. 
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The hypothesis of this study was that the cryopreservation of hepatocyte microbeads could be 
improved by supplementation of the cryopreservation solution with appropriate cytoprotectant 
agents such as an iron chelator (desferoxamine; DFO), anti-apoptosis drug (ZVAD), and human 
serum albumin (HSA) targeting protection of hepatocytes from oxidative stress and apoptosis 
(Yagi et al. 2001; Kerkweg et al. 2002; Fujita et al. 2005) and maintaining microbeads integrity 
(Schneider et al. 2003). The aim of this study was to develop an optimised protocol for 
cryopreservation of hepatocyte microbeads for clinical transplantation. Different types of 
cryopreservation solutions and cytoprotectants which potentially can be used for clinical 
application were investigated.  
6.2 Materials and Methods 
6.2.1 Materials 
Bambanker (Nippon Genetics, Tokyo, Japan), CryoStor CS10™ (Sigma-Aldrich, Dorset, UK), 
Histidine-tryptophan-ketoglutarate (HTK: Custodiol™; DR. Franz Kohler Chemie GMB, 
Alsbach-Hähnlein, Germany), desferoxamine (Sigma-Aldrich, Dorset, UK), ZVAD (R&D 
system, Abington, UK), and propidium iodide (BD Pharmingen, Oxford, UK). 
6.2.2 Methods 
Experimental Design 
At first, the effects of 4 different freezing solutions were evaluated on non-encapsulated human 
and rat hepatocytes. The best two freezing solutions that resulted in high cell viability and 
function after thawing were then selected for study of HMBs and rat hepatocyte microbeads 
(RMBs) cryopreservation. Then, cytoprotective agents were examined in order to improve the 
microbeads cryopreservation protocol.  
Hepatocytes were isolated from the same donor tissues for each set of experiments. Non-
cryopreserved (fresh) hepatocytes and hepatocyte microbeads were prepared identically and 
maintained in cultures as cryopreserved samples. All assays for cryopreserved samples were 
performed and compared to fresh samples at similar time points. 
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6.2.2.1   Hepatocyte Isolation  
Human and rat hepatocyte isolations were performed according to the methods described in 
Section 2.2.1 and 2.2.2, respectively.  
6.2.2.2   Encapsulation of Hepatocytes 
Human and rat hepatocytes were encapsulated using the optimised technique in Chapter 4 where 
the microbeads were produced at cell density of 3.5x10
6 
cell/ml alginate and polymerised for 
15min. See Section 2.2.6 for the encapsulation processes.  
6.2.2.3   Cryopreservation of Hepatocytes in Different Freezing Solutions  
Human and rat hepatocytes were used to evaluate four different cryopreservation media. They 
consisted of two types of hypothermic organ preservation solutions (UW and HTK) and two 
commercial cryopreservation solutions (CryoStor CS10 and Bambanker). All cryopreservation 
solutions contained 10% DMSO as cryoprotectant. Based on published and standard protocols 
used for cryopreservation of human hepatocytes at King’s College Hospital, 5% glucose 
(300mM) was added to UW and HTK (Table 6.1). Briefly, isolated hepatocytes were split into 
four groups. In each group, hepatocytes were resuspended in ice-cold freezing medium at a 
density of 1x10
7
 hepatocyte per ml. Hepatocyte suspension was then transferred into 2ml 
cryovials. Cryopreservation was performed using the standard freezing protocol on the CRF 
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6.2.2.4   Cryopreservation of Hepatocyte Microbeads using Different Freezing 
Solutions 
HMBs and RMBs were used to further investigate two of the four freezing solutions for 
cryopreservation of hepatocyte microbeads. Each ice-cold freezing medium was slowly added to 
the microbeads (1ml microbeads+4ml freezing solution in a 5ml cryovial). The microbead 
suspensions were then maintained on ice for 15-30min before transfer to the CRF. 
The freezing protocol was chosen based on results of a preliminary study. The published 
protocols by Terry et al. (2010) for cryopreservation of human hepatocytes and for freezing 
alginate-encapsulated liver cell (HepG2) spheroids by Massie et al. (2011) were compared. 
These two protocols are multi-step slow cooling which contain an important holding step to 
allow samples to reach equilibrium and a shock cooling step (from 8C to28C) to control 
nucleation of ice. They are different in terms of starting temperature (8C vs 0C) and total 
duration of cryopreservation (62min vs 39min, Table 6.2). The findings from a pilot study 
showed that HMBs cryopreserved according to the Massie et al. protocol provided intact 
microbeads and higher MTT activity and albumin production at day 1 and 3 post thawing than 
those cryopreserved with the standard protocol for hepatocytes by Terry et al. Therefore, the 
freezing protocol by Massie et al. was applied in all following experiments of microbeads 





Table 6.2: Multi-step slow cooling cryopreservation protocols using CRF 
Protocol for human hepatocytes (Terry et al. 2010) 
Step Start 
Temperature 
Rate Time End 
Temperature 
1 8C -1ºC/min 8 min 0C 
2 0C Hold 8 min 0C 
3 0C -2ºC/min 4 min -8C 
4 -8C -35ºC/min 33 sec -28C 
5 -28C -2.5 ºC/min 2 min -33C 
6 -33C +2.5ºC/min 2 min -28C 
7 -28C -1 ºC/min 32 min -60C 
8 -60C -10 ºC/min 4 min -100C 
9 -100C -20 ºC/min 2 min -140C 
Protocol for encapsulated liver spheroids (Massie et al. 2011) 
Step Start 
Temperature 
Rate Time End 
Temperature 
1 0C Hold 8 min 0C 
2 0C -2ºC/min 4 min -8C 
3 -8C -35ºC/min 6sec -28C 
4 -28C -2.5 ºC/min 2 min -33C 
5 -33C +2.5ºC/min 2 min -28C 
6 -28C -2ºC/min 16min -60C 
7 -60C -10 ºC/min 4 min -100C 






Figure 6.1: Controlled-rate freezer trace of the programmed freezing protocol (below line) and 
actual temperature of samples (above line). 
6.2.2.5   Effect of Cytoprotectant on Hepatocyte Microbeads 
The cytoprotectant compounds were chosen based on published data which demonstrated 
beneficial effects during culture, cold storage or cryopreservation of cells or microencapsulated 
cells. Compounds which have different mechanisms to protect cells include caspase inhibitor 
(ZVAD), iron chelator (DFO) and human serum albumin were evaluated. The concentrations 
used in current study were adjusted according to previously published data. The details of 
selected cytoprotectants are shown in Table 6.3. 
The effects of the compounds were tested on RMBs by adding them to the most effective 
freezing medium from the prior experiments. RMBs were produced from the same donors. Four 
experimental groups were performed: a) freezing media without cytoprotectant, b) freezing 
media with HAS, c) freezing media with DFO, and d) freezing media with ZVAD. The freezing 
solution for each group was added to 1ml RMBs up to a final volume of 5ml in a cryovial. 
Cryovials were kept on ice for 15-30min prior to starting freezing using CRF. Cryopreserved 






Table 6.3: Cytoprotective compounds used in this study 





ZVAD 60µM Inhibit caspase -1,-4, -3 
and -7 
Prevent apoptosis Mahler et al. 
(2003) 




1mM Inhibit loss of MMP 
Prevent ROS formation  
Reduce oxidative stress 
Prevent apoptosis  
and necrotic cell 
death 
Kerkweg et al. 
(2002) 
Niu et al. (2010) 






2% Mechanical protection  
Buffering capacity 
(reduce DMSO toxicity) 
Prevent apoptosis  
Enhance integrity 
of microbeads  
Schneider et al. 
(2003) 
De Castro et al. 
(2006) 
MMP, mitochondrial membrane potential; and ROS, Reactive Oxygen Species. 
6.2.2.6   Thawing and Culturing Cryopreserved Cells and Microbeads  
Hepatocytes and microbeads stocks were rapidly thawed using a 37C water bath (Section 
2.2.8.3). Thawed hepatocytes were then plated and maintained in a humidified incubator at 
37C, 5% CO2 for 7 days (Section 2.2.5). Similarly, thawed microbeads were resuspended in 
culture medium and incubated for 7 days (Section 2.2.7). 
6.2.2.7   Plated Hepatocyte Viability and Function 
Cell viability was determined immediately after thawing using the Trypan blue exclusion test 
(Section 2.2.3). MTT assay, SRB assay (cell attachment) and hepatocyte specific function were 
evaluated after maintenance in culture for 24h (Section 2.2.9 and 2.2.10). 
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6.2.2.8   Hepatocyte Microbeads Viability and Function 
Viability of hepatocyte microbeads was evaluated using FDA/PI and MTT assay (Section 
2.2.11) immediately post-thaw, day 1, day 3 and day 7. Hepatocyte specific functions of 
microbeads were studied in supernatants on day 1, day 3 and day 7 cultures (Section 2.2.12). 
6.2.2.9   Morphological Examination Using Light Microscopy 
The morphology of hepatocytes from each group was examined after thawing and plating on 
collagen-coated plates for 24h. Microbeads morphology was evaluated immediately post 
thawing.  
6.2.2.10   Hepatocyte Microbeads Ultrastructure Examination Using Electron 
Microscopy 
The exterior and interior ultrastructural morphology of hepatocyte microbeads were studied 
using scanning electron microscopy (SEM) and transmission electron microscopy (TEM). 
Microbeads were processed at the Centre for Ultrastructural Imaging, King's College London. 
Briefly, samples were fixed overnight with 2.5% glutaraldehyde in 0.15M cacodylate buffer (pH 
7.3) at 4°C. For SEM, after the initial fixation, samples were rinsed several times in cacodylate 
buffer and post fixed with 1% osmium tetroxide in 0.15 M cacodylate buffer (pH 7.3) for 1h. 
Samples were then washed, dehydrated in a graded series of ethanol and dried by 
hexamethyldislazane. Dried samples were mounted on stubs (Hitachi) with adhesive carbon tab 
(TAAB) and sputter coated with gold (Emitech K550X) before examination under a scanning 
electron microscope. Images recorded using a FEI Quanta 200F field emission scanning 
electron microscope operated at 5kV in high vacuum mode. 
For TEM, after the initial fixation, samples were rinsed several times in cacodylate buffer and 
post fixed with 1% osmium tetroxide in 0.15M cacodylate buffer (pH 7.3) for 1.5h. Samples 
were then washed, dehydrated in a graded series of ethanol and equilibrated with propylene 
oxide before infiltration with SPURR resin (TAAB). Samples were embedded and polymerised 
at 70°C for 24 hours. Ultrathin Sections (70-90 nm) were prepared using a Reichert-Jung 
Ultracut E ultramicrotome, mounted on 150 mesh copper grids, contrasted using uranyl acetate 
and lead citrate and examined on a FEI Tecnai 12 transmission microscope operated at 120 kV. 
Images were acquired with an AMT 16000M digital camera. 
110 
 
6.2.2.11   Detection of Apoptotic Cells using FACS Analysis 
The four groups of cryopreserved hepatocyte microbeads from the cytoprotectant study (Section 
6.2.2.5), 1ml per group, were thawed and cultured in 6 well-plates. Additional sample of 
hepatocyte microbeads which had been cryopreserved in freezing solution without any 
cryoprotectant were thawed and then incubated with ZVAD (60µM) for 30min prior to culture. 
After 24h in culture, hepatocytes were released from the microbeads according to the 
depolymerisation protocol (Section 2.2.7.1). Cells were then washed twice with PBS/1% FCS 
followed by PI staining. Stained cells were incubated at 4C for 30 min in the dark, then washed 
with PBS/1% FCS and re-suspended in 400L PBS/1% FCS. An equivalent number of cells 





Figure 6.2: A typical flow cytometry histogram for estimation of the percentage of apoptotic 




6.3.1 Effect of Freezing Solutions on Hepatocytes 
Cell viability of fresh human hepatocytes, immediately after isolation assessed by trypan blue 
and after plating assessed by overall mitochondrial activity (MTT activity) were 77.0±1.3% and 
1.13±0.29 OD reading units, respectively. After cryopreservation with 4 different freezing 
media and subsequent thawing, there was a significant decrease in cell viability evaluated 
immediately after thawing and after plating with all freezing media compared to fresh cells 
(trypan blue: p<0.05 and MTT assay: p<0.001). There was a no significant difference in post 
thawing viability between cells cryopreserved with the 4 different solutions (CryoStor CS10: 
57.3±5.8%, Bambanker: 54.7±4.3%, UW/DMSO/glucose: 50.4±4.5% and 
HTK/DMSO/glucose: 44.5±5.3%). Cell attachment (SRB assay) onto collagen-coated plates 
data showed similar results as cell viability. However, when comparing between cryopreserved 
cells group, UW/DMSO/glucose group had highest attachment efficacy (0.35±0.09 OD reading 
units) but this did not reach statistically significance (Figure 6.3). 
The morphology of cryopreserved hepatocytes after attachment to the collagen-coated plates 
was examined under light microscopy and compared with freshly isolated hepatocytes. The 
appearance of the typical hexagonal shape of hepatocytes was observed in cryopreserved cells. 
There was no obvious difference in morphological appearance between cryopreserved groups, 
except in the Bambanker group which showed some “damaged” hepatocytes and irregular cell 
shape (Figure 6.4). 
Comparing albumin synthesis between fresh (167.0±28.3 ng/mg protein) and cryopreserved 
groups showed a minimal decrease with no statistically significant difference. Nevertheless, 
cells cryopreserved with HTK/DMSO/glucose produced the lowest amount of albumin 
(135.5±36.5 ng/mg protein) compared to the other groups. Furthermore, urea synthesis was 
significantly reduced in HTK/DMSO/glucose cryopreserved cells compared to fresh cells 








































































































































































































Figure 6.3: Effects of cryopreservation using the four different freezing solutions on human 
hepatocytes viability and cell attachment. (A) cell viability immediately after thawing assessed 
by trypan blue exclusion. (B) cell viability post thawing and plating for 24h assessed by MTT 
assay and, (C) cell attachment after thawed and plated for 24h assessed by SRB assay. 









Figure 6.4: Representative images of human hepatocyte morphology after plating and 
maintained in culture for 24h (under light microscopy); (A) fresh hepatocytes (control). 
Cryopreserved hepatocytes using (B) UW/DMSO/glucose, (C) HTK/DMSO/glucose, (D) 
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Figure 6.5: Effects of cryopreservation using four different freezing solutions on human 
hepatocyte-specific functions (albumin and urea production) after plating for 24h. Statistical 




The results obtained from experiments using rat hepatocytes showed a similar outcome to 
human hepatocytes. Cell viability of cryopreserved cells in all groups was significantly lower 
than the fresh cells (73.1±2.0%, p<0.01). Comparing between cryopreserved cells, CryoStor 
CS10 group (54.0±2.6%) demonstrated significantly higher cell viability than Bambanker 
(41.0±1.5%, p=0.003), HTK/DMSO/glucose (40.0±1.2%, p=0.002), and UW/DMSO/glucose 
(45.3±0.8%, p=0.04). Interestingly, cells cryopreserved in UW/DMSO/glucose were able to 
maintain their overall mitochondrial activity and attachment after plating and culturing for 24h 
(MTT=0.35±0.07 and SRB=1.50±0.10 OD reading unit) better than the other three groups, and 
showed no statistical difference compared to fresh cells (MTT=1.52±0.68 and SRB=3.01±0.85), 
(Figure 6.6). When compared to fresh cells, urea production was significantly decreased in all 
cryopreserved cells (p<0.05), however, albumin production was significantly reduced only in 
cells cryopreserved in Bambanker (p=0.02), (Figure 6.7).  
The similar results for the freezing solution on human hepatocytes were detected with 
UW/DMSO/glucose, CryoStor CS10 and Bambanker. For rat hepatocytes, CryoStor CS10 
showed better outcome in cell viability immediately after thawing, while UW/DMSO/glucose 
demonstrated better cell attachment and viability afterward. In addition, hepatocyte functions of 
cell cryopreserved with HTK/DMSO/glucose and Bambanker were dramatically dropped than 
those with UW/DMSO/glucose and CryoStor CS10. Therefore, UW/DMSO/glucose which is 
freezing solution used for clinical use at King’s College Hospital, and CryoStor CS10 were 
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Figure 6.6: Effects of cryopreservation using four different freezing solutions on rat hepatocyte 
viability and cell attachment. Cell viability assessed (A) immediately after thawing using trypan 
blue exclusion, and (B) post-thawing and plating for 24h using MTT assay. (C) SRB assay for 
cell attachment after thawing and plating for 24h. Statistical significance compared to fresh 
hepatocytes (control): *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. Statistical significant 













































































































































Figure 6.7: Effects of cryopreservation using four different freezing solutions on rat hepatocyte-
specific functions (albumin and urea production) after plating for 24h. Statistical significance 




6.3.2 Effect of Freezing Solutions on Hepatocyte Microbeads 
There was no significant difference between cell viability of cryopreserved HMBs immediately 
post thawing and after maintenance in culture for 7 days (assessed by FDA/PI and MTT assay). 
Hepatocyte function of cryopreserved HMBs assessed by albumin production, urea synthesis 
and cytochrome P450 activity (CYP1A1/2) also demonstrated comparable results between the 
two freezing solutions (Figure 6.8). Interestingly, there was little difference in cell viability and 
functionality of cryopreserved HMBs after thawing and then after maintenance in culture 
throughout the 7 days, while fresh HMBs showed a significant decrease in cell viability and 
urea production. When comparing between fresh and cryopreserved HMBs, there was a 
significant decrease in both viability and urea synthesis in cryopreserved HMBs. These 
reductions were more apparent immediately after thawing and on day1 in culture (p<0.0001) 
than on days 3 and 7. However, albumin production was unexpectedly significantly higher in 
cryopreserved HMBs in both groups than those of fresh at each time points (p≤0.01), (Figure 
6.8B). In contrast, there was no significant difference in CYP1A1/2 activity between fresh and 
cryopreserved HMBs.  
The same effects of freezing solutions on HMBs were observed on rat hepatocyte microbeads 
(RMBs), (Figure 6.9). However, the difference between fresh and cryopreserved RMBs was 
more prominent than in HMBs experimental groups. On day 1, albumin production of fresh 
RMBs (736.9±113.7 ng/mg protein) was significantly higher than RMBs cryopreserved with 
UW/DMSO/glucose (359.2±43.5 ng/mg protein, p=0.001) and CryoStor CS10 (390.0±26.6 
ng/mg protein, p=0.002) and the level continued to increase up to day 7. Moreover, fresh RMBs 
showed significantly higher CYP1A1/2 activity than cryopreserved RMBs on day 1 (fresh vs. 
UW/DMSO/glucose, p=0.04, and fresh vs. CryoStor CS10, p=0.004) and on day 3 (fresh vs. 
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Figure 6.8: Effects of two freezing solutions on cell viability and function of HMBs after 
thawing and maintenance in culture for 7 days; (A) cell viability, (B) albumin production, (C) 
urea production and (D) CYP1A1/2 activity. Statistical significance: *p<0.05, **p<0.01, 
***p<0.001, and ****p<0.0001. Statistical significance compared to fresh HMBs: #p<0.05, 
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Figure 6.9: Effects of two freezing solutions on cell viability and function of RMBs after 
thawing and 7 days maintenance in culture. (A) cell viability, (B) albumin production, (C) urea 
production, and (D) CYP1A1/2 activity. [Statistical significance compared to either 
immediately post thawing or compared to day 1: *p<0.05, **p<0.01, ***p<0.001 and 











The morphology of cryopreserved microbeads (HMBs and RMBs) examined under light 
microscopy (LM) and scanning electron microscopy (SEM) was intact and well-preserved when 
compared to fresh samples (Figure 6.11). However, further investigation of ultrastructure of 
hepatocytes within microbeads using transmission electron microscopy (TEM) showed that 
microbeads cryopreserved in CryoStor CS10 provided slightly more cells with preserved 
ultrastructure than those in UW/DMSO/glucose. Figure 6.11 shows TEM images of examples of 
healthy hepatocytes versus necrotic and apoptotic hepatocytes within microbeads from fresh 
microbeads and cryopreserved microbeads. Good healthy hepatocytes exhibited a round nucleus 
with well-defined nuclear membrane, which was continuous with the rough-surfaced 
endoplasmic reticulum. They contained abundant smooth membranes and with intact cristae in 
mitochondria. In contrast, apoptotic hepatocytes showed condensation of nuclear chromatin 
located near the nuclear membrane. Plasma membrane had lost its fine demarcated continuity. 
Oedematous mitochondria due to ruptured outer mitochondrial membrane, secondary to 
necrosis were observed. The number of extensive vacuoles was increased, while intact 
cytoplasmic organelles were clearly seen. 
Overall, UW/DMSO/glucose and CryoStor CS10 had similar effects on cryopreservation of 
hepatocyte microbeads. Therefore, UW/DMSO/glucose which is the freezing media used for 
cryopreservation of clinical grade human hepatocytes was chosen as the freezing solution in 









Figure 6.10: Human hepatocyte microbeads morphology under light microscopy (LM; A, B 
and C) and scanning electron microscopy (SEM; D, E, and F). (A, D) fresh hepatocyte 
microbeads (control), (B, E) hepatocyte microbeads cryopreserved with UW/DMSO/glucose, 
and (C, F) hepatocyte microbeads cryopreserved using CryoStor CS10. Scale bar are 500µm 














Figure 6.11: Transmission electron microscopy (TEM) of hepatocytes within microbeads after 
24h culture. Representative TEM images of normal healthy hepatocytes (left panel) and 
necrotic/apoptotic hepatocytes (right panel). (A, D) at low magnification; 690x, (B, E) at 
magnification of 1400x, and (C, F) at high magnification; 4800x. G, Golgi apparatus; Ly, 
lysosomes, Mt, mitochondria; N, nuclei; Nu, nucleoli; Nm, nuclear membrane; Pm, plasma 
membrane; RER, rough-surfaced endoplasmic reticulum; sMt, swelling mitochondria; and V, 
vacuole.  







6.3.3 Effects of Cytoprotectants on Hepatocytes Microbeads 
RMBs cryopreserved in UW/DMSO/glucose (basal medium) containing 60µM ZVAD resulted 
in a significantly higher cell viability immediately post thawing (MTT=6.12±1.12 OD 
reading/100mg RMBs) than those cryopreserved with standard basal freezing medium alone 
(3.51±0.31, p=0.002). After 1 day in culture, there was a slight decrease in cell viability of 
ZVAD group (5.79±0.58), however viability remained significantly higher than of basal 
medium alone (2.42±0.45, p<0.0001), DFO group (3.39±0.49, p=0.006) and fresh RMB 
(3.41±0.44, p=0.007). Moreover, RMBs in HSA group gave significantly higher viability 
(4.48±1.11, p=0.006) than those in basal medium group. Furthermore, fresh RMBs gave better 
viability compared to the other groups (p<0.0001) on the day of production (day 0), but had 
similar viability at day 3 and day 7 (Figure 6.12). The results of cell viability assessed by 
fluorescence staining correlated well with the MTT assay data (Figure 6.13). 
There were no significant differences between hepatocyte-specific functions in the four RMBs 
cryopreserved groups. The fresh RMBs gave a significantly higher albumin production at day 1 
(p<0.0001) and day 3 (p<0.0001) compared to other four groups. At day 7, albumin synthesis of 
fresh RMB group (1331±55.8 ng/mg protein) remained higher than both the basal medium 
(950.3±104.8, p=0.03) and HSA (943.9±48.5, p=0.02) groups, but was not significantly 
different compared to both the DFO (1017±55.6) and ZVAD (1061±107.6) groups. Similar 
findings were observed in urea production where the fresh RMB group provided significantly 
higher production at day 1 than all other groups (p<0.0001), but not on day 3 and day 7. 
Interestingly, on day 3 there were significantly higher CYP1A1/2 activities in RMBs 
cryopreserved using HAS (20.7±2.5 pmol/mg protein/min, p=0.001), DFO (20.6±2.0, p=0.001) 
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Figure 6.12: Effect of cryopreservation with different cytoprotectants on viability of RMBs 
after thawing and maintained in cultured for 7 days assessed by MTT assay. [Statistical 
significance: *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001]. 
  








Figure 6.13: Effect of cryopreservation with different cytoprotectants on viability of RMBs 
after thawing and maintained in cultured for 7 days. Representative images of FDA staining 
showed viable cell (green) within RMBs.   
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Figure 6.14: Effect of cryopreservation with different cytoprotectants on hepatocyte-specific 
functions of RMBs after thawing and maintenance in culture for 7 days (A) albumin production, 
(B) urea production, and (C) CYP1A1/2 activity. [Statistical significance: *p<0.05, **p<0.01, 
***p<0.001 and ****p<0.0001]. 
128 
 
Among cryopreserved RMBs groups, the ZVAD group had the highest percentage of well-
preserved hepatocyte ultrastructure within microbeads (76.9% of the fresh RMBs group), 
followed by the HSA, the DFO and the basal medium groups, at 67.4%, 44.7% and 34.8% of 
the fresh RMB group, respectively. Representative TEM images of intact ultrastructure of 
hepatocytes RMBs obtained from fresh and cryopreserved groups at day 1 in culture are shown 
in Figure 6.15.  
 
 
Figure 6.15: Representative TEM images (1400x) of RMBs obtained after 1 day in culture (A) 
fresh RMB, and cryopreserved RMBs in (B) basal medium alone, (C) HSA, (D) DFO and (E) 
ZVAD groups. Scale bar 2µm. 
  
Fresh group 







6.3.4 Detection of Apoptotic Cells in Cryopreserved Rat Hepatocyte 
Microbeads 
The anti-apoptotic effects of cytoprotectants on RMBs were assessed by detection of sub-G1 
phase of the cell cycle using PI staining and FACS analysis. Apoptotic cells (fragmented nuclei) 
were arrested in Sub-G1 cycle. As summarised in Table 6.4, RMBs in the basal medium
 
alone 
had the highest percent of cell in sub-G1 stage (40.1%); whereas the lowest was detected in the 
ZVAD group (12.6%). Noticeably, the sub-G1 arrest of RMBs in the basal medium
 
alone was 
decreased to 19.3% when incubated with ZVAD (60µM) for 30min immediately after thawing 
before maintenance in culture. Figure 6.16 shows representative FACS histograms of cell 
population after thawing and maintenance in culture for 24h. 
 
Table 6.4: Percentage of nuclei in sub-G1 phase detected by FACS 
Sample Apoptotic nuclei in sub-G1 (%) 
UW/DMSO/glucose (basal medium) 40.13 
Basal medium+HSA 16.15 
Basal medium +DFO 15.08 
Basal medium +ZVAD 12.63 
UW/DMSO/glucose thawed then incubated 











Figure 6.16: Representative histograms of cell cycle analysis using FACS. Cryopreserved 
RMBs were thawed, and then cultured for 24h. Hepatocytes were released from microbeads and 







UW/DMSO/glucose+ZVAD UW/DMSO/glucose group 









Research into cryopreservation of encapsulated hepatocytes has recently started. However, there 
are no published studies on optimised protocols for cryopreservation of human hepatocyte 
microbeads especially for clinical use. There are many steps involved in cryopreservation and 
storage of microbeads. This current study was focused on optimising cryopreservation solutions 
that potentially can be used for cryopreservation of clinical grade microbeads. This study has 
investigated the effect of cryopreservation solutions on cell viability and functionality of 
cryopreserved hepatocyte microbeads.  
6.4.1 Basal freezing solution 
In the initial experiments basal freezing solutions were studied [UW/DMSO/glucose and 
HTK/DMSO/glucose and 2 commercially available solutions, CryoStor CS10 and Bambanker]. 
UW and HTK are organ preservation solutions which are not suitable to protect cells during 
cryopreservation. Therefore, 10% DMSO and 5% glucose were added based on the optimised 
protocol for cryopreservation of clinical grade human hepatocytes (Terry et al. 2010). The 
results showed that this basal freezing media did not have sufficient effects on the outcome of 
cryopreservation in this study. This could be due to the effects of cryoprotectant added namely 
DMSO and glucose. CryoStor CS10 and UW/DMSO/glucose were superior to both 
HTK/DMSO/glucose and Bambanker for cryopreservation of hepatocyte suspensions. In 
addition, hepatocyte cryopreservation in UW/DMSO/glucose showed higher cell attachment 
and overall mitochondrial activity after 24h in culture, while in CryoStor CS10 cells had a 
higher viability immediate post thawing. This may be due to the effect of glucose concentration 
in UW/DMSO/glucose (300mM) compared to that in CryoStor CS10 (5mM). The benefit of 
using a high concentration of glucose (300mM) is that it leads to an increase in ATP cell content 
resulting in better of hepatocyte mitochondrial function (Stéphenne et al. 2007; Terry et al. 
2010). It also protects cells against osmotic pressure which helps in the protection of cell 
membranes. Membrane protection contributes to preservation of cell attachment molecules on 
the plasma membrane leading to improvement of cell attachment. Furthermore, Janssen et al. 
(2003) also found that UW maintains a high intracellular ATP levels in human liver endothelial 
cells after ischemia and reperfusion demonstrated by MTT assay. However, 
UW/DMSO/glucose and CryoStor CS10 showed similar outcome in terms of cell functionality 
in present study. This could be explained by solutions containing similar compounds that are 
beneficial for protection of the cells during cryopreservation.  
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UW solution is an intracellular-based solution which is known as a gold standard medium for 
organ preservation (Southard and Belzer 1995). Several studies have shown the beneficial 
effects of UW for cryopreservation of hepatocytes (Terry et al. 2005; Dandri et al. 2001; 
Kunieda et al. 2003; Arikura et al. 2002). It is composed of important components which are 1) 
Non-permeating cryoprotectants; potassium lactobionate, raffinose and hydroxyethyl starch to 
prevent cells from swelling and to stabilise the cell membranes 2) adenosine, glutathione and 
allopurinol to promote ATP production and reduce oxidant damage to cells 3) K2HPO4 for 
buffering designed to work at low temperature leading to prevention of intracellular acidosis 
and 4) dexamethasone which help in membrane stabilization and 5) insulin which is growth and 
trophic factor (Southard et al. 1990). Additionally, Carini et al. (1999) found that UW solution 
effectively prevented sodium influx into the hypoxic hepatocyte due to its low sodium content. 
CryoStor CS10 is a recently developed freezing solution which has been clinically used for stem 
cell banking (Woods et al. 2009). It was developed from HypoThermosol (HTS), an organ 
preservation solution. HTS is “intracellular-like” solution consists of multiple components 
which are important to maintain ionic and osmotic balance under hypothermic conditions (Table 
6.1). Key components to protect cells from osmotic swelling are lactobionate, sucrose and 
mannitol. Dextran-40, acts as a colloid, and elevates the intracellular pressure to stabilise cell 
membranes. Similar to UW solution, it also contains adenosine and glutathione. However, it 
contains a low level of glucose (5mM) to provide energy for the cells. HTS use HEPES as a 
buffer which is effective in stabilising pH at low temperature. HTS serve as a platform for 
CryoStor family; CS 2, CS 5 and CS 10; the number after “CS” indicates the percentage of 
DMSO. Baust et al. (2001) have shown the beneficial effects of the HTS-base cryopreservation 
solution through reduction of cryopreservation-induced delayed-onset cell death, which is the 
cell death associated with cryopreservation developing over time post thawing. They 
demonstrated that improvement in cell survival was associated with a reduction in overall level 
of both apoptosis and necrosis after thawing. Subsequently, Sosef et al. showed that rat 
hepatocytes cryopreserved in CryoStor CS10 gave high viability and long-term hepatocyte-
specific functions for up to 14 days (Sosef et al. 2005) . 
The HTK-base freezing solution used in this study was the least effective for cryopreservation 
of both human and rat hepatocytes. This finding supports previously published studies, 
Staatsburg et al. (2002) demonstrated superiority of UW solution over Celsior and HTK 
solutions for cold storage of rat liver in limiting liver cell damage. Janssen et al. (2003) found 
that the level of cell necrosis and mitochondrial dysfunction in human hepatocytes after 
preservation at 4C for 48h followed by reperfusion for 6h was significantly lower in UW 
solution compared to HTK. In addition, Rauen and Groot found that organ preservation 
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solutions with the exception of UW solution, increased cell injury during cold storage (LDH 
release after 18h at 4C: HTK 76 ± 2%, Euro-Collins 78±17%, histidine-lactobionate 81±15%; 
control: Krebs–Henseleit buffer 20±6%). They studied the individual components of the 
preservation solutions, and suggested that histidine and phosphate which functions as the 
buffering system caused the toxicity (Rauen and de 2008). Furthermore, Baicu and Taylor 
(2002) recommended using HEPES instead of histidine and phosphate to avoid cytoxicity.  
Bambanker demonstrated lower efficacy compared to both UW-based freezing solution and 
CryoStor CS10 in the present study. In addition, abnormal cell shape and disintegrated 
hepatocytes were most frequently observed when cells were cryopreserved in Bambanker. 
Bambanker can be used for the freezing and preservation of wide variety of cells including 
human gastric epithelial cells, human T-cell, and stem cells (Hikichi et al. 2007; Tamai et al. 
2013; Naito et al. 2013). However, there was no study using Bambanker for cryopreservation of 
hepatocytes. The current results showed that Bambanker is not suitable for hepatocyte 
cryopreservation. 
UW/DMSO/glucose and CryoStor CS10 were further studied in order to compare the efficacy 
on cryopreservation of hepatocyte microbeads. The results showed that there were no significant 
differences between CryoStor CS10 and UW/DMSO/glucose with both cryopreserved HMBs 
and RMBs. In addition, both freezing solutions which contained DMSO (10%) in addition to 
other cryoprotectants and metabolites as describe above were able to maintain microbeads 
integrity after thawing. Morphology under LM and SEM indicated that appearance of 
cryopreserved microbeads was comparable to fresh microbeads. This suggested that alginate 
microbeads could be cryopreserved with 10% DMSO using a slow freezing step protocol 
without damaging microbeads integrity. This finding is supported by other studies, where 
Pravdyuk et al. (2013) found that using DMSO at a concentration of lower than 10% or 
cryopreservation using rapid 1-step freezing resulted in critical damage of encapsulated 
mesenchymal stem cells. Another study showed that an encapsulated kidney cell line 
cryopreserved in 25% DMSO with a rapid cooling protocol resulted in low post thawing 
viability with 20-40% damage to microbeads (Chin et al. 2004). 
The viability and functionality of microbeads after thawing were dramatically decreased 
compared to fresh microbeads in this study. This indicates that using these two freezing media 
as protocol for cryopreservation of hepatocyte microbeads were not sufficient to protect cells 
against both apoptosis cell death related to cryopreservation. However, cytochrome P450 
(CYP1A1/2) activities were well preserved and showed minimal reduced compared to fresh 
microbeads. Similarly, Aoki et al. (2005) also demonstrated that cryopreserved 
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microencapsulated hepatocytes retain gene expression of OAT22 and CYP3A2/9 up to 50 days. 
Moreover, the results showed that cryopreserved HMBs gave higher albumin production than 
fresh HMBs at all-times, which is unexplained. It was noticeable that cryopreserved HMBs 
maintained their viability and functionality over 7 days, while the fresh HMBs continued to 
decrease. The reason for this is unknown, however, Dixit et al. (1993) postulated that 
cryopreservation “selects” only good hepatocytes to be preserved a viable on thawing. 
UW/DMSO/glucose and CryoStor CS10 provided a similar outcome on cryopreservation of 
hepatocyte microbeads. UW/DMSO/glucose was chosen as a basal freezing medium used in 
further experiments. UW-based freezing solution was selected because UW has been widely 
used in clinical transplantation and less expensive than CryoStor CS10. 
6.4.2 Cytoprotectants 
Recent studies demonstrated that apoptosis plays an important role in cryopreservation failure 
(Baust et al. 2000; Baust et al. 2001; Yagi et al. 2001). The understanding of pathways involved 
with cryopreservation-induced molecular cell death could lead to improvement in the 
cryopreservation outcome as cytoprotectants can be added to specifically target or control the 
apoptosis pathway. Apoptosis signal transduction can be initiated at different levels (cell 
membrane or mitochondria) but is then followed by common proteolytic caspase cascade 
pathways (caspase-8,-9 and -3), (Baust et al. 2002). The known initiators of apoptosis associated 
with cryopreservation are membrane alteration, ionic imbalance and biochemical changes 
(Baust et al. 2009). Three cytoprotectants including the pan-caspase inhibitor; ZVAD, the iron 
chelator; DFO, and human serum albumin (HSA) were investigated. These cytoprotectants 
target different sites of cryopreservation induced cell death to enhance efficacy of cryopreserved 
hepatocyte microbeads (Table 6.3). The results demonstrated that ZVAD gave positive effects 
on cell viability and functionality of RMBs when this cytoprotectant was added to basal 
freezing media. The beneficial effects on cell viability were greater than with either DFO and 
HAS. This was shown by both overall mitochondrial activity and fluorescent staining for viable 
cells. RMBs cryopreserved with ZVAD had a reduction in cell apoptosis following 
cryopreservation when compared to basal freezing media alone or other cytoprotectant groups, 
observed on TEM. This was also supported by the PI staining (DNA defragmentation)/FACS 
which showed that sub-G1 population was lowest in the ZVAD group. In addition, adding 
ZVAD after thawing lowered the degree of apoptosis (Table 6.4) but was not as effective as 
adding it in the freezing medium. The possible explanation is that the process of apoptosis has 
already started at the time of hepatocyte isolation and continues throughout cryopreservation 
135 
 
and after thawing. Therefore the earlier the addition of the anti-apoptosis agent, the more 
beneficial effects are observed. The current data is consistent with previously published studies 
showing the beneficial effects of ZVAD used in cryopreservation and cold storage (Yagi et al. 
2001; Mahler et al. 2003). It is worth mentioning that the cytoprotective effects of ZVAD are 
dose-dependent, and related to the cell type to be preserved. Nyberg et al. (2001) investigated 
the anti-apoptotic effects of a range of ZVAD concentrations (0-120µM) on gel-entrapped rat 
hepatocytes in a bioartificial liver device and found that at the concentration of 60µM was the 
optimal dose as was used in the current study. 
The addition of human HSA showed some beneficial effects on cell viability and function. In 
fact, HSA seemed to be a good additive as it has a mechanical protection and buffering capacity 
which may have protected cells from apoptosis. Addition of HSA to the freezing medium is 
believed to be beneficial not only for the cells, but also for the microbeads physical integrity too 
(Schneider et al. 2003). Importantly, it is widely used and clinically approved. However, the 
results obtained showed that HSA was not as effective as ZVAD. This could be due to the 
concentration used being too low (2% v/v) to overcome the stress during cryopreservation and 
post-thaw. There have been no previously reported studies using HSA for cryopreservation of 
microbeads. De Castro et al. (2006) evaluated the efficacy of HSA as a substitute of fetal bovine 
serum during culturing of microencapsulated cell line (C2C12) and found that 1% HSA could 
be used instead of FBS. Whereas, Bao et al. (2013) showed that a custom made serum-free 
medium containing 3% HSA was suitable for culturing rat hepatocyte spheroid. 
Similar to HSA, DFO also had positive effects on cryopreserved RMBs (the reason could be 
that of inadequate concentration of DFO used in this study). DFO was one of the choices as a 
cytoprotectant compound due to its properties and being approved for clinical use. DFO has 
been reported to be effective in reduction of necrosis and apoptosis of hepatocytes during cold 
storage. Cold-induce injury caused by reactive oxygen species is associated with an increased 
intracellular chelatable iron (Vairetti et al. 2001; Kerkweg et al. 2002). Niu et al. (2010) showed 
cell death was significantly reduced when 5mM DFO was added before and after cold 
incubation. Terry et al. (unpublished data) found similar benefits on cell attachment when 
adding 1-10mM DFO in the freezing solution. In addition, Liu et al. (2013) also showed that 
serum-free media supplemented with 1mM DFO provided beneficial effects in reducing cellular 
damage of rat hepatocytes spheroids.  
It must be noted, these set of experiments were done using only RMBs due to the lack of good 
quality fresh human hepatocytes. Therefore, further experiments are needed to examine the 
effects of these cytoprotectants on HMBs. In addition, more experiments including the testing of 
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vary concentrations of HSA and DFO and the possible synergistic effects when added to the 
freezing media at the same time should be carried out.  
In conclusion, cryopreservation of hepatocyte microbeads using UW solution containing 
10%DMSO, 5%glucose and a cytoprotectant such as ZVAD were shown to have beneficial 
effects on the reduction of cellular and physical damage leading to maintenance of cell viability 
and function post thawing. This initial optimisation protocol for cryopreservation of hepatocyte 
microbeads supports the hypothesis that the development of freezing solution containing of 
cryoprotective agents together with compounds targeting apoptosis during the cryopreservation 
process could improve the outcome of cryopreservation. Finally, the efficacy of cryopreserved 





7. Hepatocyte Microbead Transplantation in a Rat Model of Acute 
Liver Failure 
7.1 Introduction 
ALF is a severe condition associated with high mortality. Intrahepatic hepatocyte 
transplantation has shown benefit as a bridge to transplantation (Habibullah et al. 1994; Fisher 
and Strom 2006). However, invasive catheter placement in the liver in a coagulopathic patient 
and use of immunosuppression are perceived as high risk factors. The concepts of hepatocyte 
microbeads transplantation into the peritoneal cavity has become an attractive option (Umehara 
et al. 2001; Mai et al. 2005). This approach allows cell transplantation without using 
immunosuppression and also avoids the risk of bleeding. Moreover, cryopreservation of 
microencapsulated hepatocytes may protect cells from cryoinjury leading to improved cell 
viability and function on thawing (Aoki et al. 2005; Kusano et al. 2008) allowing banked 
microbeads to be available for emergency transplantation in ALF patients.  
Success of microencapsulated hepatocytes for treatment of ALF in rats was first reported in 
1986 by Wong and Chang, since then there have been a number of studies which showed the 
promising outcome of both fresh and cryopreserved microencapsulated hepatocytes in ALF 
animal models (Sun et al. 1987; Rivas-Vetencourt et al. 1997; Umehara et al. 2001; Aoki et al. 
2005; Mai et al. 2005; Mei et al. 2009; Sgroi et al. 2011). However, the translation to clinical 
use for treatment of ALF has not been established so far. The well-known challenge is the 
clinical grade biomaterials and chemicals needed to produce GMP grade microencapsulated 
cells. In addition, hepatocyte microencapsulation used in previous studies were of alginate-poly-
L-lysine-sodium alginate (APA) which can elicit a host immune reaction (Orive et al. 2006; 
Tam et al. 2011).  
Based on the work described in previous chapters, the optimised HMBs produced with 
GMP/sterile grade materials demonstrated good viability, functionality, mechanical stability, as 
well as biocompatibility and permeability in vitro. Moreover, cryopreservation of hepatocyte 
microbeads using an optimised protocol established in Chapter 6 provided an acceptable post-
thaw outcome including cell function and physical integrity of microbead in vitro. 
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The aims of this study were: to investigate the suitability of the optimised HMBs for 
transplantation in normal rats; to evaluate the safety and efficacy of transplantation of freshly 
prepared RMBs and cryopreserved RMBs in a rat model of ALF using by D-galactosamine 
administration. 
7.2 Material and Methods 
7.2.1 Materials 





 XS system (Roche Diagnostics, Mannheim, Germany), and PocketChem BA 
(Manarini Diagnostics, Wokingham, UK). 
7.2.2 Methods 
7.2.2.1   Experimental Design 
7.2.2.1.1   Intraperitoneal Transplantation of HMBs in Normal Rats 
The initial phase of this study was to investigate the function and immune response of the 
optimised HMBs (Chapter 4) in vivo by transplantation into normal Sprague Dawley rats to 
assess their suitability for future clinical application. Animals were divided into two groups 
(n=3 each). Group 1, transplanted with EMBs, and group 2 transplanted with HMBs. The 
microbeads were produced using cryopreserved human hepatocytes and immediately 
transplanted intraperitoneally after production. Blood samples were collected on day 1, 3, and 7 
post-transplantation to evaluate the function of HMBs. Blood samples pre-transplantation (day 
0) and EMBs groups were used as controls. Transplanted rats were followed for 1 week. At day 
7, microbeads were retrieved from the abdomen by laparotomy under anaesthesia. The retrieved 








Figure 7.1: Schematic diagram of intraperitoneal transplantation of HMBs into rats. 
 
7.2.2.1.2   Intraperitoneal Transplantation of Fresh and Cryopreserved RMBs in Rats 
with ALF 
The second phase of the study was to investigate the safety and efficacy of fresh RMBs and 
cryopreserved RMBs in rats with ALF. Animals were injected with D-galactosamine (D-GalN) 
to induce ALF. RMBs were transplanted into the peritoneal cavity of ALF animals 24-28h after 
D-GalN injection. The ALF animals were divided into four experimental groups: group 1 (n=6), 
received vehicle injection of medium (Sham); group 2 (n=4), transplanted with EMBs; group 3 
(n=5), transplanted with fresh RMBs; and group 4 (n=6), transplanted with cryopreserved 
RMBs. Animals were followed up for 7 days after transplantation. Survival rate and 
biochemical assays were evaluated at different time points. Euthanasia was performed on 
surviving animals at day 7 post-transplantation or at any time if they were distressed. At that 
time, microbeads and liver tissue were collected for analysis. The diagram in Figure 7.2 
summarises the experiment. 
  


















Figure 7.2: Schematic diagram of intraperitoneal transplantation of RMBs in ALF rats. 
7.2.2.2   Animals  
Sprague Dawley (Harlan Olec, UK), male rats 8-12 weeks old and weight between 200 to 400g 
were used as hepatocyte donors and the recipients of hepatocyte microbeads. Animals were 
maintained in conventional housing facilities and received standard care. They were housed in a 
room kept at a temperature of 21±2C, humidity of 55±10% and 12-hour light-dark cycle with 
ad libitum food and water. After acclimatisation, all experimental procedures were performed 
following protocols approved by the ethical committee of King’s College London in accordance 
with the UK Animals (Scientific) Procedures Act of 1986. 
7.2.2.3   Human Hepatocytes  
Human hepatocytes used in these experiments were cryopreserved cells from King’s College 
Hospital hepatocyte research bank stored at -140C. Hepatocytes were thawed using the quick 
thawing technique (Section 2.2.8.3). Cell viability and number were checked with trypan blue 
(Section 2.2.3) after thawing. Cells with viability ≥60% were used for encapsulation. 
Day 0 
Day 1 














Ad libitum of standard diet and 5% dextrose water 
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7.2.2.4   Rat Hepatocytes  
Isolation of rat hepatocytes were performed according to the procedures described in Section 
2.2.2. Cell number and viability were accessed using trypan blue (Section 2.2.3). Cells with 
viability ≥60% were used for encapsulation. 
7.2.2.5   Encapsulation of Hepatocytes  
Human and rat hepatocyte microbeads were prepared using the optimised technique established 
in Chapter 4. Hepatocytes used for encapsulation in each set of experiments were obtained from 
identical donors and also the same batch. After production, microbeads were divided into three 
aliquots for transplantation, cryopreservation and culture. Microbeads were maintained in 
CMRL prior to transplantation (according to results in Chapter 4 that showed viability and 
function of hepatocytes microbeads were well maintained in CMRL at least for 3h at RT). 
Microbeads were kept in culture for in vitro study for 7 days. EMBs were produced using the 
same technique but without cells (Section 2.2.6). Microbeads were examined under the light 
microscopy immediately after production before transplantation. Microbeads were transplanted 
when most of them (>95%) were intact and of uniform size. 
7.2.2.6   Cryopreservation and Thawing of RMBs  
The RMBs were cryopreserved using optimised freezing media and protocol according to the 
studies in Chapter 6. Briefly, RMBs were slowly mixed with freezing media, containing 
UW/10%DMSO/5%glucose/ZVAD (60µM), at the ratio of 1ml RMB to 4ml freezing media. 
RMBs suspension was then transferred into 5ml cryovials and kept on ice for 30min before 
being placed in the CRF. The freezing protocol used was based on the one used by Massie et al 
(2011). Cryopreserved RMBs were stored at 140 C for 2 days. The RMBs thawed using the 
quick thawing method (Section 2.2.8.3). Post-thaw RMBs were resuspended in CMRL for 
transplantation and some were placed in culture for in vitro studies. 
7.2.2.7   Evaluation of Viability and Hepatocyte Metabolic Function of HMBs and 
RMBs 
Fresh HMBs, fresh RMBs and cryopreserved RMBs were cultured in supplemented medium 
and incubated at 37C in 5% CO2 for 7 days (Section 2.2.7).  
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Cell viability of hepatocyte microbeads was evaluated using MTT assay together with FDA/PI 
staining at day 0 (immediately after production, after thawing or after retrieval from animals), 
day 1, day 3 and day 7 (Section 2.2.11). 
The amount of albumin production (Section 2.2.12.1), urea synthesis (Section 2.2.12.2) and 
CYP1 A1/2 activity (Section 2.2.12.3) of hepatocyte microbeads in vitro were analysed in 
culture medium collected at day 1, day 3 and day 7. 
7.2.2.8   Induction of Acute Liver Failure 
A model of acute liver failure using D-GalN was performed in Sprague Dawley rats. D-GalN 
was freshly prepared at the time of use by dissolving in dH2O to a final concentration of 
240mg/ml and the pH was adjusted to 7.4 using 5M NaOH. Each rat was received a single 
intraperitoneal injection of D-GalN at a dose of 1.2 g/kg. After injection, all animals were 
allowed a standard diet and 5% dextrose water ad libitum to prevent hypoglycemia. 
7.2.2.9   Intraperitoneal Transplantation of Microbeads  
The microbeads were suspended in transplant medium (CMRL) and were transplanted 
intraperitoneally via 18-guage intravascular catheter into rats under sterile technique. Each 





cells per rat. The plain transplant medium was injected into peritoneum using 25-gauge 
needle in sham group (group 1). Animals were anesthetised with isoflurane throughout the 
procedure.  
7.2.2.10   Blood Tests 
Animals were placed in a warming cabinet (39
o
C) for 15-20 minutes before blood sampling. 
The rats were restrained using a restraint tube and their tails were cleaned in order to see the 
blood vessel. Immersion of the tails in warm water was also applied to enhance visibility of the 
tail vessels in some animals. Blood samples (0.5ml) were taken from lateral tail veins via 23G 
butterfly needle collected in microtainer
® 
tube (serum separator tube). Gentle pressure was 
applied on the bleeding site to ensure haemostasis before the animals returned to a cage. The 
blood samples were then allowed to clot for ≥30min followed by centrifugation at 10,000xg for 
5min to separate serum. The serums were kept at -80C for further analysis. 
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7.2.2.10.1   Measurement of Human Albumin  
Assessment of HMBs function was performed on peripheral blood of rats collected from tail 
vein on day 1, 3, and 7 post-transplantation. Human serum albumin in rat serum samples was 
detected using ELISA quantitation kits (Section 2.2.10.1).  
7.2.2.10.2   Measurement of Prothrombin Time, Ammonia, Liver Enzymes and 
Creatinine 
Assessment of the severity of hepatic damage after D-GalN-induced ALF was performed on 
blood samples collected on day 1, 2, 4 and 8 post-ALF induction compared to day 0 (baseline 
control). Prothrombin time (PT), ammonia, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), bilirubin and creatinine were analysed at the same time point. PT and 
ammonia were determined using fresh whole blood without anticoagulants (8µl and 20µl, 
respectively). PT was measured using an automated coagulation monitor device (CoaguCheck
®
 
XS system, Roche Diagnostic, Mannheim, Germany) with the maximum recorded value of >96 
seconds. Ammonia was determined using a blood ammonia analyser (PocketChem BA, 
Manarini Diagnostics, Wokingham, UK). The measurement range of this test is 7-286µmol/L. 
ALT, AST, bilirubin and creatinine were measured in serum samples (150µl) using a routine 
biochemical AutoAnalyser (Advia 2400; Siemen Healthcare Diagnostics, Camberley, UK).  
7.2.2.11   Animals Follow-up and Microbeads Retrieval 
General appearance, body weight and neurological status of all animals were recorded before 
ALF induction as a baseline condition, and then were recorded on day 1, day 3 and day7 post 
transplantation. The neurological status was classified into four stages of hepatic coma which 
were grade 1 (lethargy), grade 2 (confusion and stupor but awake), grade 3 (sleeping most of the 
time, but arousable, with occasional convulsions), and grade 4 unarousable and unresponsive to 
pain, occasional convulsions) according to Ryan et al. (2001). Survival rate was followed for 7 
days post-transplantation. Animals were euthanised at day 7 or when distress was observed, and 
microbeads and liver tissue were harvested from the abdomen by laparotomy. To retrieve 
microbeads, the peritoneal cavity was flushed several times with CMRL (50ml) followed by 
thorough inspection of the abdominal cavity for signs of inflammation or adhesion.  
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7.2.2.12   Evaluation of Retrieved Microbeads and Liver Histology 
The retrieved microbeads were examined for morphology, including host cell adhesion to their 
surface to determine the extent of host immune responses (Figure 7.3). Cell viability and 
function of retrieved microbeads were evaluated after maintained in culture for 24h after 





Figure 7.3: Classification of host immune reaction by the degree of host cells covering on the 
surface of retrieved microbeads [adapted from Tam et al (2011)]. 
7.2.2.13   Statistic Analysis 
Survival curves were calculated using the Kaplan-Meier method and compared with a log-rank 
test. A value of p<0.05 was considered statistically significant. Other statistical analysis 
methods used are as described in Section 2.2.13. 
  




7.3.1 Intraperitoneal Transplantation of HMBs into Rats 
7.3.1.1   In Vitro Studies of HMBs and Morphology 
The viability of (cryopreserved) hepatocytes before encapsulation assessed by trypan blue was 
70%. Viability immediately after encapsulation was evaluated by FDA/PI (Figure 7.4A) and 
MTT assay (2.59 OD reading/100mg HMBs). The viability decreased after maintenance in 
culture for 7 days at which time MTT was about only 10% of the initial value. The albumin and 
urea production gradually decreased according to the time in culture. However, CYP1A1/2 
activity was increased at day 3 and then diminished slightly at day 7. The viability and function 
of HMBs over one week in culture was summarised in Table 7.1. 98% of HMBs and EMBs 
obtained were uniform in shape and size with (Figure 7.4B). 
 


















Day 1 1.10 699.5 16.60 5.36 
Day 3 0.60 398.4 6.55 10.24 












Figure 7.4: Microbeads morphology and cell viability immediately after production and prior to 
transplantation. (A) Cell viability of HMBs demonstrated by FDA (green)/PI (red) staining and 








7.3.1.2   In Vivo Study of HMBs in Normal Rats 
Seven days post-transplantation, microbeads in both EMBs and HMBs groups were freely 
dispersed throughout the peritoneal cavity. There were no signs of inflammation or adhesion of 
microbeads to any structure within peritoneal cavity (Figure 7.5A). A large proportion of 
microbeads were retrieved from rats transplanted with EMBs (73.3±6.7%), and HMBs 
(62.2±2.2%). Some microbeads were loosely attached to the omentum and mesentery which 
came off easily after flushing with transplant medium. The retrieved microbeads were intact 
without any deformities. There was a small number of EMBs (≤ 1%) minimally covered with 
adherent host cells, while with HMBs the surface was totally clear (Figure 7.5B).  
The function of transplanted HMBs was evaluated by detection of human serum albumin in 
peripheral blood of rats. Human serum albumin was detected in rats transplanted with HMBs on 
day 1 (32.65.8 ng/ml), day 3 (10.3±2.9) and was just detectable on day 7 (1.7±0.1) post-
transplantation (Figure 7.6). The level of human albumin production from HMBs on day 3 and 
day 7 was statistically lower than first day after transplantation (p<0.01). The viability and 
hepatocyte function of transplanted HMBs was also examined on recovered (retrieved) samples. 
There were viable cells in retrieved HMBs as demonstrated by fluorescence staining, and MTT 
activity both immediately after recovery (0.50.1 OD reading/100mg HMBs) and after culturing 
for 24h (0.60.3). Moreover, albumin (10.20.6 ng/mg protein) and urea (1.19  0.02 µg/mg 
protein) were detected in the culture medium. CYP1A1/2 activity was detected at level of 
7.9±1.1 pmol/mg protein/min. These results indicated that the retrieved encapsulated 











Figure 7.5: Microbeads 7 days post-transplantation. (A) Microbeads were freely distributed in 
the peritoneal cavity. Many were seen attached along the omentum (black arrow) and no 
inflammation or fibrosis was observed. (B) Recovered EMBs (left) partly covered with (<50%) 








Figure 7.6: Human serum albumin levels in serum samples of rats transplanted with HMBs. 
[**p<0.01] 
 
7.3.2 In Vitro Study of Fresh and Cryopreserved RMBs 
After microencapsulation, RMBs obtained were uniform in shape and the viability of RMBs 
was 7.65±1.26 OD reading/100mg microbeads. Cryopreserved RMBs maintained their cell 
viability and morphology after thawing. Figure 7.7 shows the viability of fresh RMBs 
immediately after production and cryopreserved RMBs post-thawing, respectively. Over the 
period of one week in culture, cell viability and hepatocyte-specific functions of both fresh and 
cryopreserved RMBs were comparable. Cryopreserved RMBs tended to have a lower initial cell 
viability and urea production compared to fresh microbeads, however the levels were 
maintained for a later period, while with fresh RMBs they continued to drop (Figure 7.8). Cell 
viability of fresh and cryopreserved RMBs progressively decreased, and the significant 
reduction in viability was observed in fresh RMBs between days 1 and 7 (6.30±0.30 vs 
1.45±0.15; p<0.05), but this was not observed in cryopreserved RMBs (Figure 7.8A). Urea 
production also continuously decreased in both fresh and cryopreserved RMBs (Figure 7.8C). 
Albumin production remained stable during the study. CYP1A1/2 activity of RMBs in both 
groups showed similar pattern but slightly increased by day 3, then decreased by day 7 to the 










































Figure 7.7: Cell viability of fresh and cryopreserved RMBs prior to transplantation. 
Representative images of FDA (green)/PI (red) staining demonstrating cell viability of fresh 
RMBs immediately after production (top panel) and cryopreserved microbeads immediately 
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Figure 7.8: In vitro data of fresh and cryopreserved RMBs. (A) cell viability; MTT assay, (B) 






7.3.3 Acute liver Failure Induction 
Out of 44 rats, 21 showed ALF determined by PT >36sec (INR≥3) at 24h after ALF induction. 
When comparing ALF-rats (n=21) to the ones without ALF (n=23), there was no statistical 
differences in baseline parameters including body weight, PT or ammonia levels. A statistical 
significant increase in liver function tests was observed in ALF-rat at 24h after ALF induction 
compared to normal baseline (p<0.0001). These included ammonia, median 25 (range 7-67 
µmol/l) vs 6 (6-26 µmol/l); PT, 63.6 (37.4-96.0 sec) vs 12.1 (9.6-12.4 sec); AST, 2549 (1017-
6255 IU/l) vs 105 (78-163 IU/l); ALT, 2263 (803-5584 IU/l) vs 69 (39-93 IU/l); and bilirubin, 3 
(1-13 µmol/l) vs 1 (1-1 µmol/l), at 24h versus baseline control, respectively (Figure 7.9).  
7.3.4 Transplantation of RMBs in ALF-rats 
Intraperitoneal transplantation of EMBs (group 2), fresh RMBs (group 3), cryopreserved RMBs 
(group 4) and transplant medium injection (group 1; sham) was performed on day 1 (24-28h) 
after ALF induction under general anesthesia. All of animals fully recovered after the procedure 
without any post-operative complications and became ambulatory. Encephalopathy was limited 
in the animals throughout the follow up period. Only two animals had hepatic coma grade 2-3. 
One was observed on day 2 and the other on day 3 after ALF induction. 
7.3.4.1 Animal Survival 
All animals survived immediately after post transplantation. In group 1, one animal developed 
hepatic coma and suffered from respiratory distress and eventually died on day 3. Two animals 
in group 2, transplanted with EMBs, died on day 2 and day 3 after ALF induction. On day 4, 
three animals in group 4 transplanted with cryopreserved RMBs found dead. All animal in 
group 3 transplanted with fresh RMBs were survived up to one week post-transplantation. The 
72-hour survival rates were 83.3%, 50%, 100% and 100% in group 1, 2, 3 and 4, respectively. 
The 96-hour survival rate decreased to 50% in group 4, while other groups remained stable. 
Subsequently, the survival rate did not change in all experimental groups. The rats in group 3 
were survived better than the other three groups; however there was no statistical significance 
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Figure 7.9: Biochemical profiles of acute liver injury. Liver functions test assessed 24h after D-
galactosamine (D-GalN) administration compared to baseline controls; (A) blood ammonia 
level, (B) prothrombin time (PT), (C) serum aspartate aminotransferase (AST) level, (D) serum 
alanine aminotransferase (ALT) level, and (E) serum bilirubin level. Data are expressed as 
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7.3.4.2   Liver Function Tests and Creatinine Level  
The overall blood tests of liver function results showed an increase from baseline to significant 
levels by 24h, which then progressively rose up to reach a peak at 48h after ALF induction, 
indicating maximum liver injury. A general improvement in liver function was observed in 
surviving animals on day 4 post-ALF induction. Noticeably, all parameters almost completely 
returned to normal levels (baseline) on day 8 post-ALF induction (Figure 7.11). There was no 
significant difference in biochemical profiles including PT, ammonia, ALT, bilirubin and 
creatinine levels at 24h after ALF induction. However, the AST level was significantly higher in 
group 4 (median 4594, range 1372-5795 IU/l) compared to group 3 (1244, range 1017-2672 
IU/l; p<0.05). This degree of liver injury was similar in all groups before receiving any 
treatment. The differences between groups were clearly seen on the following day after 
transplantation of microbeads (day 2 post-ALF induction). Transplantation of fresh RMBs in 
group 3 decreased the severity of ALF showing statistically significant lower levels of liver 
enzymes including ALT (1937, range 1407-2461 IU/l; p<0.01), AST (1997, range 1565-2613 
IU/l; p<0.001) and bilirubin (41.5, range 37-61 µmol/l; p<0.01) than those of the other three 
groups. In addition, the creatinine levels in rats transplanted with fresh RMBs (24.5, range 22-
31 umol/l) and cryopreserved RMBs (29.5, range 25-36) were significantly lower than in those 
transplanted with EMBs (48, range 45-51; p<0.01). PT and ammonia levels were not 
significantly different between the four groups, however, one animal in group 2, transplanted 
with EMBs had an extremely high ammonia level (>286µmol/l). There was no significant 
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Figure 7.11: Biochemical parameters of rats with D-GalN induced ALF. (A) blood ammonia 
level, (B) PT, (C) serum AST level, (D) serum ALT level, (E) serum bilirubin level, and (F) 
serum creatinine level. Significance*p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001 






p<0.001 compared to 
group 3 (transplanted with fresh RMBs at 48h after ALF induction. Significance 
++
p<0.01 






7.3.4.3   Body Weight of ALF-rats 
The animal weight loss showed similar trend as the liver function tests, when animals had lost 
weight starting from 24h after ALF induction. The overall maximum weight loss was observed 
on day 2 post-ALF induction except in the sham group that continuously lost weight (peaked on 
day 4). Animals in group 2, 3 and 4 started to gain weight on day 4. Noticeably, animals in 
group 3 and 4, transplanted with fresh and cryopreserved RMBs had significantly recovered 
from the weight loss better those in the sham group (p<0.01). On day 8, animals in all groups 
had returned to their baseline weight (Figure 7.12). 
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Figure 7.12: Assessment of body weight of ALF-rats. Data are expressed as percentage of 
weight loss compared to individual baseline, and represented as median (range); **p<0.01. 




7.3.4.4   Metabolic Morphology and Function of Retrieved Microbeads  
Microbeads were recovered from surviving animals after 7 days of transplantation (n=10) and at 
the other time points when the animals died or were euthanised (n=5). Microbeads were found 
scattered throughout the peritoneal cavity, and loosely attached to the omentum and mesentery 
in the three groups (group 2, 3 and 4). No signs of inflammation or adhesion were observed. 
The total volume of microbeads retrieved was found to be 70±2.4% of transplanted microbeads. 
The morphology and integrity of microbeads in all groups were well maintained. The retrieved 
RMBs from 2 animals in group 4 (cryopreserved RMBs) had some host cells adherent to the 
microbeads surface (2-5%), whereas retrieved RMBs from the other 4 animals were clean. 
There was hardly any host cells adherent to the surface of retrieved microbeads in groups 2 
(EMBs) and 3 (fresh RMBs). The retrieved RMBs in group 3 and group 4 showed viable cells 
and hepatocyte-specific functions in culture (Figure 7.13 and 7.14). Retrieved RMBs from 
group 4 had a significantly higher cell viability (MTT=0.61±0.10 OD reading/100mgRMBs; 
p<0.05) and albumin production (1161±11.2 ng/mg protein; p<0.01) than those retrieved from 








Figure 7.13: Retrieved microbeads after transplantation for 1 week. FDA (green)/PI (red) 
staining demonstrated cell viability in retrieved fresh (top panel) and cryopreserved microbeads 
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Figure 7.14: Viability and metabolic function of retrieved RMBs after transplantation for 7 
days. (A) MTT assay, (B) albumin production, (C) urea production and (D) CYP1A1/2 activity. 
[*p<0.05 and **p<0.01]. 
 
7.3.4.5   Liver Histopathology 
Gross appearance of liver in surviving rats looked similar to normal controls. On the other hand, 
livers of severe ALF rats (died) were pale yellowish in color, hemorrhagic and with atrophy 
leading to a liver weight loss three times greater than that of surviving rats (5.9±0.7g and 
14.8±0.2g, respectively), (Figure 7.15A and B). Histopathology of surviving rats showed 
completely normal intact lobular architecture without signs of hepatocellular injury one week 
post RMBs transplantation (Figure 7.15C). Livers from dead ALF-rats showed evidence of 









Figure 7.15: Liver gross anatomy and histopathology of rats with ALF. (A) Surviving rats at 
day 7 post transplantation and (B) dead rats at day 2 after D-GalN injection. Representative of 
histopathology of liver tissue from rat with D-GalN induced ALF; H&E staining (200x), [scale 
bars= 100µm]. (C) surviving rat at 7 days post transplantation showed normal lobular 
architecture; portal tract [black arrow] and central lobular region [white arrow], (D)-(E) dead rat 
at 48h after ALF induction showed confluent hepatocellular necrosis affecting centrilobular and 
periportal region with mild inflammatory cell infiltration [black arrow head], and (F) dead rat at 
72hr post-ALF induction showed ductular reaction in keeping with an attempt to regeneration 











7.4.1 Intraperitoneal Transplantation of HMBs in Rats 
This study demonstrated encouraging results in terms of the physical integrity, biocompatibility, 
viability, and functionality of optimised HMBs during and after xenotransplantation into wild 
type rats without the need for immunosuppression. Transplantation of the optimised microbeads 
in vivo showed EMBs and HMBs retrieved were intact and maintained their shape and size after 
1 week in the peritoneum. Most microbeads were free from host cell adhesion. Previous studies 
reported transplanted microcapsules (sodium alginate-poly-L-lysine-sodium alginate 
copolymer; APA) surrounded with fibrous tissue within 4 days to 4 weeks (Umehara et al. 
2001; Mei et al. 2009; Zhang et al. 2011). However, in this study there was no evidence of 
fibrosis or tissue adhesion surrounding the microbeads. The possible explanations could be that 
the ultra-pure alginate used did not provoke the host immune response which is supported by 
the in vitro data previously described in Chapter 5. Previous studies used poly-L-lysine in 
microbeads which could have induced immune reaction against the microbeads. Interestingly, 
there were no host cells adherent to HMBs despite human hepatocytes being administered to 
rats (xenotransplantation). The detection of human albumin in the serum of rats transplanted 
with HMBs, and the in vitro demonstration of viability, albumin and urea production by the 
retrieved HMBs proves that the microbeads remained functional. The low level of human 
albumin in rat serum on day 7 could be possibly explained by the use of cryopreserved cells to 
prepare microbeads in this experiment, and also the total number of cells transplanted was low. 
In addition, as the albumin produced was human, the rat immune system might have reacted 
against the foreign protein and started to eliminate it from the blood. Overall, these findings 
show that the optimised microencapsulation protocol protects cells from host immune response, 
while allowing cell survival and function. 
7.4.2 Viability and Function of Fresh RMBs and Cryopreserved RMBs 
It is well known that isolated primary hepatocytes are difficult to maintain in culture, and that 
cryopreservation also has substantial detrimental effects on their function and viability. 
Interestingly, the results from this current study showed that there was no significant difference 
in function of encapsulated cells between fresh and cryopreserved RMBs over the period of one 
week in culture. Although, the cryopreserved RMBs showed slightly lower viability, urea and 
albumin production level at day 1, this remained stable afterwards. Albumin synthesis and 
cytochrome P450 activity were well preserved in both groups. These findings suggest that an 
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optimised protocol for production of hepatocyte microbeads has been established in this present 
study. Moreover, the microbeads cryopreservation protocol tested gave encouraging results too 
(Chapter 4 and Chapter 6). 
7.4.3 D-galactosamine and Acute Liver Failure 
The ALF rat model using D-GalN intraperitoneal injection was used because the liver injury 
caused by this compound closely resembles that of human ALF in terms of histology and 
biochemical parameters. The severity of liver damage was dose-dependent and is more 
predictable (Keppler et al. 1968; Diaz-Buxo et al. 1997; Kalpana et al. 1999) than the 
acetaminophen model, plus the extrahepatic toxicity of D-GalN is not significant. The main 
concern of chemical model is that variable factors such as species, strain, sex, weight and time 
of administration could play an important role in the severity of the response (Terblanche and 
Hickman 1991). The dosage used was based on previous studies, as a dose of 850mg/kg to 
1g/kg was too low and allowed for a spontaneous recovery of liver injury. Keppler et al (1968) 
showed that D-GalN injected intraperitoneally at dose of 1.5g/kg produced ALF features within 
24-48 in Wistar rat equally in both sex. Rivas-Vetencourt et al. (1997) using 3g/kg 
(intraperitoneally) to induce Sprague Dawley rats and found that mortality rate>85%. They 
suggested that at this high dose the persistence of D-GalN in the circulation may be toxic to the 
encapsulated cells when transplanted at 24h after administration. However, Jauregui et al 
demonstrated that D-GalN (1g/kg; intravenously) was completely cleared from rabbits’ blood 
after 3-6h after administration (Jauregui et al. 1995). 
In the current study, the induction of ALF was carefully conducted in consideration the animals 
and the variable factors involved to minimise the variation of response. However, variable 
effects of D-GalN at the dose of 1.2g/kg were observed in the study. The PT ≥36 sec (INR≥3) 
was the main criterion of ALF in this study, since the impaired synthetic function of coagulation 
factors (I, II, V, VII and X) is a highly sensitive indicator of liver injury owing to the relatively 
short half-life. In humans, a diagnosis of ALF is made in patients who develop coagulopathy 
with encephalopathy in adults. In children, the signs of hepatic encephalopathy may be subtle 
and difficult to identify hence the diagnosis is based on INR ≥2 alone or INR ≥1.5 plus hepatic 
encephalopathy (Squires et al. 2006; Bernal et al. 2010). Four animals had a PT range from 18 
to 32 sec. All of them spontaneously recovered within 72h after ALF induction. The mortality 
rate at this dose was about 20% in untreated animals similar to that in the previous study in our 
department by Puppi et al. (2014). The animals transplanted with empty microbeads and 
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cryopreserved microbeads showed 50% mortality rate. However, it is difficult to interpret the 
result based on the small subgroups of animals and increased potential for type 2 error.  
7.4.4 Intraperitoneal Transplantation of RMBs 
To determine the efficacy and safety of optimised microbeads, we transplanted RMBs in rats 
with ALF as this approach would better mimic the transplantation of HMBs in patients. This 
current study showed promising outcome of intraperitoneal transplantation of optimised 
microbeads in ALF-rats. The technique was safe without any immediate or late complications. 
The hepatocytes inside the microbeads survived and were able to function without using 
immunosuppression. Rats with transplantation of RMBs all survived, which tended to be better 
than with cryopreserved RMBs, EMBs and untreated animals, however, this did not reached 
statistical significance as the number of animals was small. The low mortality of ALF with D-
GalN at this dose (Puppi et al. 2014) made it difficult to assess survival. Interestingly, 
transplantation with cryopreserved RMBs prolonged survival rate at 72h similar to 
transplantation with fresh RMBs. Nevertheless, the mortality rate in the cryopreserved group 
increased to 50% at 96h. There was a significant improvement in biochemical parameters of 
liver injury including ALT, AST, and bilirubin of the fresh RMBs group compared to the other 
three groups. We also evaluated serum creatinine to determine the severity of ALF and 
multiorgan failure and found that both fresh and cryopreserved RMBs groups had significantly 
lower creatinine levels than the EMB group. Additionally, the body weight, one of the 
indicators of animal well-being was also significantly better in both fresh and cryopreserved 
RMBs groups compared to control groups (EMBs and sham). The liver histology of surviving 
rats showed complete recovery 7 days after transplantation. These data suggest that 
intraperitoneal transplantation of fresh hepatocyte microbeads containing only a small part of 
the total liver mass could support the failing liver and improve outcome. The possible reason 
why transplantation with cryopreserved RMBs did not show significant improvement of liver 
injury as effectively as fresh RMBs is the small number of cells transplanted. It could be 
hypothesised that transplantation of cryopreserved hepatocyte microbeads required a greater cell 
number to provide sufficient metabolism in order to support and improve survival rate 
compared to freshly prepared microbeads. However, a larger volume transplanted into 
peritoneal cavity might lead to intra-abdominal hypertension and abdominal compartment 
syndrome with compromised blood flow to abdominal organs and multiple organ dysfunction 
syndrome and death. This perhaps could be avoided by repeating transplantation in the next 
following day.  
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Other investigators showed that transplantation of cryopreserved encapsulated cells improve 
survival rate in ALF mice. However, the total cell number transplanted in those studies was high 
up to 30% of liver mass (Mai et al. 2005; Mei et al. 2009). Umehara et al. proposed that 
transplanting encapsulated cells at 4% of total liver volume improved metabolism and survival 
rate of ALF-rats (Umehara et al. 2001). The optimal cell number required to provide efficient 
function in the clinical setting of ALF remains controversial and further studies are needed. 
Transplantation of the optimised fresh or cryopreserved microbeads in this rat model of ALF 
also showed encouraging results in terms of the physical integrity and biocompatibility of 
hepatocyte microbeads and their survival and function. The retrieved microbeads were intact 
and maintained their shape and size in the peritoneal cavity. Minimal percentage of host cell 
adherence was observed. Nevertheless, cryopreserved RMBs seemed to have higher number of 
host cell adherent on the surface than non-cryopreserved microbeads. This could be due to the 
uneven damage to the microbead surface and/or the permeability change that may have occurred 
during cryopreservation and thawing. The reaction of the individual animal may be important as 
data showed that the host cell adherence on microbeads was found in 2 out of 6 animals only. 
The cell viability and the detection of albumin and urea production, and cytochrome activity 
produced by the retrieved RMBs confirmed the microbeads were functioning after 
transplantation. A significantly higher cell viability and albumin synthesis were observed in the 
cryopreserved RMBs compared to fresh RMBs after retrieval. This result was again in 
agreement with the in vitro study which showed that cryopreserved microbeads maintained their 
metabolic functions well over a week. 
In conclusion, the current study shows that the optimised protocol using production of GMP 
grade materials provided high quality and biocompatible hepatocyte microbeads. The alginate 
encapsulated cells maintained their hepatocyte-specific functions both in vitro and in vivo. 
Intraperitoneal transplantation of optimised microbeads provided metabolic support in ALF 
without immunosuppression. This along with the safety of this approach allows repeated 
transplantation if required. Transplantation of cryopreserved microbeads is an attractive option 
and comprehensive investigations are required. Therefore, these high quality alginate human 





8. General Discussion and Conclusions 
The concept of hepatocyte microencapsulation for treatment of liver disease was developed over 
two decades ago. Transplantation of microencapsulated hepatocytes has been studied in animal 
models of acute liver failure with promising outcomes. Hepatocyte microbeads (HMBs) can 
replace the missing metabolic and synthetic functions of damaged hepatocytes either for a short 
period bridging the patient to liver transplantation or allowing time for the liver to regenerate 
and recovery. Importantly, encapsulation avoids the need for immunosuppression. The progress 
in this field has been slow mainly due to the poor biocompatibility of the biomaterials used and 
reproducibility of the technique. In order to implement HMBs as a therapeutic option in clinical 
practice, some important parameters needed to be optimised. These parameters include (i) 
mechanical and chemical stability, (ii) morphology and permeability, (ii) inflammatory potential 
of microbeads containing hepatocytes, (iv) the cell viability and function performance of 
microbeads, and (v) biosafety (Santos et al. 2013; Rokstad et al. 2014). Another important issue 
that must be considered is long-term storage of HMBs, such as cryopreservation of these 
microbeads to make them readily available for emergency use. There are no published protocols 
for production of microbeads for the clinical treatment of acute liver disease. The main purpose 
of the current study was aimed at clinical translation, therefore a stepwise comprehensive 
investigation and optimisation of the important parameters involved were conducted. 
This study has used a highly purified (ultra-pure) type of alginate to produce GMP grade 
alginate microencapsulated human hepatocytes. Optimisation of polymerisation time required a 
careful balance between the mechanical stability and its effects on cell viability and function, 
and permeability of HMBs. It was observed that polymerisation for 15min provided good 
mechanical stability without any detrimental effects on cell viability and function of HMBs 
compared to a shorter (10min) and a longer duration (20min) polymerisation time. Investigation 
of the effects of cell density on the physical integrity, cell viability and function of the 
encapsulated hepatocytes was required, since overcrowding within a microbead may result in 
competition for nutrients and increased cell death. Microbeads produced with cell density up to 
of 3.5x10
6
cell/ml alginate were found to be uniform in shape and intact. The even distribution 
of cells and cell viability across the microbeads were demonstrated using confocal microscopy 
imaging and 3D reconstruction. A cell density of 3.5x10
6
cell/ml alginate showed a good cell 
viability and function. After establishing the protocol for production of HMBs, permeability of 
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these optimised microbeads was evaluated. It was found that the maximum molecular weight of 
protein that can diffuse through microbeads was 164kDa.  
It is well established that APA has strong immunogenicity due to the positive charge of PLL, 
therefore uncoated alginate microbeads were used in the current study to minimise the host 
immune reaction. The potential immunogenicity of these optimised microbeads was 
investigated with human polymorphonuclear cells (PBMCs). Initially freshly prepared empty 
microbeads (EMBs) and HMBs were co-cultured with PBMCs. No evidence of cellular immune 
activation was found. Unexpectedly, EMBs and particularly HMBs had a significant inhibitory 
effect on monocyte activation marker expression. The later study better mimicked the real 
transplantation setting by incubating microbeads with ascitic fluid followed by co-culturing with 
PBMCs. Microbeads showed excellent biocompatibility by demonstrating no immune cell 
adherence onto their surface, and no differences in immune activation and cytokine production 
levels. Nevertheless, it would be ideal to directly measure the amount of protein adsorbed on the 
surface of microbeads. These proteins would include immunoglobulins and complement 
particularly C3 that can activate classical and alternative complement pathways. In the in vivo 
study, the evaluation of immunogenicity was performed in both xenogenic and syngeneic 
transplantation in immunocompetent animals. The degree of immune response was evaluated by 
the assessment of host cell adhesion on microbead’s surface, percentage of microbeads recovery 
and cell viability of recovered microbeads. The results were encouraging and demonstrated that 
both freshly prepared and cryopreserved HMBs hardly stimulated host immune reaction. These 
in vitro and in vivo results also suggest that the optimised HMBs has the potential for clinical 
application. 
The cryopreservation of microbeads part of this study focused on developing a modified 
cryopreservation solution by adding cytoprotectants to reduce some of the detrimental effects of 
stress related to apoptotic cell death during freezing and post-thawing. The cryopreservation 
protocol was based on a previously published study (Massie et al. 2011). Improvements of the 
ultrastructure of encapsulated hepatocytes, viability and some functions were observed in 
HMBs cryopreserved with UW solution containing of 10% DMSO, 5% glucose and 60µM 
ZVAD. Human serum albumin and desferoxamine also showed positive effects on 
cryopreserved HMBs. These findings have resulted in improvement of the cryopreservation 
outcome that could be implemented in the cryopreservation protocols for future clinical use. 
However, optimisation of cryopreservation of microbeads remains complex and involves many 
steps. Hepatocyte microbeads consist of two elements to freeze which are mainly the water in 
the alginate structure and the entrapped cells which makes it more difficult for cryopreservation 
especially controlling the intracellular ice formation. Therefore, further studies are needed to 
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develop an optimised protocol that systematically evaluates the freezing solutions, freezing and 
thawing stages. In addition, using advanced techniques such as cryomicroscopy for evaluation 
the degree of cryodamage would be of interest. 
Ttransplantation of optimised HMBs in immunocompetent rats, the function of these 
microbeads was evaluated for 7 days and host immune response after transplantation was 
assessed on day 7 post-transplantation. Human serum albumin was detected throughout the 7 
days and no inflammatory reaction was observed in the peritoneal cavity or on the microbeads. 
The therapeutic effect and the safety/acceptability of rat hepatocyte microbeads produced were 
confirmed in rats with acute liver failure. The results suggested that freshly prepared hepatocyte 
microbeads containing hepatocytes equivalent to a small part of total liver mass could provide 
effective metabolic function to support the failing liver, but not when cryopreserved hepatocytes 
microbeads were used, as a greater number of cells is required due to loss of hepatocyte 
function. It would be interesting to investigate the optimum dose of encapsulated hepatocytes 
that efficiently provides metabolic function to support damaging liver and lead to an improved 
survival rate. Although in this model recovery of animals and restoration of liver function were 
achieved in less than 7 day, long-term effect and biocompatibility of microbeads after 
transplantation is another issue needs to be evaluate. 
8.1 Limitations of the Study 
Optimisation of Microbeads 
Ideally, freshly isolated hepatocytes should be used in all experiments. However, the scarcity of 
good quality donor liver for hepatocyte isolation for every set of experiments remained an 
important issue. Also the quality of cells obtained from liver resections of patients with 
malignancy was relatively low, viability 40-50%, due to the steatotic liver tissue which might 
have resulted from the underlying disease and chemotherapy effects consistent with the findings 
of Bhogal and colleagues (2011).  
The common techniques used to determine permeability are inverse-size exclusion 
chromatography (Brissová et al. 1998), more recently, radiolabeled IgG (Mørch et al. 2007), and 
confocal laser scanning microscopy to detect fluorescently labeled IgG (Qi et al. 2012). In 
present study, permeability was evaluated with proteomic analysis as it provides information 
including identification and quantity of proteins that diffuse out of microbeads in the 
supernatants. However, smaller proteins such as factor VII may have been masked by abundant 
and larger proteins such as albumin.  
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Cryopreservation of Microbeads 
The use of rat hepatocytes instead of human hepatocytes to optimise microbead 
cryopreservation protocol was useful due to the insufficient supply of high quality human 
hepatocytes. Although, the initial results showed similar outcomes using both human and rat 
hepatocytes, it would have been better to conduct all experiments using human hepatocytes. 
Animal Experiments 
The achieved rate of ALF after D-GalN induction was unexpectedly low in this study. Also 
there was a considerable variation in the severity of ALF between animals given the same dose 
of D-GalN. Therefore, establishing an ALF animal model that is highly reproducible and close 
to clinical features in humans is important. As the sample size of the current study was small, it 
is difficult to draw definite conclusions about some data such as survival rate which may have 
been affected by type 2 error. It must be noted that due to time constraint it was difficult to 
study a larger number of animals. Further work should be carried out in large scale experiments 
and also in larger animal models of ALF to help confirm the efficacy of microbead 
transplantation with both fresh and cryopreserved microbeads.  
8.2 Conclusion and Future Work 
8.2.1 Conclusion 
In conclusion, the work described fulfilled the central hypothesis of this thesis, and the results 
suggest that the optimised protocol established for production of GMP grade human hepatocyte 
microbeads could be safely use for transplantation in patients with ALF. 
8.2.2 Future Work 
It is well known that, human hepatocytes are fragile and vulnerable after isolation. Therefore, 
co-encapsulation of hepatocytes with other types of cells such as mesenchymal stem cells or 
non-parenchymal cell could be beneficial, as several studies have shown their beneficial effects 
in terms of prolonging cell viability and enhancing metabolic function (Table 1.6). The 
mechanisms of action between these cells and hepatocytes remain unknown whether from direct 
contact or paracrine effects. It would be interesting to study the effects of co-encapsulation of 
human hepatocytes with various types of cells and elucidate the mechanisms of action between 
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them. This might require the use of in alginate microbeads with a depolymerised center as cell-
to-cell contact is essential. 
There is still potential for improvements in cryopreservation of hepatocyte microbeads. Further 
experiments are still needed to achieve an optimised protocol to provide improve cell viability 
and function of hepatocyte microbeads. The stepwise development of cryopreservation protocol 
by focusing on structural (physical) preservation of microbeads and encapsulated cells together 
with inhibition of cellular death cascades (biological) will improve the outcome of the protocol. 
We believe that clinically a large amount of hepatocyte microbeads may be required 
immediately for emergency cases such as ALF. Therefore, scaling-up production of microbeads 
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10.  APPENDICES  
Appendix I: A summary of human liver tissues used for hepatocyte isolation. 




1 Segment 4 DBD 8h 36/F 63% Mild-mod fatty 
2 Left lobe DBD 9h 52/M 70% Mod fatty 
3 Segment 4 DBD 10h 34/M 60%  
4 Left lateral segment DBD 9h 30min 40/F 72%  
5
a Left lateral segment DCD 27min 35/M 53% Severe fatty 
6
a Resection Biliary cyst NA 62/F 67%  
7
a Resection Colorectal CA NA 70/M 66%  
8 Segments 1& 4 DBD 11h 30min 26/M 69%  
9 Left lateral segment DBD 11h 30min 59/F 71% Mild-mod fatty 
10 Segments 1& 4 DBD 9h 30min 13/F 65%  
11 Right lobe DBD 11h 20min 17/F 72%  
12 Resection Cholangio-CA NA 66/F 60% Mod fatty 
13 Left lateral segment DCD 27min 64/F 60%  
14 Right lobe DBD 6h 47/M 76%  
15 Left lateral segment DBD 13h 39/F 80% Mild-mod fatty 
16 Resection Liver cyst NA 46/F 78%  
17 Right lobe DCD 14min 49/M 74%  
18 Right lobe DCD 22min 29/M 67%  
19 Segment 1&4 DBD 7h 31/F 65%  
20 Segment 1 DBD 7h 18/F 83%  
21 Segment 1 DBD 8h 35/F 77%  
22 Segment 1&4 DBD 22h 37/M 60% Mild-mod fatty 
23 Left lobe DCD 14min 17/M 78% Mild-mod fatty 
24 Resection NET NA 68/F 77% Mod fatty 
25 Segment 1&4 DBD 16h 42/M 68%  





Appendix II: Cryopreserved human hepatocytes 
 
No. Tissue Type CIT/WIT Age/Sex 
Viability 
Fresh Post-thaw Percoll® 
1 Right lobe DBD NA 8/F 85% 60% - 
2 Whole liver DCD NA 29/M 79% 49% 63% 
3 Left lobe DCD 13min 67/M 76% 45% 65% 
4 Left lateral segment DBD 5h 52/F 72% 48% 72% 
5 Segment 1 DBD 14h 20min 37/F 74% 46% 62% 
6 Left lateral segment DCD 16min 58/M 72% 42% 64% 
7 Right lobe DCD NA 6/F 78% 45% 63% 
8 Segment 4 DBD 7h 12/M 86% 62% - 
9 Left lateral segment DCD 23min 68/M 84% 48% 60% 
10 Right lobe DBD 6h 47/M 76% 50% 70% 
a
 Hepatocytes used in optimisation of Percoll® protocol. CA, cancer/carcinoma; CIT, cold ischemic time; 
DBD, donor after brain-dead; DCD, donor after cardiac death; NA, not available; NET, neuroendocrine 




Appendix III: Proteomics analysis in supernatants of HMBs culture medium. 
Accession Entry Protein description MW Amount 
 (fmol) 
CH10_HUMAN P61604 10 kDa heat shock protein mitochondrial  10924 10.2902 
FABPL_HUMAN P07148 Fatty acid binding protein liver  14199 46.8011 
UK114_HUMAN P52758 Ribonuclease UK114  14484 27.3915 
PROF1_HUMAN P07737 Profilin 1  15044 8.5285 
SODC_HUMAN P00441 Superoxide dismutase Cu Zn 15925 13.8232 
ISCU_HUMAN Q9H1K1 Iron sulfur cluster assembly enzyme ISCU  17987 62.957 
TWST1_HUMAN Q15672 Twist related protein 1  20941 17.279 
PEBP1_HUMAN P30086 Phosphatidylethanolamine binding protein 1  21043 32.4102 
PRDX6_HUMAN P30041 Peroxiredoxin 6  25019 15.6806 
GPX5_HUMAN O75715 Epididymal secretory glutathione peroxidase  25186 18.0216 
GSTA1_HUMAN P08263 Glutathione S transferase A1  25614 57.4934 
GSTA2_HUMAN P09210 Glutathione S transferase A2  25647 30.7457 
DCXR_HUMAN Q7Z4W1 L xylulose reductase  25896 19.3082 
PA1_HUMAN Q9BTK6 PAXIP1 associated protein 1  27699 4.7046 
CES1P_HUMAN Q9UKY3 Putative inactive carboxylesterase 4  30659 17.8128 
NPM_HUMAN P06748 Nucleophosmin  32554 5.0989 
ARGI1_HUMAN P05089 Arginase 1  34713 10.5881 
ECH1_HUMAN Q13011 Delta 3 5 Delta 2 4 dienoyl CoA isomerase  35793 9.2902 
FETUA_HUMAN P02765 Alpha 2 HS glycoprotein 39299 184.094 
ALDOB_HUMAN P05062 Fructose bisphosphate aldolase B  39448 56.0584 
ADH1B_HUMAN P00325 Alcohol dehydrogenase 1B  39828 105.182 
ADH1A_HUMAN P07327 Alcohol dehydrogenase 1A  39832 12.718 
ADH1G_HUMAN P00326 Alcohol dehydrogenase 1C  39841 11.2842 
OTC_HUMAN P00480 Ornithine carbamoyltransferase 
mitochondrial  
39909 12.4154 
ADH4_HUMAN P08319 Alcohol dehydrogenase 4  40195 42.0025 
ACTG_HUMAN P63261 Actin cytoplasmic 2  41765 10 
THIM_HUMAN P42765 3 ketoacyl CoA thiolase mitochondrial  41897 28.2113 
SPYA_HUMAN P21549 Serine pyruvate aminotransferase  42982 28.8985 
HPPD_HUMAN P32754 4 hydroxyphenylpyruvate dioxygenase  44905 7.3992 
HSDL2_HUMAN Q6YN16 Hydroxysteroid dehydrogenase like protein  45365 2.7366 
ASSY_HUMAN P00966 Argininosuccinate synthase  46501 26.2836 





Accession Entry Protein description MW Amount 
 (fmol) 
ENOA_HUMAN P06733 Alpha enolase  47139 12.1431 
PSG1_HUMAN P11464 Pregnancy specific beta 1 glycoprotein 1 47193 278.194 
SOX4_HUMAN Q06945 Transcription factor SOX 4  47233 20.2055 
AATM_HUMAN P00505 Aspartate aminotransferase mitochondrial 47487 13.5309 
CALR_HUMAN P27797 Calreticulin  48111 12.1226 
GATM_HUMAN P50440 Glycine amidinotransferase mitochondrial  48424 11.7616 
AP1M1_HUMAN Q9BXS5 AP 1 complex subunit mu 1  48556 7.5842 
SBP1_HUMAN Q13228 Selenium binding protein 1  52357 9.1889 
K2C8_HUMAN P05787 Keratin type II cytoskeletal 8  53671 18.1546 
AL1A1_HUMAN P00352 Retinal dehydrogenase 1  54826 24.7068 
ALDH2_HUMAN P05091 Aldehyde dehydrogenase mitochondrial  56345 6.2671 
GABT_HUMAN P80404 4 aminobutyrate aminotransferase 56402 15.204 
ATPB_HUMAN P06576 ATP synthase subunit beta mitochondrial  56524 9.6364 
UGPA_HUMAN Q16851 UTP glucose 1 phosphate uridylyltransferase  56904 11.7059 
CH60_HUMAN P10809 60 kDa heat shock protein mitochondrial  61016 10.657 
DHE3_HUMAN P00367 Glutamate dehydrogenase 1 mitochondrial 61359 29.2852 
DHE4_HUMAN P49448 Glutamate dehydrogenase 2 mitochondrial 61395 1.9264 
EST1_HUMAN P23141 Liver carboxylesterase 1  62481 35.8419 
ALBU_HUMAN P02768 Serum albumin  69321 450.054 
PCKGM_HUMAN Q16822 Phosphoenolpyruvate carboxykinase GTP  70684 2.7961 
TRFL_HUMAN P02788 Lactotransferrin  78131 91.6639 
RHG10_HUMAN A1A4S6 Rho GTPase activating protein 10 89318 8.1146 
ITIH2_HUMAN P19823 Inter alpha trypsin inhibitor heavy chain H2  106396 14.0697 
CPSM_HUMAN P31327 Carbamoyl phosphate synthase ammonia  164834 44.8113 
Proteins having at least two peptides identifications found in supernatants of HMBs culture medium are 
listed by molecular weight. Green, 100% confident; yellow, 50% confident; and pink, possible hit. 
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